Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
572ea94e6d5c2b110b1dd86b8ba4d78a24a3dc2f5c0747a6663751aa788f84ee.png
complex
<table><tr><td rowspan="2">Feature</td><td colspan="2">Univariate</td><td colspan="2">Multivariate</td></tr><tr><td>Hazard ratio (95% CI)</td><td><i>P</i></td><td>Hazard ratio (95% CI)</td><td><i>P</i></td></tr><tr><td>Age (y) &#8805; 45 vs &lt; 45</td><td>1.213 (0.782&#8211;1.883)</td><td>0.388</td><td></td><td></td></tr><tr><td>Gender F VSM</td><td>0.781 (0.109&#8211;5.613)</td><td>0.806</td><td></td><td></td></tr><tr><td>Smoking status Present vs Absent</td><td>0.967 (0.498&#8211;1.876)</td><td>0.921</td><td></td><td></td></tr><tr><td>Drinking status Present vs Absent</td><td>0.760 (0.478&#8211;1.208)</td><td>0.245</td><td></td><td></td></tr><tr><td>Pathological differentiation</td><td></td><td>0.023</td><td></td><td></td></tr><tr><td>Highly</td><td>1.000</td><td></td><td></td><td></td></tr><tr><td>Moderately</td><td>1.767 (1.071&#8211;2.914)</td><td>0.026</td><td></td><td></td></tr><tr><td>Poorly</td><td>2.253 (1.187&#8211;4.276)</td><td>0.013</td><td></td><td></td></tr><tr><td>Site Non-glottic va Glottic</td><td>0.641 (0.412&#8211;0.995)</td><td>0.047</td><td></td><td></td></tr><tr><td>T stage</td><td></td><td>&lt; 0.001</td><td></td><td></td></tr><tr><td>T1+T2</td><td>1.000</td><td></td><td></td><td></td></tr><tr><td>T3</td><td>2.415 (1.427&#8211;4.087)</td><td>0.001</td><td></td><td></td></tr><tr><td>T4</td><td>2.989 (1.744&#8211;5.125)</td><td>&lt; 0.001</td><td></td><td></td></tr><tr><td>N stage</td><td></td><td>&lt; 0.001</td><td></td><td>&lt; 0.001</td></tr><tr><td>N0</td><td>1.000</td><td></td><td>1.000</td><td></td></tr><tr><td>N1</td><td>2.044 (1.163&#8211;3.592)</td><td>0.013</td><td>1.961 (1.115&#8211;3.451)</td><td>&lt; 0.001</td></tr><tr><td>N2</td><td>3.862 (2.129&#8211;7.007)</td><td>&lt; 0.001</td><td>3.027 (1.659&#8211;5.522)</td><td>0.019</td></tr><tr><td>CISd2 High vs Low</td><td>3.761 (2.280&#8211;6.203)</td><td>&lt; 0.001</td><td>3.318 (2.030&#8211;5.425)</td><td>&lt; 0.001</td></tr></table>
39ba1d627bfeada625f99ce9d693d05881eb797d6a9cebab6f2dac27e626c68e.png
simple
<table><tr><td>Item</td><td>1. Understood</td><td>2. Sufficient information</td><td>3. Active management</td><td>4. Social support</td><td>5. Appraisal</td><td>6. Active engagement</td><td>7. Navigate</td><td>8. Good information</td><td>9. Understand information</td></tr><tr><td>P1Q2</td><td>0.83</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q8</td><td>0.93</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q17</td><td>0.53</td><td>0.17</td><td></td><td></td><td></td><td></td><td></td><td></td><td>&#8722;0.10</td></tr><tr><td>P1Q22</td><td>0.86</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q1</td><td></td><td>0.39</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q10</td><td></td><td>0.65</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q14</td><td></td><td>0.92</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q23</td><td></td><td>0.88</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q6</td><td></td><td></td><td>0.72</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q9</td><td></td><td></td><td>0.78</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q13</td><td></td><td></td><td>0.92</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q18</td><td></td><td></td><td>0.81</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q21</td><td></td><td></td><td>0.96</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q3</td><td>0.18</td><td></td><td></td><td>0.55</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q5</td><td></td><td></td><td></td><td>0.68</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q11</td><td></td><td></td><td></td><td>0.93</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q15</td><td></td><td></td><td></td><td>0.70</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q19</td><td></td><td></td><td></td><td>1.02</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q4</td><td></td><td></td><td></td><td></td><td>0.76</td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q7</td><td></td><td></td><td></td><td></td><td>0.78</td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q12</td><td></td><td></td><td></td><td></td><td>0.86</td><td></td><td></td><td></td><td></td></tr><tr><td>P1Q16</td><td></td><td>0.19</td><td></td><td></td><td>0.47</td><td>0.09</td><td>0.09</td><td>0.09</td><td></td></tr><tr><td>P1Q20</td><td>0.15</td><td></td><td></td><td></td><td>0.48</td><td></td><td></td><td></td><td></td></tr><tr><td>P2Q2</td><td></td><td></td><td></td><td></td><td></td><td>0.71</td><td></td><td></td><td></td></tr><tr><td>P2Q4</td><td></td><td></td><td></td><td></td><td></td><td>0.78</td><td></td><td></td><td></td></tr><tr><td>P2Q7</td><td></td><td></td><td></td><td></td><td></td><td>0.75</td><td></td><td></td><td></td></tr><tr><td>P2Q15</td><td></td><td></td><td></td><td></td><td></td><td>0.77</td><td></td><td></td><td></td></tr><tr><td>P2Q20</td><td></td><td></td><td></td><td></td><td></td><td>0.83</td><td></td><td></td><td></td></tr><tr><td>P2Q1</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.68</td><td></td><td></td></tr><tr><td>P2Q8</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.88</td><td></td><td>&#8722;0.13</td></tr><tr><td>P2Q11</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.89</td><td></td><td></td></tr><tr><td>P2Q13</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.78</td><td></td><td></td></tr><tr><td>P2Q16</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.57</td><td></td><td></td></tr><tr><td>P2Q19</td><td>&#8722;0.16</td><td></td><td></td><td></td><td></td><td></td><td>0.62</td><td></td><td></td></tr><tr><td>P2Q3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.86</td><td></td></tr><tr><td>P2Q6</td><td></td><td></td><td></td><td></td><td>0.14</td><td></td><td></td><td>0.84</td><td></td></tr><tr><td>P2Q10</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.92</td><td></td></tr><tr><td>P2Q14</td><td></td><td></td><td></td><td></td><td></td><td>0.22</td><td></td><td>0.40</td><td>0.29</td></tr><tr><td>P2Q18</td><td>&#8722;0.16</td><td></td><td></td><td></td><td></td><td></td><td>0.22</td><td>0.41</td><td>0.20</td></tr><tr><td>P2Q5</td><td></td><td></td><td></td><td></td><td></td><td>0.14</td><td></td><td>0.14</td><td>0.63</td></tr><tr><td>P2Q9</td><td></td><td></td><td></td><td></td><td></td><td>0.15</td><td>0.17</td><td>0.15</td><td>0.22</td></tr><tr><td>P2Q12</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.08</td><td></td><td>0.83</td></tr><tr><td>P2Q17</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.76</td></tr><tr><td>P2Q21</td><td></td><td></td><td></td><td></td><td></td><td>0.25</td><td></td><td>0.25</td><td>0.36</td></tr></table>
70b8e3d9442043f92ad77476aea33aa572dcebf3d39725c0d176c97d3c1fea98.png
complex
<table><tr><td>Characteristic</td><td><i>n</i> = 15</td></tr><tr><td colspan="2">GENDER</td></tr><tr><td>Male</td><td>14</td></tr><tr><td>Female</td><td>1</td></tr><tr><td colspan="2">AGE (YEARS)</td></tr><tr><td>Mean</td><td>60 &#177; 6.8</td></tr><tr><td>Range</td><td>52&#8211;74</td></tr><tr><td colspan="2">BASELINE MEDICINE USE</td></tr><tr><td>Mean duration (years)</td><td>2.2 &#177; 1.4</td></tr><tr><td>Mean l-DOPA equivalents (mg/day)</td><td>451 &#177; 304</td></tr><tr><td colspan="2">BASELINE UPDRS SCORE</td></tr><tr><td>Mean total</td><td>39 &#177; 14</td></tr><tr><td>Mean UPDRS-III</td><td>15 &#177; 8.5</td></tr></table>
971ad168181cb620134b239a31b37a47e26fe095f939803e31a94e9f412cfc8b.png
complex
<table><tr><td rowspan="2">Fear</td><td colspan="2">Attraction</td><td></td></tr><tr><td>Call</td><td>No call</td><td>Total</td></tr><tr><td>Suspension bridge</td><td>9</td><td>9</td><td>18</td></tr><tr><td>Solid bridge</td><td>2</td><td>14</td><td>16</td></tr><tr><td>Total</td><td>11</td><td>23</td><td>34</td></tr></table>
69f0f047876ad9a084d6844d5a3451b0bcff581e8dee637439a7cbb3b8b8903e.png
complex
<table><tr><td rowspan="2">Vaccine</td><td rowspan="2">Sample time-point</td><td colspan="2">SCR/booster SCR<sup>&#8224;</sup></td><td colspan="2">SPR</td></tr><tr><td colspan="2">n/N; % (95% CI)</td><td colspan="2">n/N; % (95% CI)</td></tr><tr><td> </td><td> </td><td>Primary strain</td><td>Booster strain</td><td>Primary strain</td><td>Booster strain</td></tr><tr><td rowspan="5">AS03<sub>A</sub>-H5N1</td><td>Day 0</td><td>&#8211;</td><td>&#8211;</td><td>15/933; 1.6</td><td>1/933; 0.1</td></tr><tr><td> </td><td> </td><td> </td><td>(0.9, 2.6)</td><td>(0.0, 0.6)</td></tr><tr><td>Day 21</td><td>393/925; 42.5</td><td>24/925; 2.6</td><td>412/925; 44.5</td><td>27/925; 2.9</td></tr><tr><td> </td><td>(39.3, 45.7)</td><td>(1.7, 3.8)</td><td>(41.3, 47.8)</td><td>(1.9, 4.2)</td></tr><tr><td>Day 42</td><td>866/924; 93.7</td><td>464/924; 50.2</td><td>871/924; 94.3</td><td>464/924; 50.2</td></tr><tr><td> </td><td> </td><td>(92.0, 95.2)</td><td>(46.9, 53.5)</td><td>(92.6, 95.7)</td><td>(46.9, 53.5)</td></tr><tr><td rowspan="3"><i>Heterologous booster</i></td><td>Month 6</td><td>&#8211;</td><td>&#8211;</td><td>103/251; 41.0</td><td>9/251; 3.6</td></tr><tr><td> </td><td> </td><td> </td><td>(34.9, 47.4)</td><td>(1.7, 6.7)</td></tr><tr><td>Month 6 + 21</td><td>233/256; 91.0<sup>&#8224;</sup></td><td>241/256; 94.1<sup>&#8224;</sup></td><td>242/251; 96.4</td><td>238/251; 94.8</td></tr><tr><td> </td><td> </td><td>(86.8, 94.2)</td><td>(90.5, 96.7)</td><td>(93.3, 98.3)</td><td>(91.3, 97.2)</td></tr><tr><td rowspan="5">Non-adjuvanted-H5N1</td><td>Day 0</td><td>&#8211;</td><td>&#8211;</td><td>5/236; 2.1</td><td>0/236; 0.0</td></tr><tr><td> </td><td> </td><td> </td><td>(0.7, 4.9)</td><td>(0.0, 1.6)</td></tr><tr><td>Day 21</td><td>8/234; 3.4</td><td>0/234; 0.0</td><td>16/234; 6.8</td><td>0/234; 0.0</td></tr><tr><td> </td><td>(1.5, 6.6)</td><td>(0.0, 1.6)</td><td>(4.0, 10.9)</td><td>(0.0, 1.6)</td></tr><tr><td>Day 42</td><td>13/234; 5.6</td><td>1/234; 0.4</td><td>24/234; 10.3</td><td>1/234; 0.4</td></tr><tr><td> </td><td> </td><td>(3.0, 9.3)</td><td>(0.0, 2.4)</td><td>(6.7, 14.9)</td><td>(0.0, 2.4)</td></tr><tr><td rowspan="5"><i>Heterologous booster</i></td><td>Month 6</td><td>&#8211;</td><td>&#8211;</td><td>4/224; 1.8</td><td>0/224; 0.0</td></tr><tr><td> </td><td> </td><td> </td><td>(0.5, 4.5)</td><td>(0.0, 1.6)</td></tr><tr><td>Month 6 + 21</td><td>112/228; 49.1<sup>&#8224;</sup></td><td>106/228; 46.5<sup>&#8224;</sup></td><td>120/223; 53.8</td><td>105/223; 47.1</td></tr><tr><td> </td><td>(42.5, 55.8)</td><td>(39.9, 53.2)</td><td>(47.0, 60.5)</td><td>(40.4, 53.9)</td></tr><tr><td>Month 6 + 42</td><td>173/228; 75.9<sup>&#8224;</sup></td><td>189/228; 82.9<sup>&#8224;</sup></td><td>180/228; 78.9</td><td>189/228; 82.9</td></tr><tr><td> </td><td> </td><td>(69.8, 81.3)</td><td>(77.4, 87.5)</td><td>(73.1, 84.1)</td><td>(77.4, 87.5)</td></tr></table>
87427af756e96f681824a417fe436be2ed32864f30ee11b40dc9f6c97f2ff19c.png
complex
<table><tr><td rowspan="2">Bacteria spp.</td><td colspan="5">Specimen</td><td rowspan="2">Total</td></tr><tr><td>Aspirate</td><td>Blood</td><td>Pus swab</td><td>Sputum</td><td>Urine</td></tr><tr><td><i>K. pneumoniae </i></td><td>1</td><td>23</td><td>28</td><td>0</td><td>24</td><td>76</td></tr><tr><td><i>E. coli </i></td><td>1</td><td>8</td><td>31</td><td>1</td><td>15</td><td>56</td></tr><tr><td><i>P. aeruginosa </i></td><td>1</td><td>16</td><td>22</td><td>0</td><td>2</td><td>41</td></tr><tr><td><i>C. freundii </i></td><td>0</td><td>1</td><td>8</td><td>0</td><td>6</td><td>15</td></tr><tr><td><i> A. baumannii </i></td><td>0</td><td>2</td><td>8</td><td>0</td><td>0</td><td>10</td></tr><tr><td><i>P. vulgaris </i></td><td>0</td><td>0</td><td>7</td><td>0</td><td>0</td><td>7</td></tr><tr><td><i>E. cloacae </i></td><td>0</td><td>3</td><td>0</td><td>0</td><td>2</td><td>5</td></tr><tr><td><i>M. morganii </i></td><td>0</td><td>0</td><td>2</td><td>0</td><td>1</td><td>3</td></tr><tr><td><i>P. mirabilis </i></td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td><td>2</td></tr><tr><td><i>S. marcescens </i></td><td>0</td><td>2</td><td>4</td><td>0</td><td>3</td><td>9</td></tr><tr><td><i>Salmonella typhi</i></td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>1</td></tr><tr><td><i>Salmonella</i> spp.</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td><td>2</td></tr><tr><td>Total</td><td>3</td><td>55</td><td>112</td><td>1</td><td>56</td><td>227</td></tr></table>
7e60194571d5d0c13e372b0bb8a47ffdaa317eeb7d5aac5ae0b6b2c141ac1554.png
complex
<table><tr><td></td><td colspan="2">SUV 2.0</td><td colspan="2">SUV 2.5</td><td rowspan="2">r</td><td rowspan="2">P</td></tr><tr><td></td><td>Range</td><td>Mean &#177; SD</td><td>Range</td><td>Mean &#177; SD</td></tr><tr><td>SUV<sub>max</sub></td><td>3.85-43.1</td><td>13.2 &#177; 6.74</td><td>3.85-43.1</td><td>13.2 &#177; 6.74</td><td>1</td><td>.000</td></tr><tr><td>SUV<sub>mean</sub></td><td>2.44-11.0</td><td>5.06 &#177; 1.66</td><td>3.00-12.4</td><td>5.71 &#177; 1.79</td><td>.997</td><td>&lt;.001</td></tr><tr><td>MTV</td><td>5.77-204</td><td>42.1 &#177; 46.8</td><td>1.74-178</td><td>33.9 &#177; 39.5</td><td>.989</td><td>&lt;.001</td></tr><tr><td>COV</td><td>.188-.933</td><td>.513 &#177; .144</td><td>.132-.839</td><td>.438 &#177; .138</td><td>.996</td><td>&lt;.001</td></tr><tr><td>Entropy</td><td>4.58-7.52</td><td>6.53 &#177; .76</td><td>4.10-7.56</td><td>6.38 &#177; .84</td><td>.996</td><td>&lt;.001</td></tr><tr><td>Correlation</td><td>.032-.555</td><td>.255 &#177; .159</td><td>-.126-.515</td><td>.189 &#177; .152</td><td>.963</td><td>&lt;.001</td></tr><tr><td>Contrast</td><td>13.3-411</td><td>234 &#177; 110</td><td>12.2-395</td><td>226 &#177; 105</td><td>.990</td><td>&lt;.001</td></tr><tr><td>Busyness</td><td>.432-.708</td><td>.557 &#177; .071</td><td>.370-.692</td><td>.544 &#177; .072</td><td>.933</td><td>&lt;.001</td></tr><tr><td>Coarseness</td><td>.007-.104</td><td>.044 &#177; .025</td><td>.009-.158</td><td>.050 &#177; .029</td><td>.813</td><td>&lt;.001</td></tr></table>
0273c968d5367995b0acc39a951dd874f7aef9718aa1ad3cac817f3af1a32d81.png
complex
<table><tr><td></td><td>8 Gy &#215; 1N patients (%)</td><td>4 Gy &#215; 5N patients (%)</td></tr><tr><td colspan="3">Age</td></tr><tr><td> &#8804;65 years (<i>N</i> = 78)</td><td>39 (50)</td><td>39 (50)</td></tr><tr><td> &#8805;66 years (<i>N</i> = 78)</td><td>39 (50)</td><td>39 (50)</td></tr><tr><td colspan="3">Gender</td></tr><tr><td> Female (<i>N</i> = 36)</td><td>18 (23)</td><td>18 (23)</td></tr><tr><td> Male (<i>N</i> = 120)</td><td>60 (77)</td><td>60 (77)</td></tr><tr><td colspan="3">ECOG Performance status</td></tr><tr><td> 1&#8211;2 (<i>N</i> = 26)</td><td>13 (17)</td><td>13 (17)</td></tr><tr><td> 3&#8211;4 (<i>N</i> = 130)</td><td>65 (83)</td><td>65 (83)</td></tr><tr><td colspan="3">Type of primary tumor</td></tr><tr><td> Breast cancer (<i>N</i> = 12)</td><td>6 (8)</td><td>6 (8)</td></tr><tr><td> Prostate cancer (<i>N</i> = 36)</td><td>18 (23)</td><td>18 (23)</td></tr><tr><td> Myeloma/lymphoma (<i>N</i> = 0)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td> Lung cancer (<i>N</i> = 46)</td><td>23 (29)</td><td>23 (29)</td></tr><tr><td> Unknown primary (<i>N</i> = 32)</td><td>16 (21)</td><td>16 (21)</td></tr><tr><td> Other tumors (<i>N</i> = 30)</td><td>15 (19)</td><td>15 (19)</td></tr><tr><td colspan="3">Involved vertebrae (n)</td></tr><tr><td> 1&#8211;2 (<i>N</i> = 34)</td><td>17 (22)</td><td>17 (22)</td></tr><tr><td> &#8805;3 (<i>N</i> = 122)</td><td>61 (78)</td><td>61 (78)</td></tr><tr><td colspan="3">Other bone metastases</td></tr><tr><td> No (<i>N</i> = 34)</td><td>17 (22)</td><td>17 (22)</td></tr><tr><td> Yes (<i>N</i> = 122)</td><td>61 (78)</td><td>61 (78)</td></tr><tr><td colspan="3">Visceral metastases</td></tr><tr><td> No (<i>N</i> = 36)</td><td>18 (23)</td><td>18 (23)</td></tr><tr><td> Yes (<i>N</i> = 120)</td><td>60 (77)</td><td>60 (77)</td></tr><tr><td colspan="3">Interval from tumor diagnosis to MESCC</td></tr><tr><td> &#8804; 15 months (<i>N</i> = 136)</td><td>68 (87)</td><td>68 (87)</td></tr><tr><td> &gt; 15 months (<i>N</i> = 20)</td><td>10 (13)</td><td>10 (13)</td></tr><tr><td colspan="3">Pre-RT ambulatory status</td></tr><tr><td> Not ambulatory (<i>N</i> = 110)</td><td>55 (71)</td><td>55 (71)</td></tr><tr><td> Ambulatory (<i>N</i> = 46)</td><td>23 (29)</td><td>23 (29)</td></tr><tr><td colspan="3">Time developing motor deficits</td></tr><tr><td> 1&#8211;7 days (<i>N</i> = 110)</td><td>55 (71)</td><td>55 (71)</td></tr><tr><td> 8&#8211;14 days (<i>N</i> = 30)</td><td>15 (19)</td><td>15 (19)</td></tr><tr><td> &gt; 14 days (<i>N</i> = 16)</td><td>8 (10)</td><td>8 (10)</td></tr></table>
51d860f4bd1a7c7ce01b0fba1fed7b316e7686d18b1bebef3290c8c69dd8a487.png
simple
<table><tr><td>Characteristics</td><td>Placebo (n = 59)</td><td>NAC (n = 55)</td></tr><tr><td>Age (years)</td><td>78.2 &#177;11.8</td><td>78.1 &#177; 12.0</td></tr><tr><td>Sex (M/F)</td><td>29/30</td><td>28/27</td></tr><tr><td>BMI (kg/m2)</td><td>24.4 &#177; 4.6</td><td>25.0 &#177; 4.8</td></tr><tr><td>Diabetes</td><td>11 (19%)</td><td>15 (27%)</td></tr><tr><td>Blood pressure (mmHg)</td><td> </td><td> </td></tr><tr><td>Diastolic</td><td>69.1 &#177; 11.7</td><td>67.0 &#177; 17.2</td></tr><tr><td>Systolic</td><td>129.5 &#177; 20.8</td><td>132.9 &#177; 22.5</td></tr><tr><td>Contrast medium (mL)</td><td>117.7 &#177; 3.2</td><td>117.4 &#177; 1.8</td></tr><tr><td>Creatinine (&#956;mol/L)</td><td>133.5 &#177; 34.8</td><td>132.4 &#177; 34.8</td></tr><tr><td>Cystatin C (mg/L)</td><td>1.9 &#177; 0.5</td><td>1.9 &#177; 0.6</td></tr><tr><td>eGFR (MDRD) (ml/min/1.73)</td><td>41.7 &#177; 1.2</td><td>42.7 &#177; 1.2</td></tr><tr><td>Antibiotics</td><td>16 (27%)</td><td>16 (29%)</td></tr><tr><td>Angiotensin-converting enzyme inhibitor (ACE-1 inhibitor)</td><td>28 (48%)</td><td>25 (45%)</td></tr><tr><td>Non-steroidal antiinflammatory drugs (NSAIDS)</td><td>1 (2%)</td><td>5 (9%)</td></tr><tr><td>Diuretics</td><td>27 (46%)</td><td>25 (45%)</td></tr></table>
e73773b7f9b2364888d9c8b9042621b836929ee503cd23eff8f9227df4a12374.png
simple
<table><tr><td>Sample type</td><td>Herd A</td><td>Herd B</td></tr><tr><td>Peat</td><td>na</td><td>20</td></tr><tr><td>Water</td><td>1</td><td>1</td></tr><tr><td>Sawdust</td><td>20</td><td>20</td></tr><tr><td>Faeces from sows</td><td>15</td><td>17</td></tr><tr><td>Faeces at 6 weeks of age</td><td>95</td><td>146</td></tr><tr><td>Faeces at 8 weeks of age</td><td>95</td><td>164</td></tr><tr><td>Mandibular lymph nodes</td><td>95</td><td>123</td></tr><tr><td>Jejunal lymph nodes</td><td>nd</td><td>127</td></tr></table>
2c822ebb751d50cfe5f855d206e0b748ebb8b88afd952ad9072b3f99f2560d13.png
complex
<table><tr><td rowspan="2">Knowledge</td><td colspan="3">Lecture method</td><td colspan="3">Blended method</td></tr><tr><td>Low (&lt;10)</td><td>Average (11-15)</td><td>High (16-20)</td><td>Low (&lt;10)</td><td>Average (11-15)</td><td>High (16-20)</td></tr><tr><td>Pre-test (%)</td><td> 2 (4.5) </td><td> 43 (95.5) </td><td> 0 </td><td> 1 (2.1) </td><td> 47 (97.9) </td><td> 0 </td></tr><tr><td>Post-test (%)</td><td> 0 </td><td> 5 (11.1) </td><td> 40 (88.9) </td><td> 0 </td><td> 4 (8.3) </td><td> 44 (91.7) </td></tr></table>
6fa9efb17f9fe5a678a4ffcc0ba31aa3f93422533feaa08453aef6d80e562a1e.png
simple
<table><tr><td> </td><td>n</td><td>%</td></tr><tr><td>Prevention of postpartum hemorrhage</td><td> </td><td> </td></tr><tr><td>Target population: women giving birth in health facilities</td><td>132</td><td>100.00%</td></tr><tr><td>Oxytocin</td><td>114</td><td>86.36%</td></tr><tr><td>Any uterotonic (including oxytocin)</td><td>115</td><td>87.12%</td></tr><tr><td>Treatment of severe postpartum hemorrhage</td><td> </td><td> </td></tr><tr><td>Target population: women with severe PPH</td><td>84</td><td>100.00%</td></tr><tr><td>Oxytocin</td><td>57</td><td>67.86%</td></tr><tr><td>Ergometrine</td><td>52</td><td>61.90%</td></tr><tr><td>Misoprostol</td><td>35</td><td>41.67%</td></tr><tr><td>Other uterotonics</td><td>3.</td><td>3.57%</td></tr><tr><td>Any of the above uterotonics</td><td>57</td><td>67.86%</td></tr><tr><td>Tranexamic acid</td><td>6</td><td>7.14%</td></tr><tr><td>Removal of retained products</td><td>16</td><td>19.05%</td></tr><tr><td>Balloon or condom tamponade</td><td>1.</td><td>1.19%</td></tr><tr><td>Artery ligation</td><td>4</td><td>4.76%</td></tr><tr><td>Hysterectomy</td><td>50</td><td>59.52%</td></tr><tr><td>Abdominal packing</td><td>4</td><td>4.76%</td></tr><tr><td>Proportion of cases with SMO</td><td>80</td><td>95.24%</td></tr><tr><td>Mortality</td><td>6.</td><td>7.14%</td></tr><tr><td>Anticonvulsants for Eclampsia</td><td> </td><td> </td></tr><tr><td>Target population: women with eclampsia</td><td>43</td><td>100.00%</td></tr><tr><td>Magnesium sulfate</td><td>29</td><td>67.44%</td></tr><tr><td>Other anticonvulsant</td><td>22</td><td>51.16%</td></tr><tr><td>Any anticonvulsant</td><td>40</td><td>93.02%</td></tr><tr><td>Proportion of cases with SMO</td><td>26</td><td>60.47%</td></tr><tr><td>Mortality</td><td>4</td><td>9.30%</td></tr><tr><td>Prevention of caesarean section related infection</td><td> </td><td> </td></tr><tr><td>Target population: women undergoing caesarean section</td><td>107</td><td>100.00%</td></tr><tr><td>Prophylactic antibiotic during caesarean section</td><td>65</td><td>60.75%</td></tr><tr><td>Treatment for sepsis</td><td> </td><td> </td></tr><tr><td>Target population: women with sepsis</td><td>10</td><td>100.00%</td></tr><tr><td>Parenteral therapeutic antibiotics</td><td>10</td><td>100.00%</td></tr><tr><td>Proportion of cases with SMO</td><td>6</td><td>60.00%</td></tr><tr><td>Mortality</td><td>2</td><td>20.00%</td></tr><tr><td>Ruptured uterus</td><td> </td><td> </td></tr><tr><td>Target population: women with ruptured uterus</td><td>29</td><td>100.00%</td></tr><tr><td>Laparotomy</td><td>28</td><td>96.55%</td></tr><tr><td>Laparotomy after 3 hours of hospital stay</td><td>5</td><td>17.24%</td></tr><tr><td>Proportion of cases with SMO</td><td>24</td><td>82.76%</td></tr><tr><td>Mortality</td><td>3</td><td>10.34%</td></tr><tr><td>Preterm birth</td><td> </td><td> </td></tr><tr><td>Target population: women having a preterm delivery after 3 hours of hospital stay</td><td>18</td><td>100.00%</td></tr><tr><td>Corticosteroids for fetal lung maturation</td><td>10</td><td>55.56%</td></tr></table>
9c23fa63bed1387f171c012e361c3aac8fcd0f7aa67dc25798714b0f7871fc79.png
complex
<table><tr><td rowspan="2">Year</td><td colspan="4">Centro Hospitalar Tondela-Viseu</td><td colspan="4">National data (NationalTransplantation Coordination)<sup>(</sup><sup>9</sup><sup>)</sup></td></tr><tr><td>Effective donorsn (%)</td><td>Mean age (years)</td><td>Harvested organsn (%)</td><td>Number of organs per donor</td><td>Effective donorsn</td><td>Mean age (years)</td><td>Harvested organsn</td><td>Number of organs per donor</td></tr><tr><td>2015</td><td>19 (6.0)*</td><td>58.6</td><td>59 (6.6)&#8224;</td><td>3.1</td><td>318</td><td>54.2</td><td>894</td><td>2.8</td></tr><tr><td>2014</td><td>20 (6.9)*</td><td>58.8</td><td>59 (7.1)&#8224;</td><td>3.0</td><td>289</td><td>51.4</td><td>0.83</td><td>2.9</td></tr><tr><td>2013</td><td>12 (4.1)*</td><td>61.2</td><td>31 (3.6)&#8224;</td><td>2.6</td><td>295</td><td>53.7</td><td>859</td><td>2.9</td></tr><tr><td>2012</td><td>12 (4.8)*</td><td>66.2</td><td>30 (4.0)&#8224;</td><td>2.5</td><td>252</td><td>53.3</td><td>749</td><td>3.0</td></tr><tr><td>2011</td><td>16 (5.3)*</td><td>56.6</td><td>46 (5.0)&#8224;</td><td>2.9</td><td>301</td><td>48.7</td><td>928</td><td>3.1</td></tr><tr><td>2010</td><td>5 (1.5)*</td><td>57.4</td><td>11 (1.2)&#8224;</td><td>2.2</td><td>323</td><td>51.3</td><td>0.83</td><td>2.9</td></tr><tr><td>Total</td><td>84 (4.7)*</td><td>59.7</td><td>236 (4.5)&#8224;</td><td>2.8</td><td>1,778</td><td>52.1</td><td>5,187</td><td>2.9</td></tr></table>
38ff30acb16edfe9d75ee0064e1c4f9a925bbdeed51907561c14cc7b734cc3af.png
simple
<table><tr><td>Characteristic</td><td>Control mean (SD) or n (%)</td><td>Intervention mean (SD) or n (%)</td><td>Total mean (SD) or n (%)</td></tr><tr><td>Female</td><td>128 (76 %)</td><td>123 (72 %)</td><td>251 (74 %)</td></tr><tr><td>Male</td><td>41 (24 %)</td><td>48 (38 %)</td><td>89 (26 %)</td></tr><tr><td>Age, years</td><td>81 (8)</td><td>82 (8)</td><td>81 (8)</td></tr><tr><td>Weight loss &#8805; 5 % body weight</td><td>23 (14 %)</td><td>16 (9 %)</td><td>39 (12 %)</td></tr><tr><td>Co-morbidities, number</td><td>6.9 (2.7)</td><td>7.2 (2.9)</td><td>7.1 (2.8)</td></tr><tr><td>History of falls</td><td>52 (31 %)</td><td>48 (28 %)</td><td>100 (29 %)</td></tr><tr><td>Falls as the presenting problem to hospital</td><td>67 (40 %)</td><td>76 (44 %)</td><td>143 (42 %)</td></tr><tr><td>Length of original hospital stay<sup>*</sup></td><td>9 (12)</td><td>11 (15)</td><td>10 (13)</td></tr><tr><td>Living in low-care residential facility</td><td>12 (7 %)</td><td>8 (5 %)</td><td>20 (6 %)</td></tr><tr><td>** MMSE score, mean (SD)/30</td><td>28.0 (1.8)</td><td>27.9 (2.0)</td><td>28.0 (1.9)</td></tr></table>
abb8bfad88c0ba0fdaabcdd54476d06277eaa04a316df1a750fbd01712100a30.png
complex
<table><tr><td>Characteristic</td><td>HSF</td><td>AAF</td><td>BF</td></tr><tr><td>Number</td><td>26</td><td>20</td><td>11</td></tr><tr><td>Sex:</td><td></td><td></td><td></td></tr><tr><td>Female, <i>n</i> (%)</td><td>9 (36) </td><td>11 (52) </td><td>5 (45) </td></tr><tr><td>Male, <i>n</i> (%)</td><td>17 (64)</td><td>9 (48)</td><td>6 (55)</td></tr><tr><td>Mean age at T0 (months)</td><td>8.0 &#177; 0.8</td><td>5.6 &#177; 0.6</td><td rowspan="2">-</td></tr><tr><td>(range)</td><td>2&#8211;17</td><td>2&#8211;13</td></tr><tr><td>Mean age at T1 (months)</td><td>12.0 &#177; 0.8</td><td>9.4 &#177; 0.6</td><td>12.5 &#177; 1.8</td></tr><tr><td>(range)</td><td>6&#8211;21</td><td>6&#8211;17</td><td>8&#8211;25</td></tr><tr><td>Mode of birth:</td><td></td><td></td><td></td></tr><tr><td>Cesarean, <i>n</i> (%)</td><td>23 (89) **</td><td>19 (97) **</td><td>3 (27)</td></tr><tr><td>Vaginal, <i>n</i> (%)</td><td>3 (11) **</td><td>1 (3) **</td><td>8 (73)</td></tr><tr><td>Birth weight (g)</td><td>3122 &#177; 56</td><td>3115 &#177; 41</td><td>3158 &#177; 88</td></tr><tr><td>Length at birth (cm)</td><td>47.9 &#177; 0.4</td><td>47.9 &#177; 0.9</td><td>47.8 &#177; 0.6</td></tr><tr><td>Exclusive breastfeeding (months)</td><td>2.7 &#177; 0.5 *</td><td>2.4 &#177; 0.4 *</td><td>4.9 &#177; 0.3</td></tr><tr><td>Maternal age (years)</td><td>29.3 &#177; 1.5</td><td>30.5 &#177; 1.7</td><td>26.3 &#177; 0.9</td></tr><tr><td>Maternal education:</td><td></td><td></td><td></td></tr><tr><td>High school, <i>n</i> (%)</td><td>8 (30) **</td><td>8 (40) **</td><td>100 (11)</td></tr><tr><td>College, <i>n</i> (%)</td><td>19 (70) **</td><td>12 (60) **</td><td>0 (0)</td></tr></table>
fdf68472f01bf39505edb191931d0a845823c8e749a0fb9eacdd471ddae5be1b.png
complex
<table><tr><td></td><td colspan="3">Sheep</td><td colspan="2">Pig</td></tr><tr><td>thickness</td><td>10 mm</td><td>6 mm</td><td>5 mm</td><td>7.5 mm</td><td>5 mm</td></tr><tr><td><i>n </i>=</td><td>35</td><td>12</td><td>121</td><td>38</td><td>17</td></tr><tr><td>V<sub>total </sub>(ml)</td><td>16.0 (-60.7 to 92.8)</td><td>25.1 (48.0 to 98.2)</td><td>18.4 (-57.5 to 94.4)</td><td>3.0 (-57.0 to 63.0)</td><td>9.6 (-52.2 to 71.4)</td></tr><tr><td>V<sub>non </sub>(%)</td><td>-0.1 (-0.9 to 0.8)</td><td>-0.1 (-0.4 to 0.3)</td><td>0.0 (-0.4 to 0.4)</td><td>0.0 (-1.2 to 1.2)</td><td>0.0 (-0.4 to 0.5)</td></tr><tr><td>V<sub>poor </sub>(%)</td><td>-0.5 (-2.6 to 1.6)</td><td>-0.2 (-0.8 to 0.3)</td><td>-0.1 (-0.9 to 0.7)</td><td>0.2 (-1.6 to 2.0)</td><td>-0.2 (-1.5 to 1.2)</td></tr><tr><td>V<sub>normal </sub>(%)</td><td>0.6 (-1.8 to 3.0)</td><td>0.3 (-0.4 to 1.0)</td><td>0.1 (-0.9 to 1.1)</td><td>-0.2 (2.0 to 1.7)</td><td>-0.2 (1.2 to 1.5)</td></tr><tr><td>V<sub>hyper </sub>(%)</td><td>0.0 (-0.2 to 0.3)</td><td>0.0 (-0.1 to 0.1)</td><td>0.0 (-0.6 to 0.6)</td><td>0.0 (-0.1 to 0.1)</td><td>-0.1 (-0.7 to 0.6)</td></tr><tr><td>M<sub>total </sub>(g)</td><td>3.9 (-23.4 to 31.2)</td><td>4.7 (-19.3 to 28.8)</td><td>4.2 (-21.8 to 30.3)</td><td>1.9 (-32.7 to 36.5)</td><td>1.0 (-34.4 to 36.5)</td></tr><tr><td>M<sub>non </sub>(%)</td><td>-0.1 (-1.5 to 1.4)</td><td>-0.2 (1.1 to 0.7)</td><td>0.1 (1.0 to 1.1)</td><td>-0.1 (-1.3 to 1.2)</td><td>0.1 (-1.2 to 1.4)</td></tr><tr><td>M<sub>poor </sub>(%)</td><td>-0.5 (-2.5 to 1.6)</td><td>-0.4 (-1.4 to 0.6)</td><td>0.1 (-1.5 to 1.2)</td><td>0.2 (-1.7 to 2.2)</td><td>-0.1 (-1.8 to 1.7)</td></tr><tr><td>M<sub>normal </sub>(%)</td><td>0.5 (-1.5 to 2.5)</td><td>-0.6 (-0.8 to 1.9)</td><td>0.1 (-1.5 to 1.7)</td><td>-0.2 (-2.0 to 1.7)</td><td>0.0 (-1.6 to 1.5)</td></tr><tr><td>M<sub>hyper </sub>(%)</td><td>0.0 (-0.1 to 0.1)</td><td>0.0 (0.0 to 0.0)</td><td>0.0 (-0.2 to 0.2)</td><td>0.0 (-0.1 to 0.1)</td><td>0.0 (-0.3 to 0.3)</td></tr><tr><td>V<sub>gas </sub>(ml)</td><td>12.1 (-42.8 to 67.0)</td><td>20.4 (-32.6 to 73.4)</td><td>14.2 (-46.3 to 74.7)</td><td>1.2 (-37.3 to 39.6)</td><td>8.5 (-30.2 to 47.2)</td></tr></table>
7326d5e36104700226b26dbb9584edecca7c700b74c7b0e57d0caf2cbeeada0d.png
complex
<table><tr><td rowspan="2">Variables</td><td colspan="3"><i>B. tabaci</i> B (<i>p</i> Value) <sup>1</sup></td><td colspan="3"><i>B. tabaci</i> Q (<i>p</i> Value)</td></tr><tr><td>Sex</td><td>Virus</td><td>Sex * Virus</td><td>Sex</td><td>Virus</td><td>Sex * Virus</td></tr><tr><td><i>Non-phloem variables</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>A, duration of 1st probe (min)</td><td>0.522</td><td>0.776</td><td>0.511</td><td>0.447</td><td>0.153</td><td>0.111</td></tr><tr><td>B, total number of C <sup>3</sup> (#)</td><td>0.267</td><td>0.057</td><td>0.533</td><td>0.730</td><td>0.373</td><td>0.237</td></tr><tr><td>C, total duration of C (min)</td><td>0.237</td><td>0.764</td><td>0.262</td><td>0.024</td><td>0.127</td><td>0.983</td></tr><tr><td>D, total duration of np (min)</td><td>0.016</td><td>0.591</td><td>0.006</td><td>0.003</td><td>0.166</td><td>0.111</td></tr><tr><td>E, total number of pd (#)</td><td>0.024</td><td>&lt;0.001</td><td>0.004</td><td>0.45</td><td>0.043</td><td>0.802</td></tr><tr><td>F, time to 1st E from 1st probe (min)</td><td>0.550</td><td>0.014</td><td>0.036</td><td>0.085</td><td>&lt;0.001</td><td>0.906</td></tr><tr><td>G, total number of probes before 1st E (#)</td><td>0.747</td><td>0.060</td><td>0.580</td><td>0.160</td><td>0.082</td><td>0.396</td></tr><tr><td>H, Time to 1st E (min)</td><td>0.453</td><td>0.005</td><td>0.041</td><td>0.202</td><td>&lt;0.001</td><td>0.657</td></tr><tr><td><i>Phloem variables</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>I, total duration of 1st E1 (min)</td><td>0.721</td><td>0.558</td><td>0.135</td><td>0.978</td><td>0.347</td><td>0.580</td></tr><tr><td>J, total number of E1 (#)</td><td>0.558</td><td>0.110</td><td>0.335</td><td>0.006</td><td>0.001</td><td>0.084</td></tr><tr><td>K, total duration of E1 (min)</td><td>0.950</td><td>0.762</td><td>0.488</td><td>0.484</td><td>0.001</td><td>0.146</td></tr><tr><td>L, total number of E2 (#)</td><td>0.361</td><td>0.026</td><td>0.246</td><td>0.019</td><td>&lt;0.001</td><td>0.006</td></tr><tr><td>M, total duration of E2 (min)</td><td>0.006</td><td>0.061</td><td>0.005</td><td>0.989</td><td>&lt;0.001</td><td>0.003</td></tr><tr><td>N, total number of E1 after 1st E2 (#)</td><td>0.655</td><td>0.049</td><td>0.279</td><td>0.031</td><td>0.001</td><td>0.094</td></tr><tr><td>O, total duration of E1 after 1st E2 (min)</td><td>0.493</td><td>0.575</td><td>0.351</td><td>0.116</td><td>0.007</td><td>0.049</td></tr><tr><td>P, percentage of E (%) <sup>2</sup></td><td>0.235</td><td>0.302</td><td>0.319</td><td>0.189</td><td>&lt;0.001</td><td>0.231</td></tr></table>
18c83697a687a89408fde483a65ab11f92d49b0cb2becb66d5dabcfa5fd398b5.png
simple
<table><tr><td>Body Point</td><td>Body Side</td><td>Localization</td></tr><tr><td>Foot</td><td>bilaterally</td><td>Basis Metatarsales V</td></tr><tr><td>Ankle</td><td>bilaterally</td><td>Malleolus lateralis</td></tr><tr><td>Knee</td><td>bilaterally</td><td>Epicondylus lateralis femoris</td></tr><tr><td>Hip</td><td>bilaterally</td><td>Trochanter major</td></tr><tr><td>Elbow</td><td>bilaterally</td><td>Epicondylus lateralis humeri</td></tr><tr><td>Shoulder</td><td>bilaterally</td><td>Acromio-clavicular join</td></tr><tr><td>Wrist</td><td>bilaterally</td><td>Os capitatum</td></tr></table>
9f23ce028c9ee99884b8ab002ebf2a6aefde8beb8cd817125d459004ad27a984.png
complex
<table><tr><td rowspan="2">Type of surgery</td><td rowspan="2">Number of cases(<i>n</i> = 128)</td><td colspan="2">Surgeons&#8217; experience in years</td></tr><tr><td>&#8804;5(<i>n</i> = 44)</td><td>&gt;5(<i>n</i> = 84)</td></tr><tr><td>Level 1<sup>*</sup></td><td>27 (21.1%)</td><td>11 (25.0%)</td><td>16 (19.0%)</td></tr><tr><td>Level 2<sup>&#8224;</sup></td><td>60 (46.9%)</td><td>20 (45.5%)</td><td>40 (47.6%)</td></tr><tr><td>Level 3<sup>&#8225;</sup></td><td>41 (32.0%)</td><td>13 (29.5%)</td><td>28 (33.3%)</td></tr></table>
778d19ec888a30a808efed7d45f6c4523d161a36b9907a39afffe7152a7ec38f.png
complex
<table><tr><td colspan="9">Patient medication and outcome</td></tr><tr><td>Type</td><td><i>n</i></td><td>LEV</td><td>VPA(&#8722;/+)</td><td>Na<sup>+</sup> channel(&#8722;/+)</td><td>mTOR(&#8722;/+)</td><td>GABAR(&#8722;/+)</td><td>other AEDs(&#8722;/+)</td><td>post OP outcomeWieser (1a/1/2/3/4/5)</td></tr><tr><td>TSC</td><td>8</td><td>1:7</td><td>4:4</td><td>2:6</td><td>6:2</td><td>2:6</td><td>1:7</td><td>3/1/1/2/1/0</td></tr><tr><td>MMCD</td><td>6</td><td>0:6</td><td>0:6</td><td>0:6</td><td>6:0</td><td>2:4</td><td>1.5</td><td>1/1/0/0/1/3</td></tr><tr><td>FCD IIA</td><td>6</td><td>4:2</td><td>5:1</td><td>0:6</td><td>6:0</td><td>5:1</td><td>3:3</td><td>2/1/0/0/1/2</td></tr><tr><td>FCD IIB</td><td>22</td><td>6:13*</td><td>7:12*</td><td>2:17*</td><td>19:0*</td><td>8:11*</td><td>7:12*</td><td>13/4/0/1/0/1*</td></tr><tr><td>Total</td><td>42</td><td>13:28</td><td>16:23</td><td>4:35</td><td>37:2</td><td>17:22</td><td>12:27</td><td>19/8/1/3/3/6</td></tr></table>
b380b4fd6e1effdae7a41774e468ac01008d9a28dd1980f5073bfeb99f02dff8.png
simple
<table><tr><td><i>pilE</i></td><td>No. isolates</td><td>No. countries</td><td>Years</td><td>No. ccs</td><td>No. alleles</td></tr><tr><td>Class I</td><td>219</td><td>5</td><td>1963-2011</td><td>21 + n/a</td><td>219</td></tr><tr><td>Class II</td><td>77</td><td>29</td><td>1937-2011</td><td>6</td><td>15</td></tr></table>
ff6cb5682cbc385d10d2998be82660522623c4ae4b19ea76caa6cb574a8cfa8c.png
simple
<table><tr><td>Characteristic</td><td>Baseline value</td></tr><tr><td>Age (years)</td><td>48.63 (&#177; 13.5)</td></tr><tr><td>Ethnicity</td><td></td></tr><tr><td> White</td><td>125 (46.99%)</td></tr><tr><td> Hispanic</td><td>77 (28.95%)</td></tr><tr><td> African American</td><td>54 (20.3%)</td></tr><tr><td> Other</td><td>10 (3.76%)</td></tr><tr><td>Female sex</td><td>221 (83.08%)</td></tr><tr><td>Current smoker</td><td>49 (18.42%)</td></tr><tr><td>Ever smoker</td><td>134 (50.38%)</td></tr><tr><td>Disease duration (years)<sup>a</sup></td><td>2.53 (&#177; 1.63)</td></tr><tr><td>Limited skin involvement</td><td>110 (41.35%)</td></tr><tr><td>Autoantibodies</td><td></td></tr><tr><td> Antinuclear antibodies</td><td>254 (95.49%)</td></tr><tr><td> Anti-centromere antibodies</td><td>32 (12.03%)</td></tr><tr><td> Anti-topoisomerase antibodies</td><td>49 (18.42%)</td></tr><tr><td> Anti-RNA polymerase III</td><td>61 (22.93%)</td></tr><tr><td> Anti-U1-ribonucleoprotein</td><td>30 (11.28%)</td></tr><tr><td> Anti-Ro</td><td>10 (3.8%)</td></tr><tr><td> Anti-fibrillarin</td><td>28 (10.69%)</td></tr><tr><td>Percentage predicted forced vital capacity</td><td></td></tr><tr><td> &gt; 80%</td><td>132 (58.15%)</td></tr><tr><td> 50 to 80%</td><td>81 (35.68%)</td></tr><tr><td> &lt; 50%</td><td>14 (6.17%)</td></tr></table>
081270f93fa6aa0c6e012080f1449b0ca5f587a36b249189c632c254cd469f27.png
simple
<table><tr><td></td><td>Group 2</td><td>Group 4</td><td>P value</td></tr><tr><td>Number</td><td>59</td><td>154</td><td></td></tr><tr><td>Age</td><td>63 &#177; 5</td><td>58 &#177; 3</td><td>0.08</td></tr><tr><td>Sex (m:f)</td><td>35:24</td><td>87:67</td><td></td></tr><tr><td>Weight</td><td>79 &#177; 7</td><td>76. &#177; 6</td><td>0.16</td></tr><tr><td>Hb</td><td>121 &#177; 3</td><td>120 &#177; 3</td><td>0.57</td></tr><tr><td>PT</td><td>10.8 &#177; 4</td><td>10.7 &#177; 1</td><td>0.56</td></tr><tr><td>INR</td><td>1 &#177; 3</td><td>1 &#177; 3</td><td>0.53</td></tr><tr><td>Creatinine</td><td>140 &#177; 3</td><td>129 &#177; 3</td><td>0.97</td></tr></table>
c7b9ff95b7a930b96416ecbe7c621dd26b4577332d9bf03ec7b9043f02443b5e.png
complex
<table><tr><td></td><td colspan="4">Distal tibia</td><td colspan="4">Talus</td></tr><tr><td></td><td colspan="2">Left</td><td colspan="2">Right</td><td colspan="2">Left</td><td colspan="2">Right</td></tr><tr><td>OARSI</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>0</td><td>9</td><td>11.3</td><td>12</td><td>15.0</td><td>18</td><td>22.5</td><td>12</td><td>15.0</td></tr><tr><td>1</td><td>37</td><td>46.3</td><td>33</td><td>41.3</td><td>35</td><td>43.8</td><td>32</td><td>40.0</td></tr><tr><td>2</td><td>26</td><td>32.5</td><td>26</td><td>32.5</td><td>17</td><td>21.3</td><td>21</td><td>26.3</td></tr><tr><td>3</td><td>5</td><td>6.3</td><td>7</td><td>8.8</td><td>6</td><td>7.5</td><td>11</td><td>13.8</td></tr><tr><td>4</td><td>1</td><td>1.3</td><td>1</td><td>1.3</td><td>3</td><td>3.8</td><td>3</td><td>3.8</td></tr><tr><td>5</td><td>2</td><td>2.5</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>1</td><td>1.3</td></tr><tr><td>6</td><td>0</td><td>0.0</td><td>1</td><td>1.3</td><td>1</td><td>1.3</td><td>0</td><td>0.0</td></tr></table>
85ad099eaec96ec5f04a2e4ec71d34c15573b52598006782200681e9e74429f6.png
simple
<table><tr><td>Characteristic</td><td>n = 432</td><td>(%)</td></tr><tr><td>Age group (years)</td><td></td><td></td></tr><tr><td>6&#8211;9</td><td>93</td><td>21.5</td></tr><tr><td>10&#8211;14</td><td>339</td><td>78.5</td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td>Female</td><td>224</td><td>51.9</td></tr><tr><td>Male</td><td>208</td><td>48.1</td></tr><tr><td>Location of school</td><td></td><td></td></tr><tr><td>Rural</td><td>203</td><td>47.0</td></tr><tr><td>Urban slums</td><td>229</td><td>53.0</td></tr><tr><td>Ownership of school</td><td></td><td></td></tr><tr><td>Public</td><td>217</td><td>50.2</td></tr><tr><td>Private</td><td>215</td><td>49.8</td></tr></table>
79b6e54e29c4a6660bdf0b4e6564469999594ea80dd0309fb44a8ad79c93dcef.png
complex
<table><tr><td rowspan="2">Cardiac enzymes</td><td colspan="3">Case1</td><td colspan="3">Case2</td></tr><tr><td>1st set</td><td>2nd set</td><td>3rd set</td><td>1st set</td><td>2nd set</td><td>3rd set</td></tr><tr><td>CPK (35&#8211;230 IU/L)</td><td>2176</td><td>2174</td><td>4895</td><td>271</td><td>481</td><td>365</td></tr><tr><td>CK-MB (0.0&#8211;5.0 ng/mL)</td><td>55.5</td><td>40</td><td>9.7</td><td>29.4</td><td>56.5</td><td>23.8</td></tr><tr><td>Troponin (0.00&#8211;0.03 ng/mL)</td><td>2.22</td><td>1.3</td><td>0.31</td><td>1.73</td><td>9.57</td><td>6.74</td></tr><tr><td>Myoglobin (0&#8211;450 pg/mL)</td><td>467</td><td>139</td><td>287</td><td>79</td><td>55</td><td>19</td></tr></table>
2e40812f747c4afed4878901c9344857cd9ec5d9634499a59791f2341ef345bc.png
complex
<table><tr><td> </td><td colspan="3">Odds ratio estimates (95% confidence interval)</td></tr><tr><td> </td><td>CRM</td><td>N-CPAP</td><td>MV</td></tr><tr><td>Gest. age, weeks 39&#8211;40&#8211;41</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Gest. age, week 38</td><td>1.5 (0.9&#8211; 2.4)</td><td>2.0 (0.9&#8211;4.5)</td><td>0.96 (0.3&#8211;3.1)</td></tr><tr><td>Gest. age, week 37</td><td>3.3 (2.0&#8211;5.5)</td><td>5.1 (2.3&#8211;11.4)</td><td>3.4 (1.2&#8211;10.0)</td></tr><tr><td>Gest. age, week 36</td><td>9.1 (5.1&#8211;16.2)</td><td>13.3 (5.5&#8211;32.2)</td><td>11.1 (3.2&#8211;38.8)</td></tr><tr><td>Gest. age, week 35</td><td>21.8 (11.5&#8211;41.5)</td><td>34.9 (13.5&#8211;90.0)</td><td>18.0 (4.2&#8211;77.5)</td></tr><tr><td>Gest. age, week 34</td><td>40.8 (19.7 &#8211;84.9)</td><td>55.9 (19.3&#8211;162.0)</td><td>34.4 (6.7&#8211;180.6)</td></tr><tr><td>Spontaneous delivery</td><td>1</td><td>1</td><td>1</td></tr><tr><td>CS without labor</td><td>3.0 (2.1&#8211;4.2)</td><td>3.7 (2.3&#8211;6.0)</td><td>2.9 (1.3&#8211;6.3)</td></tr><tr><td>CS with labor</td><td>2.2 (1.4&#8211;3.4)</td><td>2.5 (1.4&#8211;4.8)</td><td>2.1 (0.8&#8211;5.6)</td></tr><tr><td>Maternal medical disorders no</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Maternal medical disorders yes</td><td>1.3 (0.9&#8211;1.8)</td><td>1.3 (0.7&#8211;1.6)</td><td>1.7 (0.8&#8211;3.4)</td></tr><tr><td>Twins birth no</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Twins birth yes</td><td>0.9 (0.5&#8211;1.4)</td><td>1.0 (0.6&#8211;1.7)</td><td>0.3 (0.1&#8211;1.3)</td></tr><tr><td>Birth weight, g</td><td>1.0 (0.98&#8211;1.1)</td><td>1.0 (0.9&#8211;1.05)</td><td>1.1 (0.98&#8211;1.2)</td></tr><tr><td>Female</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Male</td><td>1.4 (1.1&#8211;1.9)</td><td>1.5 (1.0&#8211;2.3)</td><td>1.8 (0.9&#8211;3.6)</td></tr><tr><td>Malformation no</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Malformation yes</td><td>8.9 (5.3&#8211;15.1)</td><td>2.4 (0.9&#8211;6.2)</td><td>26.0 (12.5&#8211;54.1)</td></tr><tr><td>Small for gestational age no</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Small for gestational age yes</td><td>1.0 (0.6&#8211;1.8)</td><td>0.6 (0.3&#8211;1.3)</td><td>2.6 (0.9&#8211;7.9)</td></tr></table>
4d40ac6f69592a11e17c7309ea6f6e680d0d05d445c5ca0a2898c44990d2f140.png
complex
<table><tr><td></td><td colspan="3">Alternative therapyModerate protein C deficiency24 &#956;g/kg/hr</td><td colspan="3">Standard therapyModerate protein C deficiency24 &#956;g/kg/hr</td></tr><tr><td>Duration of study drug infusion</td><td>Number of patients</td><td>Number of deaths</td><td>Percent deaths</td><td>Number of patients</td><td>Number of deaths</td><td>Percent deaths</td></tr><tr><td>Total</td><td>172</td><td>43</td><td>25.0</td><td>173</td><td>20</td><td>11.6</td></tr><tr><td>&#8805;97 hours*<sup>&#8224;</sup></td><td>71</td><td>17<sup>a</sup></td><td>23.9</td><td>70</td><td>8<sup>b</sup></td><td>11.4</td></tr><tr><td>&lt; 97 hours<sup>&#8224;</sup></td><td>71</td><td>20<sup>c</sup></td><td>28.2</td><td>65</td><td>9<sup>d</sup></td><td>13.8</td></tr><tr><td>Patients with shorter infusions of DAA <sup>&#8225;</sup></td><td>30</td><td>6<sup>e</sup></td><td>20.0</td><td>38</td><td>3<sup>f</sup></td><td>7.9</td></tr></table>
963cb1409b6d7a63636c9658db14a8c509610e351674a19016baedd0af3277cb.png
complex
<table><tr><td rowspan="2">Factor</td><td colspan="2">&#8804; 3visits</td><td colspan="2">&#8805; 4visits</td><td rowspan="2">*Significance level (&#967; <sup>2</sup>; p-value)</td><td rowspan="2"><sup>#</sup>OR (95% CI)</td><td rowspan="2"><sup>&#8224;</sup>OR (95% CI)</td><td rowspan="2">P-value</td></tr><tr><td>% (n)</td><td>95% CI</td><td>% (n)</td><td>95% CI</td></tr><tr><td>Age (years)</td><td> </td><td> </td><td> </td><td> </td><td rowspan="4">7.670; 0.022</td><td> </td><td> </td><td> </td></tr><tr><td>&#8804;20</td><td>40.7 (35)</td><td>30.9 &#8211; 51.3</td><td>25.8 (51)</td><td>20.2 &#8211; 32.3</td><td>2.0 (1.2 &#8211; 3.4)</td><td>2.0 (1.0 &#8211; 4.4)</td><td>0.069</td></tr><tr><td>21-25</td><td>34.9 (30)</td><td>25.7 &#8211; 45.4</td><td>36.4 (72)</td><td>30.0 &#8211; 43.2</td><td>0.9 (0.6 &#8211; 1.2)</td><td>1.5 (0.7&#8211; 3.2)</td><td>0.254</td></tr><tr><td>&gt;25</td><td>24.4 (21)</td><td>16.6 &#8211; 34.5</td><td>37.9 (75)</td><td>31.4 &#8211; 44.8</td><td>REF</td><td> </td><td> </td></tr><tr><td>Parity</td><td> </td><td> </td><td> </td><td> </td><td rowspan="4">0.765;0.682</td><td> </td><td> </td><td> </td></tr><tr><td>Primiparous</td><td>34.1 (30)</td><td>25.0 &#8211; 44.4</td><td>29.2 (58)</td><td>23.3 &#8211; 35.8</td><td>1.3 (0.7 &#8211; 2.2)</td><td>1.2 (0.6 &#8211; 2.6)</td><td>0.671</td></tr><tr><td>Secundiparous</td><td>28.4 (25)</td><td>20.0 &#8211; 38.6</td><td>29.2 (58)</td><td>23.3 &#8211; 35.8</td><td>1.0 (0.6 &#8211; 1.7)</td><td>1.4 (0.7 &#8211; 2.8)</td><td>0.327</td></tr><tr><td>Multiparous</td><td>37.5 (33)</td><td>28.1 &#8211; 47.9</td><td>41.7 (83)</td><td>35.1 &#8211; 48.7</td><td>REF</td><td> </td><td> </td></tr><tr><td>Marital status</td><td> </td><td> </td><td> </td><td> </td><td rowspan="3">7.693; 0.006</td><td> </td><td> </td><td> </td></tr><tr><td>Unmarried</td><td>35.6 (31)</td><td>26.4 &#8211; 46.1</td><td>20.2 (40)</td><td>15.2 &#8211; 26.3</td><td>2.2 (1.3 &#8211; 3.8)</td><td>2.5 (1.3 &#8211; 4.6)</td><td>0.006</td></tr><tr><td>Married</td><td>64.4 (56)</td><td>53.9 &#8211;73.6</td><td>79.8 (158)</td><td>73.7 &#8211; 84.8</td><td>REF</td><td> </td><td> </td></tr><tr><td>Educational level</td><td> </td><td> </td><td> </td><td> </td><td rowspan="6">3.740; 0.291</td><td> </td><td> </td><td> </td></tr><tr><td>None</td><td>3.8 (3)</td><td>1.2 &#8211;10.5</td><td>7.6 (14)</td><td>4.6 &#8211; 12.3</td><td>0.5 (0.1 &#8211; 1.7)</td><td>0.8 (0.1 &#8211; 5.1)</td><td>0.827</td></tr><tr><td>Primary</td><td>70.0 (56)</td><td>59.2 &#8211; 78.9</td><td>58.9 (109)</td><td>51.7 &#8211; 65.8</td><td>1.6 (0.9 &#8211; 2.9)</td><td>1.4 (0.4 &#8211; 5.5)</td><td>0.594</td></tr><tr><td>Secondary</td><td>21.3 (17)</td><td>13.7 &#8211; 31.4</td><td>29.2 (54)</td><td>23.1 &#8211; 36.1</td><td>0.7 (0.4 &#8211; 1.2)</td><td>0.8 (0.2 &#8211; 3.3)</td><td>0.780</td></tr><tr><td>Tertiary</td><td>5.0 (4)</td><td>2.0 &#8211; 12.0</td><td>4.3 (8)</td><td>2.2 &#8211; 8.3</td><td>REF</td><td> </td><td> </td></tr><tr><td>Fever history</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>32.5 (26)</td><td>23.2 &#8211; 43.4</td><td>48.4 (93)</td><td>41.5 &#8211; 55.5</td><td rowspan="2">5.829; 0.016</td><td>0.5 (0.3 &#8211; 0.9)</td><td>0.5 (0.3 &#8211; 0.8)</td><td>0.009</td></tr><tr><td>No</td><td>67.5 (54)</td><td>56.6 &#8211; 76.8</td><td>51.6 (99)</td><td>44.5 &#8211; 58.5</td><td>REF</td><td> </td><td> </td></tr><tr><td>IPTp-SP dosage</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>one</td><td>70.3 (45)</td><td>58.2 &#8211; 80.1</td><td>39.1 (75)</td><td>32.4 &#8211; 46.1</td><td rowspan="2">18.824; 0.001</td><td>3.7 (2.0 &#8211; 6.8)</td><td>NA</td><td> </td></tr><tr><td>Two or more</td><td>29.7 (19)</td><td>19.9 &#8211; 41.8</td><td>60.9 (117)</td><td>53.9 &#8211; 67.6</td><td> </td><td> </td><td> </td></tr></table>
15c431cd6941e86b919ba57bf1dd0396ab6d371674dd9a7acc428dbfc63e983c.png
simple
<table><tr><td>Type</td><td>Description</td><td>Example</td></tr><tr><td>Change in environment</td><td>The Plan structure, that is the totality of means for satisfying basic needs, does not fit to changes in the environment or to a new environment</td><td>An individual with first-episode psychosis is not able to satisfy his need for autonomy within the restricted setting of a secure ward with his usual Plan &#8220;Decide on appointments for yourself,&#8221; due to a predefined weekly schedule</td></tr><tr><td>Loss of individual abilities</td><td>The means for a purpose (e.g., skills) are no longer available</td><td>Neuropsychological deficits accompanying schizophrenia impede studying and block the Plan &#8220;graduate&#8221;</td></tr><tr><td>Rigid Plan structure</td><td>An important Plan has only a single (or too few) means for its realization</td><td>The Plan &#8220;Heighten self-esteem&#8221; is exclusively realized with the means &#8220;Stick to conviction of being loved by Jodie Foster&#8221; (erotomanic delusion)</td></tr><tr><td>Conflicting Plans</td><td>The means of a Plan endangers another important Plan</td><td>The Plan &#8220;Conceal hearing voices&#8221; endangers the Plan &#8220;Seek help when distressed&#8221;</td></tr><tr><td>Dominance of avoidance Plans</td><td>A high number of avoidance Plans reduce the degrees of freedom for realizing approach plans</td><td>The Plans &#8220;Avoid stress&#8221; and &#8220;Avoid a new psychotic episode&#8221; hinder the approach Plan &#8220;Try to make new friends&#8221;</td></tr></table>
afc98bd09ecc40158f23dd5abf43e6e6f5ee785c43c0ce3e5556c6176b01fe18.png
complex
<table><tr><td></td><td colspan="2">Function</td><td colspan="2">Direct interaction</td></tr><tr><td>R2TP complex target</td><td>Target complex</td><td>R2TP complex</td><td>R2TP component</td><td>Target complex component</td></tr><tr><td>Confirmed</td></tr><tr><td>RNA polymerase II</td><td>Transcription</td><td>Assembly</td><td>?</td><td>?</td></tr><tr><td>snoRNPs</td><td>Biogenesis of ribosomes, spliceosomes, and telomerase</td><td></td><td></td><td></td></tr><tr><td>boxC/D snoRNPs</td><td>2<sup>&#8242;</sup>-<i>O</i>-methylation of preRNA</td><td>Assembly</td><td>PIH1D1?</td><td>NOP58?</td></tr><tr><td>H/ACA snoRNPs</td><td>Pseudouridylation of prerRNA</td><td>Assembly</td><td>PIH1D1?</td><td>NAP57?</td></tr><tr><td>SMG1</td><td>Nonsense mediated mRNA decay</td><td>Assembly</td><td>PIH1D1</td><td>TEL2</td></tr><tr><td>mTORC1</td><td>Central regulator of cell metabolism</td><td>Assembly</td><td>PIH1D1</td><td>TEL2</td></tr><tr><td>ATM/ATR/DNA-PK</td><td>Kinases involved in DNA damage signaling</td><td>Possibly assembly</td><td>PIH1D1</td><td>TEL2</td></tr><tr><td>Potential</td></tr><tr><td>ECD/p53</td><td>Transcription factor involved in DNA damage response</td><td>possibly assembly</td><td>PIH1D1</td><td>ECD</td></tr><tr><td>UBR5</td><td>E3 ubiquitin ligase involved in DNA damage signaling</td><td>?</td><td>PIH1D1</td><td>UBR5</td></tr><tr><td>INO80</td><td>Chromatin remodeling complex, involved in repair of DNA double strand breaks</td><td>Possibly loading RUVBL1/2</td><td>?</td><td>?, RUVBL1/2</td></tr><tr><td>TIP 60</td><td>Chromatin remodeling complex, acetyl-transferase activity important for DNA damage response</td><td>Possibly loading RUVBL1/2</td><td>?</td><td>?, RUVBL1/2</td></tr><tr><td>SWI/SCRAP</td><td>Chromatin remodeling complex, DNA damage signaling</td><td>Possibly loading RUVBL1/2</td><td>?</td><td>?, RUVBL1/2</td></tr><tr><td>Fanconi anemia core complex</td><td>Recognition and repair of DNA crosslinks</td><td>Possibly loading RUVBL1/2</td><td>?</td><td>?, RUVBL1/2</td></tr></table>
a5e161edb4ef3827271cd450d5b314a35836090029324d830fe8439634a32e6a.png
complex
<table><tr><td></td><td></td><td colspan="2">Albino</td><td colspan="2">Pigmented</td></tr><tr><td></td><td></td><td>m-dRGCs</td><td>m-oRGCs</td><td>m-dRGCs</td><td>m-oRGCs</td></tr><tr><td>A: Total</td><td>Melanopsin (<i>n</i> = 6/strain)</td><td>54 &#177; 12</td><td>2329 &#177; 198</td><td>212 &#177; 21</td><td>2216 &#177; 154</td></tr><tr><td></td><td>mRGC population (displaced + orthotopic)</td><td colspan="2">2383 &#177; 178</td><td colspan="2">2428 &#177; 172</td></tr><tr><td>B: Ipsilateral</td><td>FG<sup>+</sup> and melanopsin<sup>+</sup> (<i>n</i> = 3&#8211;5/strain)</td><td>0.2 &#177; 0.4</td><td>64 &#177; 14</td><td>12 &#177; 4</td><td>89 &#177; 8</td></tr><tr><td></td><td>Total ipsilateral m-RGCs (displaced + orthotopic)</td><td colspan="2">65 &#177; 14</td><td colspan="2">101 &#177; 8</td></tr></table>
f430134d6be19591532d4be70da30c37f966be067ac0137f6fb4ddb99ef774b0.png
simple
<table><tr><td>Group</td><td>Number of mice</td><td>Wt/Wt(% of total)</td><td>Wt/KO(% of total)</td><td>KO/KO(% of total)</td></tr><tr><td>Fetus<sup>&#8224;</sup></td><td></td><td></td><td></td><td></td></tr><tr><td> Conventional</td><td>28</td><td>7 (25)</td><td>12 (43)</td><td>9 (32)</td></tr><tr><td> Cre-loxP</td><td>14</td><td>2(14)</td><td>8 (57)</td><td>4 (29)</td></tr><tr><td>Adult<sup>&#167;</sup></td><td></td><td></td><td></td><td></td></tr><tr><td> Conventional</td><td>127</td><td>40 (32)</td><td>66 (52)</td><td>21 (16)**</td></tr><tr><td> Cre-loxP</td><td>251</td><td>126 (50)<sup>&#167;&#167;</sup></td><td>97 (39)<sup>&#8225;&#8225;</sup></td><td>28 (11)<sup>&#167;&#167;</sup></td></tr><tr><td>Dead<sup>&#167;</sup></td><td></td><td></td><td></td><td></td></tr><tr><td> Conventional</td><td>14</td><td>0**</td><td>4 (29)<sup>&#8225;&#8225;</sup></td><td>10 (71)<sup>&#167;&#167;</sup></td></tr></table>
c8dda94e71dac34a073ec60ca280db346d0f5d0196123b1916051fdfccbf1dec.png
complex
<table><tr><td rowspan="3" colspan="2"></td><td colspan="3">Intervention received</td></tr><tr><td>A</td><td>B</td><td>C</td></tr><tr><td><i>n</i></td><td><i>n</i></td><td><i>n</i></td></tr><tr><td rowspan="4">Formal responsibility for doing or managing research in CCG?</td><td>Yes, doing and managing</td><td>5</td><td>2</td><td>2</td></tr><tr><td>Yes, managing</td><td>3</td><td>3</td><td>7</td></tr><tr><td>Yes, doing</td><td>1</td><td>2</td><td>0</td></tr><tr><td>Neither</td><td>28</td><td>35</td><td>17</td></tr><tr><td rowspan="4">Highest educational achievement?</td><td>School level</td><td>2</td><td>0</td><td>0</td></tr><tr><td>Undergraduate</td><td>17</td><td>27</td><td>12</td></tr><tr><td>Master&#8217;s degree</td><td>14</td><td>13</td><td>8</td></tr><tr><td>Higher degree</td><td>3</td><td>2</td><td>6</td></tr><tr><td rowspan="2">Clinical qualifications?</td><td>No</td><td>16</td><td>8</td><td>6</td></tr><tr><td>Yes</td><td>21</td><td>34</td><td>20</td></tr><tr><td rowspan="2">Worked as a researcher in an academic context</td><td>No</td><td>34</td><td>42</td><td>24</td></tr><tr><td>Yes</td><td>5</td><td>11</td><td>13</td></tr><tr><td rowspan="2">Commissioned research</td><td>No</td><td>29</td><td>47</td><td>32</td></tr><tr><td>Yes</td><td>10</td><td>6</td><td>5</td></tr><tr><td rowspan="2">Been a co-applicant or advisor on a research project</td><td>No</td><td>30</td><td>44</td><td>30</td></tr><tr><td>Yes</td><td>9</td><td>9</td><td>7</td></tr><tr><td rowspan="2">Been employed as a researcher</td><td>No</td><td>35</td><td>49</td><td>32</td></tr><tr><td>Yes</td><td>4</td><td>4</td><td>5</td></tr></table>
c1271f885164bde2c6486036d5366a4bd4244ee4a76d06dc45b7ab92247cfbae.png
complex
<table><tr><td rowspan="2" colspan="3">Features</td><td colspan="2">Thoughts about using a contraceptive method</td><td rowspan="2">&#967;<sup>2</sup></td><td rowspan="2">p</td></tr><tr><td>Yes</td><td>No</td></tr><tr><td colspan="2">Age</td><td></td><td></td><td></td><td>1.712</td><td>0.310</td></tr><tr><td></td><td colspan="2">17-25</td><td>60 (33%)</td><td>22 (12.1%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">26-34</td><td>65 (35.7%)</td><td>24 (13.2%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">35+</td><td>6 (3.3%)</td><td>5 (2.7%)</td><td></td><td></td></tr><tr><td>Level of education</td><td colspan="2"></td><td></td><td></td><td>2.747</td><td>0.109</td></tr><tr><td></td><td colspan="2">Primary and below</td><td>63 (34.6%)</td><td>24 (13.2%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">Secondary</td><td>30 (16.5%)</td><td>14 (7.7%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">High school/ university </td><td>42 (23.1%)</td><td>9 (4.9%)</td><td></td><td></td></tr><tr><td colspan="3">Husband education level</td><td></td><td></td><td>5.526</td><td>0.457</td></tr><tr><td></td><td colspan="2">Primary and below</td><td>43 (23.6%)</td><td>13 (7.2%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">Secondary</td><td>30 (16.5%)</td><td>17 (9.3%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">High school/ university </td><td>62 (34.1%)</td><td>17 (9.3%)</td><td></td><td>0.097</td></tr><tr><td colspan="3">Duration of marriage</td><td></td><td></td><td>7.897</td><td></td></tr><tr><td></td><td colspan="2">0-5 year</td><td>63 (34.6%)</td><td>31 (17.1%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">6-10 year</td><td>41 (22.5%)</td><td>14 (7.7%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">11 years and over</td><td>28 (15.3%)</td><td>5 (2.8%)</td><td></td><td></td></tr><tr><td>Number of births</td><td colspan="2"></td><td></td><td></td><td>6.306</td><td>0.184</td></tr><tr><td></td><td colspan="2">0</td><td>38 (20.9%)</td><td>19 (10.4%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">1</td><td>54 (29.7%)</td><td>15 (8.2%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">2</td><td>27 (14.8%)</td><td>12 (6.6%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">3+</td><td>16 (8.8%)</td><td>1 (0.6%)</td><td></td><td></td></tr><tr><td colspan="3">Status of contraceptive use before</td><td></td><td></td><td>6.514</td><td>0.004</td></tr><tr><td></td><td colspan="2">Used</td><td>78 (42.9%)</td><td>14 (7.7%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">Not-used</td><td>53 (29.1%)</td><td>37 (20.3%)</td><td></td><td></td></tr><tr><td colspan="3">Receiving contraception counseling</td><td></td><td></td><td>7.984</td><td>0.035</td></tr><tr><td></td><td colspan="2">Yes</td><td>39 (21.4%)</td><td>5 (2.7%)</td><td></td><td></td></tr><tr><td></td><td colspan="2">No</td><td>92 (50.5%)</td><td>46 (25.3%)</td><td></td><td></td></tr></table>
d13f489773c3d792d31fc71792c880819733adf887c4bb2966a4e7515d747601.png
complex
<table><tr><td></td><td colspan="3">All</td><td colspan="3">Male</td><td colspan="3">Female</td></tr><tr><td></td><td>Coefficient (&#946;)</td><td>t-statistic</td><td>P</td><td>Coefficient (&#946;)</td><td>t-statistic</td><td>P</td><td>Coefficient (&#946;)</td><td>t-statistic</td><td>P</td></tr><tr><td>Arm circumference (cm)</td><td>0.222</td><td>2.564</td><td>0.011</td><td>0.200</td><td>2.446</td><td>0.017</td><td>-0.230</td><td>-2.214</td><td>0.029</td></tr><tr><td>Waist circumference (cm)</td><td>0.183</td><td>1.605</td><td>0.110</td><td>-0.227</td><td>-1.656</td><td>0.102</td><td>0.100</td><td>0.876</td><td>0.383</td></tr><tr><td>Hip circumference (cm)</td><td>-0.154</td><td>-1.298</td><td>0.196</td><td>0.627</td><td>4.405</td><td>0.000</td><td>2.451</td><td>2.451</td><td>0.016</td></tr><tr><td>Thigh circumference (cm)</td><td>-0.149</td><td>-1.352</td><td>0.178</td><td>0.056</td><td>0.465</td><td>0.643</td><td>-0.029</td><td>-0.248</td><td>0.805</td></tr><tr><td>Calf circumference (cm)</td><td>0.718</td><td>6.736</td><td>0.000</td><td>0.306</td><td>2.874</td><td>0.005</td><td>0.714</td><td>5.778</td><td>0.000</td></tr><tr><td colspan="10">Multiple linear regression was used for the analysis, adjusted with each other.</td></tr></table>
8e5b9a7490e1e6387f4f89a7807a25dc85316e18a1088259a98e4af886c87d36.png
simple
<table><tr><td>Data Source</td><td>Total N</td><td>Mean # days</td><td>Median # days</td><td>Max # days</td><td><i>P</i>-value for &#967;<sup>2</sup></td></tr><tr><td>Provider</td><td>1878</td><td>10.5</td><td>5</td><td>375</td><td>Reference</td></tr><tr><td>Faxed-LR</td><td>1142</td><td>3.6</td><td>2</td><td>367</td><td>&lt;0.0001</td></tr><tr><td>HIE-ELR</td><td>7393</td><td>2.0</td><td>1</td><td>320</td><td>&lt;0.0001</td></tr><tr><td>Any Laboratory<sup>a</sup></td><td>8535</td><td>2.2</td><td>1</td><td>367</td><td>&lt;0.0001</td></tr></table>
012da06a413b9480cc6eccbb2643407f783aa62934b2160b8ac7fa49d56cd05b.png
simple
<table><tr><td></td><td>RF</td><td>MSNODmax</td><td>NAR</td></tr><tr><td>Training</td><td>171</td><td>171</td><td>171</td></tr><tr><td>Evaluation</td><td>16 + 2 parents</td><td>15 + 2 parents</td><td>9 + 2 parents</td></tr></table>
1e3b65c2de097e86c369a60e404d25a00136d041d236b3d5aeed9b43e52fd607.png
complex
<table><tr><td rowspan="2">SNP</td><td rowspan="2">Gene</td><td rowspan="2">Alleles*</td><td rowspan="2">PV MAF (n=38)</td><td rowspan="2">ET MAF (n=74<sup>&#8224;</sup>)</td><td rowspan="2">MF MAF (n=9)</td><td colspan="2">PV vs. ET</td><td colspan="2">PV vs. MF</td><td colspan="2">ET vs. MF</td><td>PV vs. ET vs. MF</td></tr><tr><td><i>P</i> value</td><td>OR (95% CI)</td><td><i>P</i> value</td><td>OR (95% CI)</td><td><i>P</i> value</td><td>OR (95% CI)</td><td><i>P</i> value</td></tr><tr><td>rs12343867</td><td><i>JAK2</i> 46/1</td><td>C/T</td><td>0.72</td><td>0.45</td><td>0.50</td><td>&lt;0.001</td><td>3.18 (1.75-5.80)</td><td>0.067</td><td>2.62 (0.91-7.50)</td><td>0.696</td><td>0.82 (0.31-2.19)</td><td>&lt;0.001</td></tr><tr><td>rs12339666</td><td><i>JAK2</i> intron 8</td><td>T/G</td><td>0.76</td><td>0.46</td><td>0.50</td><td>1.437 &#215; 10<sup>-5</sup></td><td>3.79 (2.04-7.05)</td><td>0.027</td><td>3.22 (1.11-9.34)</td><td>0.745</td><td>0.85 (0.32-2.26)</td><td>7.334 &#215; 10<sup>-5</sup></td></tr><tr><td>rs2201862</td><td>-<i>MECOM</i></td><td>T/C</td><td>0.14</td><td>0.22</td><td>0.33</td><td>0.206</td><td>0.62 (0.29-1.31)</td><td>0.087</td><td>0.34 (0.11-1.09)</td><td>0.250</td><td>0.55 (0.19-1.58)</td><td>0.161</td></tr><tr><td>rs9376092</td><td><i>HBS1L</i>-<i>MYB</i></td><td>A/C</td><td>0.22</td><td>0.31</td><td>0.22</td><td>0.170</td><td>0.64 (0.34-1.21)</td><td>1.000</td><td>1.01 (0.29-3.47)</td><td>0.439</td><td>1.58 (0.49-5.06)</td><td>0.363</td></tr><tr><td>rs2736100</td><td><i>TERT</i></td><td>C/A</td><td>0.59</td><td>0.56</td><td>0.44</td><td>0.654</td><td>1.14 (0.65-1.99)</td><td>0.256</td><td>1.81 (0.64-5.11)</td><td>0.349</td><td>1.60 (0.60-4.27)</td><td>0.524</td></tr></table>
93ff82a2c21b319ade294c48f637fe6f0e9aceffaa00728d49da6affa0499640.png
simple
<table><tr><td></td><td>MZ</td><td>DZ</td></tr><tr><td>Age (years)</td><td>22.9 &#177; 2.8</td><td>23.7 &#177; 3.7</td></tr><tr><td>Weight(kg)</td><td>56.3 &#177; 6.5</td><td>59.2 &#177; 10.3</td></tr><tr><td>Height (cm)</td><td>165.5 &#177; 4.8</td><td>167.1 &#177; 6.1</td></tr><tr><td>Instrument playing (h/week)</td><td>1.0 &#177; 0.5</td><td>1.5 &#177; 0.2</td></tr><tr><td>Keyboard writing (h/week)</td><td>3.9 &#177; 1.0</td><td>4.1 &#177; 2.3</td></tr><tr><td>Oldfield handedness score</td><td>0.9 &#177; 0.0</td><td>0.8 &#177; 0.0</td></tr><tr><td>Physical activity score</td><td>8.5 &#177; 2.1</td><td>8.3 &#177; 2.9</td></tr></table>
d47daa735bbef4fcff8f96d62381bf75e2643f3ca56c81c1d8aaea26a57334d8.png
complex
<table><tr><td></td><td colspan="2">One-year survival</td><td><i>t</i></td><td><i>P</i> value</td></tr><tr><td></td><td>Alive (<i>n</i> = 135)</td><td>Dead (<i>n</i> = 59)</td><td></td><td></td></tr><tr><td></td><td>mean &#177; SD</td><td>mean &#177; SD</td><td></td><td></td></tr><tr><td>Child score</td><td>7.54 &#177; 1.79</td><td>10.17 &#177; 2.28</td><td>7.85</td><td>&lt; 0.001</td></tr><tr><td>MELD score</td><td>10.42 &#177; 5.44</td><td>16.42 &#177; 8.40</td><td>5.05</td><td>&lt; 0.001</td></tr><tr><td>Clichy PI</td><td>4.64 &#177; 0.94</td><td>5.89 &#177; 1.09</td><td>8.12</td><td>&lt; 0.001</td></tr><tr><td>New clichy PI</td><td>3.24 &#177; 1.18</td><td>4.82 &#177; 1.37</td><td>8.11</td><td>&lt; 0.001</td></tr><tr><td>Rotterdam index</td><td>1.78 &#177; 0.88</td><td>3.41 &#177; 2.15</td><td>5.64</td><td>&lt; 0.001</td></tr><tr><td>BCS-TIPS score1</td><td>3.61 &#177; 0.83</td><td>4.33 &#177; 0.97</td><td>2.99</td><td>0.003</td></tr></table>
aa6c97cbc18df4b26b5f3faef0112852f18929d8ec974b70d25f736887096522.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Chronic lead-exposed group <i>n</i> = 52</td><td colspan="3">Control group <i>n</i> = 22</td></tr><tr><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td><i>p</i></td></tr><tr><td>Age (years)</td><td>39</td><td>8</td><td>41</td><td>8</td><td>0.224</td></tr><tr><td>Years of work</td><td>13</td><td>10</td><td>17</td><td>9</td><td>0.128</td></tr><tr><td>Height (cm)</td><td>177</td><td>5.58</td><td>179</td><td>8.03</td><td>0.112</td></tr><tr><td>Weight (kg)</td><td>84.2</td><td>14.1</td><td>88.9</td><td>12.2</td><td>0.176</td></tr><tr><td>Smokers (%)</td><td>37 %</td><td>&#8211;</td><td>32 %</td><td>&#8211;</td><td>0.702*</td></tr><tr><td>PbB (&#956;g/dl)</td><td>36.6</td><td>8.60</td><td>2.22</td><td>1.42</td><td>&lt;0.001</td></tr><tr><td>ZPP (&#956;g/g Hb)</td><td>4.24</td><td>1.82</td><td>2.38</td><td>0.61</td><td>&lt;0.001</td></tr></table>
dc958316ef08ca61d2d47b70b9fbd00f8a9fe2abcff04c61a3de692d19895754.png
simple
<table><tr><td>Gene</td><td>Nb. Seq.</td><td>Nb. SiLiXfamilies</td><td>Nb. Seq. 1<i><sup>st </sup></i>fam. (%)</td><td>Nb. Seq. 2<i><sup>nd </sup></i>fam. (%)</td><td>Nb. Seq. 3<i><sup>rd </sup></i>fam. (%)</td><td>Nb. Singletons (%)</td></tr><tr><td>ATP8</td><td>1815</td><td>26</td><td>959 (52.8)</td><td>294 (16.2)</td><td>144 (7.9)</td><td>258 (14.2)</td></tr><tr><td>ATP6</td><td>1821</td><td>2</td><td>1814 (99.6)</td><td>2 (0.1)</td><td>-</td><td>5 (0.3)</td></tr><tr><td>COX1</td><td>1821</td><td>1</td><td>1820 (99.9)</td><td>-</td><td>-</td><td>1 (0.1)</td></tr><tr><td>COX2</td><td>1821</td><td>1</td><td>1818 (99.8)</td><td>-</td><td>-</td><td>3 (0.2)</td></tr><tr><td>COX3</td><td>1821</td><td>1</td><td>1821 (100)</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CYTB</td><td>1821</td><td>1</td><td>1820 (99.9)</td><td>-</td><td>-</td><td>1 (0.1)</td></tr><tr><td>ND1</td><td>1821</td><td>1</td><td>1821 (100)</td><td>-</td><td>-</td><td>-</td></tr><tr><td>ND2</td><td>1821</td><td>11</td><td>1714 (94.1)</td><td>53 (2.9)</td><td>3 (0.2)</td><td>34 (1.9)</td></tr><tr><td>ND3</td><td>1821</td><td>2</td><td>1813 (99.6)</td><td>2 (0.1)</td><td>-</td><td>6 (0.3)</td></tr><tr><td>ND4</td><td>1821</td><td>2</td><td>1812 (99.5)</td><td>2 (0.1)</td><td>-</td><td>7 (0.4)</td></tr><tr><td>ND4L</td><td>1821</td><td>7</td><td>1758 (96.5)</td><td>4 (0.2)</td><td>3 (0.2)</td><td>47 (2.6)</td></tr><tr><td>ND5</td><td>1821</td><td>2</td><td>1815 (99.7)</td><td>2 (0.1)</td><td>-</td><td>4 (0.2)</td></tr><tr><td>ND6</td><td>1821</td><td>16</td><td>1366 (75.0)</td><td>313 (17.2)</td><td>55 (3.0)</td><td>45 (2.5)</td></tr></table>
31becdb96bc04f0a772bfebd5e307c26ab0cba1c3ff1c187b772eba71455f090.png
complex
<table><tr><td>time</td><td><i>mTERF</i></td><td><i>LSP1</i></td><td colspan="3">ND1</td><td colspan="3">COX2</td><td colspan="3">ATP6/8</td><td colspan="3">ND4</td><td colspan="3">ND6</td><td colspan="3">CYTB</td></tr><tr><td> </td><td>Frog1</td><td> </td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td></tr><tr><td>Egg</td><td>0.0157</td><td>0.0034</td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td></tr><tr><td>+5 h</td><td>0.0448</td><td>0.0089</td><td>1.0</td><td>1.1</td><td>&#8722;12</td><td>0.9</td><td>0.8</td><td>+14</td><td>0.9</td><td>0.9</td><td>+1</td><td>0.9</td><td>2.1</td><td>&#8722;59</td><td>2.4</td><td>2.4</td><td>&#8722;1</td><td>0.8</td><td>0.7</td><td>+19</td></tr><tr><td>+10 h</td><td>0.0872</td><td>0.0157</td><td>1.2</td><td>1.3</td><td>&#8722;5</td><td>1.1</td><td>1.1</td><td>+1</td><td>1.1</td><td>0.7</td><td>+56</td><td>1.0</td><td>2.3</td><td>&#8722;57</td><td>4.1</td><td>4.0</td><td>+2</td><td>0.9</td><td>0.6</td><td>+50</td></tr><tr><td>+14 h</td><td>0.0793</td><td>0.0173</td><td>1.7</td><td>2.3</td><td>&#8722;26</td><td>1.6</td><td>1.6</td><td>&#8722;3</td><td>1.5</td><td>1.3</td><td>+18</td><td>1.4</td><td>3.0</td><td>&#8722;53</td><td>4.4</td><td>4.4</td><td>0</td><td>1.2</td><td>1.2</td><td>+3</td></tr><tr><td>+16 h</td><td>0.0960</td><td>0.0209</td><td>2.0</td><td>2.9</td><td>&#8722;31</td><td>1.7</td><td>1.4</td><td>+24</td><td>1.7</td><td>1.3</td><td>+31</td><td>1.5</td><td>4.3</td><td>&#8722;65</td><td>5.6</td><td>5.8</td><td>&#8722;4</td><td>1.3</td><td>1.3</td><td>+2</td></tr><tr><td>+18 h</td><td>0.0542</td><td>0.0157</td><td>2.1</td><td>3.2</td><td>&#8722;34</td><td>1.9</td><td>1.7</td><td>+14</td><td>1.9</td><td>1.9</td><td>+1</td><td>1.8</td><td>4.5</td><td>&#8722;60</td><td>4.4</td><td>4.2</td><td>+4</td><td>1.6</td><td>1.3</td><td>+25</td></tr><tr><td>+20 h</td><td>0.0655</td><td>0.0157</td><td>1.8</td><td>3.0</td><td>&#8722;41</td><td>1.6</td><td>1.4</td><td>+13</td><td>1.6</td><td>1.8</td><td>&#8722;12</td><td>1.5</td><td>4.6</td><td>&#8722;68</td><td>4.2</td><td>4.2</td><td>0</td><td>1.3</td><td>1.2</td><td>+8</td></tr><tr><td>+23 h</td><td>0.0721</td><td>0.0492</td><td>9.4</td><td>9.7</td><td>&#8722;4</td><td>7.6</td><td>5.1</td><td>+49</td><td>7.4</td><td>6.5</td><td>+14</td><td>6.4</td><td>16.1</td><td>&#8722;60</td><td>12.9</td><td>12.2</td><td>+5</td><td>5.3</td><td>5.2</td><td>+2</td></tr><tr><td>+48 h</td><td>0.0542</td><td>0.0872</td><td>29.3</td><td>26.6</td><td>+10</td><td>26.2</td><td>13.4</td><td>+96</td><td>26.0</td><td>26.1</td><td>0</td><td>23.8</td><td>60.3</td><td>&#8722;61</td><td>18.6</td><td>18.6</td><td>0</td><td>20.2</td><td>23.4</td><td>&#8722;14</td></tr><tr><td>+96 h</td><td>0.0407</td><td>0.0960</td><td>48.1</td><td>48.7</td><td>&#8722;1</td><td>45.3</td><td>20.9</td><td>+117</td><td>45.4</td><td>48.3</td><td>&#8722;6</td><td>43.3</td><td>104.2</td><td>&#8722;58</td><td>16.7</td><td>17.4</td><td>&#8722;4</td><td>38.8</td><td>39.3</td><td>&#8722;1</td></tr><tr><td>time</td><td><i>mTERF</i></td><td><i>LSP1</i></td><td colspan="3">ND1</td><td colspan="3">COX2</td><td colspan="3">ATP6/8</td><td colspan="3">ND4</td><td colspan="3">ND6</td><td colspan="3">CYTB</td></tr><tr><td> </td><td>Frog2</td><td> </td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td></tr><tr><td>Egg</td><td>0.0089</td><td>0.0041</td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td></tr><tr><td>+6 h</td><td>0.0045</td><td>0.0023</td><td>1.2</td><td>1.3</td><td>&#8722;8</td><td>1.2</td><td>1.0</td><td>+22</td><td>1.2</td><td>1.3</td><td>&#8722;5</td><td>1.2</td><td>1.4</td><td>&#8722;12</td><td>0.7</td><td>0.7</td><td>+6</td><td>1.2</td><td>1.2</td><td>+3</td></tr><tr><td>+9 h</td><td>0.0073</td><td>0.0045</td><td>1.3</td><td>1.5</td><td>&#8722;14</td><td>1.3</td><td>1.3</td><td>&#8722;1</td><td>1.3</td><td>1.2</td><td>+8</td><td>1.3</td><td>1.6</td><td>&#8722;19</td><td>1.1</td><td>1.1</td><td>+1</td><td>1.3</td><td>1.3</td><td>&#8722;1</td></tr><tr><td>+20 h</td><td>0.0157</td><td>0.0157</td><td>3.8</td><td>4.6</td><td>&#8722;17</td><td>3.7</td><td>3.7</td><td>+1</td><td>3.7</td><td>3.7</td><td>+1</td><td>3.7</td><td>3.7</td><td>0</td><td>2.8</td><td>2.8</td><td>&#8722;2</td><td>3.6</td><td>4.0</td><td>&#8722;11</td></tr><tr><td>+30 h</td><td>0.0157</td><td>0.0230</td><td>7.2</td><td>7.2</td><td>0</td><td>7.1</td><td>6.8</td><td>+4</td><td>7.1</td><td>8.1</td><td>&#8722;13</td><td>7.0</td><td>6.2</td><td>+14</td><td>3.7</td><td>3.7</td><td>0</td><td>6.8</td><td>8.1</td><td>&#8722;17</td></tr><tr><td>+48 h</td><td>0.0407</td><td>0.1056</td><td>20.5</td><td>19.5</td><td>+5</td><td>19.7</td><td>19.7</td><td>0</td><td>19.6</td><td>28.7</td><td>&#8722;32</td><td>19.1</td><td>17.7</td><td>+8</td><td>8.6</td><td>8.4</td><td>+2</td><td>17.3</td><td>23.1</td><td>&#8722;25</td></tr><tr><td>+7 days</td><td>0.0041</td><td>0.0073</td><td>6.5</td><td>6.1</td><td>+7</td><td>6.6</td><td>8.0</td><td>&#8722;18</td><td>6.6</td><td>8.5</td><td>&#8722;22</td><td>6.7</td><td>4.9</td><td>+36</td><td>2.4</td><td>2.3</td><td>+3</td><td>6.6</td><td>6.6</td><td>+1</td></tr><tr><td>time</td><td><i>mTERF</i></td><td><i>LSP1</i></td><td colspan="3">16 S</td><td colspan="3">ND6</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Frog3</td><td> </td><td>mod</td><td>exp</td><td>dev</td><td>mod</td><td>exp</td><td>dev</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Egg</td><td>0.0960</td><td>0.0026</td><td>1.0</td><td>1.0</td><td> </td><td>1.0</td><td>1.0</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>+5 h</td><td>0.0407</td><td>0.0050</td><td>2.2</td><td>2.2</td><td>+0.9</td><td>2.2</td><td>2.2</td><td>0.0</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>+14 h</td><td>0.0230</td><td>0.0081</td><td>5.0</td><td>5.0</td><td>0.0</td><td>4.5</td><td>4.5</td><td>&#8722;0.2</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>+20 h</td><td>0.0038</td><td>0.0028</td><td>5.9</td><td>6.0</td><td>&#8722;1.3</td><td>4.0</td><td>4.0</td><td>+0.5</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>+28 h</td><td>0.0336</td><td>0.1056</td><td>92.2</td><td>92.0</td><td>+0.2</td><td>25.1</td><td>25.0</td><td>+0.4</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>+48 h</td><td>0.0143</td><td>0.0306</td><td>44.1</td><td>44.0</td><td>+0.2</td><td>15.0</td><td>15.0</td><td>+0.3</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr></table>
e2378a37d2d6ff0da582aa7d5167e814892d0fd5f22273123971125ae4281b2a.png
complex
<table><tr><td>Chromosome Region</td><td colspan="4">Rectal adenoma</td><td colspan="4">Rectal adenocarcinoma</td></tr><tr><td> </td><td>Start</td><td>End</td><td>No. of probes</td><td>No. of cases</td><td>Start</td><td>End</td><td>No. of probes</td><td>No. of cases</td></tr><tr><td>1p36.23-p36.22</td><td> </td><td> </td><td> </td><td> </td><td>7804415</td><td>11633739</td><td>82</td><td>3</td></tr><tr><td>1p36.22-p36.13</td><td> </td><td> </td><td> </td><td> </td><td>12600054</td><td>16167534</td><td>41</td><td>3</td></tr><tr><td>1p36.12-p35.3</td><td> </td><td> </td><td> </td><td> </td><td>21802142</td><td>29525663</td><td>226</td><td>3</td></tr><tr><td>1q21.2-q21.3</td><td>148163183</td><td>149505863</td><td>60</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>1q21.3-q23.1</td><td>151880217</td><td>155031244</td><td>154</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>4q12</td><td>55913547</td><td>57653302</td><td>38</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>5p15.33-p12</td><td>260981</td><td>45865412</td><td>433</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>5q13.2</td><td>68434643</td><td>68900029</td><td>18</td><td>3</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>7p22.2-p22.1</td><td>4298590</td><td>6547570</td><td>42</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>7q11.23</td><td>72003839</td><td>75977276</td><td>77</td><td>3</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>7q22.1</td><td>99538250</td><td>101895994</td><td>79</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>8q22.2-q24.3</td><td>100781187</td><td>143914353</td><td>448</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>8q24.3</td><td>143914353</td><td>146250824</td><td>75</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>9q34.11</td><td>130111425</td><td>132321365</td><td>64</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>10p14-p11.21</td><td> </td><td> </td><td> </td><td> </td><td>11825924</td><td>35645512</td><td>315</td><td>3</td></tr><tr><td>11p15.2-p11.12</td><td>14750051</td><td>50638829</td><td>468</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>11q13.1-q14.1</td><td>63802950</td><td>80046693</td><td>442</td><td>4</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>12q24.23-q24.33</td><td>116956235</td><td>132193660</td><td>257</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>14q12-q21.1</td><td> </td><td> </td><td> </td><td> </td><td>30209271</td><td>38927323</td><td>130</td><td>3</td></tr><tr><td>14q22.1-q24.3</td><td> </td><td> </td><td> </td><td> </td><td>48874529</td><td>77750644</td><td>544</td><td>3</td></tr><tr><td>14q31.3-q32.1</td><td> </td><td> </td><td> </td><td> </td><td>87763614</td><td>93260389</td><td>110</td><td>3</td></tr><tr><td>14q32.2-q32.32</td><td> </td><td> </td><td> </td><td> </td><td>99254905</td><td>102592287</td><td>70</td><td>3</td></tr><tr><td>15q15.1-q21.1</td><td> </td><td> </td><td> </td><td> </td><td>38653893</td><td>42843706</td><td>119</td><td>3</td></tr><tr><td>15q22.31</td><td> </td><td> </td><td> </td><td> </td><td>61519869</td><td>64628895</td><td>74</td><td>3</td></tr><tr><td>15q25.1-q25.2</td><td> </td><td> </td><td> </td><td> </td><td>76206143</td><td>79967204</td><td>77</td><td>3</td></tr><tr><td>17p13.1-p11.2</td><td>84287</td><td>21386319</td><td>606</td><td>2</td><td>8327645</td><td>20974722</td><td>266</td><td>4</td></tr><tr><td>17q25.1</td><td>70528777</td><td>71603516</td><td>61</td><td>3</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>18p11.32-p11.21</td><td>170229</td><td>13875315</td><td>173</td><td>2</td><td>2580000</td><td>13752309</td><td>137</td><td>5</td></tr><tr><td>18q11.1-q11.2</td><td>16904187</td><td>76018409</td><td>684</td><td>2</td><td>16976046</td><td>20313378</td><td>51</td><td>4</td></tr><tr><td>19p13.3-p13.11</td><td>1432408</td><td>19699544</td><td>795</td><td>4</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>19q13.11-q13.43</td><td>37554715</td><td>63672832</td><td>1114</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>20q13.33</td><td>60039825</td><td>62320720</td><td>85</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>22q13.1</td><td>37689058</td><td>37715431</td><td>3</td><td>2</td><td> </td><td> </td><td> </td><td> </td></tr></table>
321f86b2a86499eee94b19b2172026ba1b3e85e20b1caa2c32db25a2d58db5ba.png
complex
<table><tr><td rowspan="2"></td><td>Possible IA</td><td>Probable and proven IA</td></tr><tr><td>n=12</td><td>n=11</td></tr><tr><td>Antifungal treatment-n <sup>a</sup></td><td></td><td></td></tr><tr><td>Liposomal amphotericin B</td><td>6</td><td>3</td></tr><tr><td>Caspofungin</td><td>3</td><td>1</td></tr><tr><td>Voriconazole</td><td>11</td><td>10</td></tr><tr><td>Duration of treatment (days)-Mean (range)</td><td></td><td></td></tr><tr><td>Liposomal amphotericin B</td><td>7 (1;12)</td><td>8 (2;20)</td></tr><tr><td>Caspofungin</td><td>6 (3;9)</td><td>11 (3;25)</td></tr><tr><td>Voriconazole</td><td>100 (2;235)</td><td>130 (42;261)</td></tr><tr><td>Causes of Voriconazole discontinuation-n <sup>b</sup></td><td></td><td></td></tr><tr><td>Complete response</td><td>10</td><td>5</td></tr><tr><td>Failure</td><td>0</td><td>1</td></tr><tr><td>Death</td><td>1</td><td>4</td></tr><tr><td>Clinical Response (days)-Mean (range)</td><td></td><td></td></tr><tr><td>Time to apyrexia</td><td>6 (1;14)</td><td>11 (1;19)</td></tr><tr><td>TDM evaluation-n</td><td>7</td><td>9</td></tr><tr><td>Aggravation</td><td>0</td><td>2</td></tr></table>
1392b903e55a561f3bdb71365d7d500cb31f47cb509c2a0a0ac92ec547d9b76f.png
simple
<table><tr><td> </td><td>Number of instances</td><td>Reasons</td></tr><tr><td>Number of &#8216;potential&#8217; PI instances in the notes (within 500 notes)</td><td>89</td><td>70.9% due to misspellings; 20.9% due to PIs being un-entered in source</td></tr><tr><td>Type of Potential PIs</td><td> </td><td> </td></tr><tr><td>Patient Nickname</td><td>20</td><td>Un-entered PI</td></tr><tr><td>Patient First Name</td><td>18</td><td>Un-entered PI or misspellings</td></tr><tr><td>Old Address Post Code</td><td>14</td><td>Un-entered PI or misspellings</td></tr><tr><td>Patient Date of Birth</td><td>13</td><td>Un-entered PI or misspellings</td></tr><tr><td>Patient Contact Number</td><td>2</td><td>Un-entered PI</td></tr><tr><td>Patient Last Name</td><td>10</td><td>Un-entered PI or misspellings</td></tr><tr><td>Old Address Line 1</td><td>5</td><td>Un-entered PI or misspellings</td></tr><tr><td>Patient Middle Name</td><td>4</td><td>Un-entered PI</td></tr><tr><td>Old Address Line 2</td><td>2</td><td>Un-entered PI or misspellings</td></tr><tr><td>Old Address Line 3</td><td>1</td><td>Un-entered PI or misspellings</td></tr></table>
4c785d4366a3f7210a603b4c6e98d02f25ede87f3aaa183e4622e349ba4a5f4b.png
simple
<table><tr><td>Features</td><td>Clinical data</td><td>Cases (%)</td></tr><tr><td>Age (yrs)</td><td>&lt;60</td><td>32 (29.0%)</td></tr><tr><td> </td><td>&#8805;60</td><td>78 (70.9%)</td></tr><tr><td> </td><td> </td><td> </td></tr><tr><td>Sex</td><td>Male</td><td>70 (63.6%)</td></tr><tr><td> </td><td>Female</td><td>40 (36.3%)</td></tr><tr><td> </td><td> </td><td> </td></tr><tr><td>Child-pugh</td><td>A</td><td>95 (86.3%)</td></tr><tr><td> </td><td>B</td><td>15 (13.6%)</td></tr><tr><td> </td><td> </td><td> </td></tr><tr><td>AFP*(&#956;g/L)</td><td>&lt;400</td><td>80 (72.7%)</td></tr><tr><td> </td><td>&#8805;400</td><td>30 (27.3%)</td></tr><tr><td>Tumour size</td><td>&lt;2 cm</td><td>97 (88.1%)</td></tr><tr><td> </td><td>2 cm &#8804; tumour &lt; 4 cm</td><td>13 (11.8%)</td></tr><tr><td>Number of tumours</td><td>Single</td><td>87 (79.1%)</td></tr><tr><td> </td><td>Multiple</td><td>23 (20.9%)</td></tr><tr><td>HBsAg</td><td>Positive</td><td>93 (84.5%)</td></tr><tr><td> </td><td>Negative</td><td>17 (15.4%)</td></tr><tr><td>BCLC stage**</td><td>0</td><td>86 (78.1%)</td></tr><tr><td> </td><td>A</td><td>19 (17.2%)</td></tr><tr><td> </td><td>B</td><td>5 (4.5%)</td></tr></table>
7c9960c011c317a676ec5cacdaffae4a29c955e37cbf0cd9ac5029a6c54f5679.png
simple
<table><tr><td>Operative data:</td><td></td></tr><tr><td>Operation time min (&#177; SD)</td><td>203.96 (&#177;58.51)</td></tr><tr><td>Cardiopulmonary bypass times min (&#177; SD)</td><td>88.71 (&#177;39.97)</td></tr><tr><td>Clamp times min (&#177; SD)</td><td>45.95 (&#177;22.63)</td></tr><tr><td>Of-pump procedures</td><td>1 (1)</td></tr><tr><td>Venous bypass grafts (exclusivly)</td><td>15 (12)</td></tr><tr><td>Total arterial revascularization</td><td>66 (52)</td></tr><tr><td>Arterial and venous revascularization</td><td>43 (34)</td></tr><tr><td>Number of performed bypass grafts n (&#177; SD)</td><td>2.87 (&#177;0.92)</td></tr><tr><td><i>Concomittant procedures</i></td><td></td></tr><tr><td>Mitral valve repair</td><td>3</td></tr><tr><td>Mitral valve replacement</td><td>3</td></tr><tr><td>Aortic valve replacement</td><td>1</td></tr><tr><td>DOR Plasty</td><td>3</td></tr><tr><td>Carotid TEA</td><td>1</td></tr></table>
7791fc98b99d3e68171a9b462e5aa191e650e8c35fd09adf62e7461437fa1e3b.png
simple
<table><tr><td></td><td>Argentina</td><td>Guatemala</td><td>Kenya</td><td>Zambia</td><td>Belgaum, India</td><td>Nagpur, India</td><td>Pakistan</td></tr><tr><td>Number of live births</td><td>7,888</td><td>26,022</td><td>33,724</td><td>26,272</td><td>77,440</td><td>38,303</td><td>38,890</td></tr><tr><td>Six-week vital status, <i>n</i> (%)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Survived</td><td>7,744 (98.2)</td><td>25,184 (96.8)</td><td>33,239 (98.6)</td><td>25,571 (97.3)</td><td>75,515 (97.5)</td><td>37,218 (97.2)</td><td>37,152 (95.5)</td></tr><tr><td> Died</td><td>96 (1.2)</td><td>662 (2.5)</td><td>427 (1.3)</td><td>463 (1.8)</td><td>1,922 (2.5)</td><td>935 (2.4)</td><td>1,174 (3.0)</td></tr><tr><td> Missing</td><td>48 (0.6)</td><td>176 (0.7)</td><td>58 (0.2)</td><td>238 (0.9)</td><td>3 (0.0)</td><td>150 (0.4)</td><td>564 (1.5)</td></tr><tr><td>Age at death for infants who died</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Median day (p25, p75)</td><td>3 (1, 8)</td><td>5 (2, 16)</td><td>3 (1, 12)</td><td>2 (1, 7)</td><td>3 (1, 7)</td><td>3 (1, 8)</td><td>5 (2, 15)</td></tr></table>
a3c14e1cfaff04293ef2e1f0bacb4b2052e61971a611960f397924f12fdfaab5.png
complex
<table><tr><td>Characteristic</td><td>Participant n (%)</td><td colspan="2">Serum Selenium Mean (SD)</td><td><i>p</i> value<sup>*</sup></td></tr><tr><td colspan="5">Sex</td></tr><tr><td> Male</td><td>158 (54)</td><td>85.3</td><td>(25.6)</td><td rowspan="2">0.94</td></tr><tr><td> Female</td><td>136 (46)</td><td>85.6</td><td>(31.2)</td></tr><tr><td colspan="5">Age</td></tr><tr><td>&lt; 50</td><td>157 (53)</td><td>83.8</td><td>(29.0)</td><td rowspan="2">0.29</td></tr><tr><td>&#8805; 50</td><td>137 (47)</td><td>87.3</td><td>(27.5)</td></tr><tr><td colspan="5">Residence</td></tr><tr><td> Location A</td><td>91 (31)</td><td>70.6</td><td>(19.6)</td><td rowspan="3"><i>p</i> &lt; 0.0001</td></tr><tr><td> Location B</td><td>58 (20)</td><td>118.8</td><td>(25.8)</td></tr><tr><td> Location C</td><td>144 (49)</td><td>81.5</td><td>(22.9)</td></tr><tr><td colspan="5">Education</td></tr><tr><td> Primary or greater</td><td>100 (34)</td><td>84.6</td><td>(25.8)</td><td rowspan="2">0.70</td></tr><tr><td> Less than primary</td><td>194 (66)</td><td>85.9</td><td>(29.5)</td></tr><tr><td colspan="5">Family history of cancer</td></tr><tr><td> Yes</td><td>33 (11)</td><td>89.8</td><td>(30.0)</td><td rowspan="2">0.35</td></tr><tr><td> No</td><td>261 (69)</td><td>84.9</td><td>(28.1)</td></tr><tr><td colspan="5">Family history of esophageal cancer</td></tr><tr><td> Yes</td><td>18 (6)</td><td>84.5</td><td>(27.4)</td><td rowspan="2">0.88</td></tr><tr><td> No</td><td>275 (94)</td><td>85.5</td><td>(28.5)</td></tr><tr><td colspan="5">Tobacco</td></tr><tr><td> Regular Use<sup>a</sup></td><td>56 (19)</td><td>85.8</td><td>(25.7)</td><td rowspan="2">0.91</td></tr><tr><td> No regular use</td><td>238 (81)</td><td>85.4</td><td>(28.9)</td></tr><tr><td colspan="5">Alcohol</td></tr><tr><td> Regular Drinking<sup>b</sup></td><td>92 (31)</td><td>83.0</td><td>(24.4)</td><td rowspan="2">0.31</td></tr><tr><td> No regular drinking</td><td>201 (69)</td><td>86.7</td><td>(30.0)</td></tr><tr><td colspan="5">Esophageal Squamous Dysplasia (ESD)</td></tr><tr><td> Dysplasia</td><td>42 (14)</td><td>94.9</td><td>(29.0)</td><td rowspan="2">0.02</td></tr><tr><td> No Dysplasia</td><td>252 (86)</td><td>83.9</td><td>(28.0)</td></tr></table>
ae19f78b6cd2648589c305affa38d38b77e62b1af6651cc0b2d6f247bd233ac3.png
complex
<table><tr><td rowspan="2" colspan="2"></td><td colspan="2">Predicted</td><td rowspan="2">Percentage Correct (%)</td></tr><tr><td>RRMS</td><td>HC</td></tr><tr><td rowspan="2">Observed</td><td>RRMS</td><td>22</td><td>3</td><td>88.0</td></tr><tr><td>HC</td><td>5</td><td>17</td><td>77.3</td></tr><tr><td colspan="2">Overall percentage</td><td></td><td></td><td>83.0</td></tr></table>
71e17820d5d9a47d77ded5a4d1450154270e39283ccbb92c561934b0623d5a58.png
complex
<table><tr><td>General characteristic</td><td>Control (%)</td><td>Case (%)</td><td><i>&#967;</i><sup>2</sup> value</td><td>OR</td><td>95 % CI</td></tr><tr><td>Number of subjects</td><td>350</td><td>320</td><td></td><td></td><td></td></tr><tr><td colspan="6">Age group:</td></tr><tr><td>&#8804;60 years</td><td>170 (48.6)</td><td>152 (47.5)</td><td>1</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>&gt;60 years</td><td>180 (51.4)</td><td>168 (52.5)</td><td>0.077</td><td>1.04</td><td>0.77&#8211;1.41</td></tr><tr><td colspan="6">Gender</td></tr><tr><td>Female</td><td>153 (43.7)</td><td>129 (40.3)</td><td>1</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Male</td><td>197 (56.3)</td><td>191 (59.7)</td><td>0.794</td><td>1.15</td><td>0.85&#8211;1.56</td></tr><tr><td colspan="6">Family history of tumors:</td></tr><tr><td>No</td><td>328 (93.7)</td><td>267 (83.4)</td><td>1</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td><i>Yes</i></td><td><i>22 (6.30)</i></td><td><i>53 (16.6)</i></td><td><i>17.76</i></td><td><i>2.96</i></td><td><i>1.76&#8211;4.99</i></td></tr><tr><td colspan="6">Smoking history:</td></tr><tr><td>No</td><td>215 (61.4)</td><td>178 (55.6)</td><td>1</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Yes</td><td>135 (38.6)</td><td>142 (44.4)</td><td>2.322</td><td>1.27</td><td>0.93&#8211;1.73</td></tr><tr><td colspan="6">Total smoking amount:</td></tr><tr><td>Never smoking</td><td>215 (61.4)</td><td>178 (55.6)</td><td>1</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Slight smoking</td><td>84 (24.0)</td><td>62 (19.4)</td><td>0.344</td><td>0.89</td><td>0.61&#8211;1.31</td></tr><tr><td><i>Heavy smoking</i></td><td><i>51 (14.6)</i></td><td><i>80 (25.0)</i></td><td><i>9.783</i></td><td><i>1.89</i></td><td><i>1.27&#8211;2.84</i></td></tr><tr><td colspan="6">Alcohol drinking:</td></tr><tr><td>No</td><td>290 (82.9)</td><td>247 (77.2)</td><td>1</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Yes</td><td>60 (17.1)</td><td>73 (22.8)</td><td>3.377</td><td>1.43</td><td>0.97&#8211;2.09</td></tr></table>
ff75e4dd9e3cfa2e034d36bef1434413b1dcc5b580f196ada357f98f0238e3ed.png
complex
<table><tr><td rowspan="2"> </td><td colspan="2">TOR120 (n = 43)</td><td colspan="2">EXE (n = 45)</td></tr><tr><td>Grade1,2</td><td>Grade3,4</td><td>Grade1,2</td><td>Grade3,4</td></tr><tr><td>Nausea</td><td>4*</td><td>0</td><td>1</td><td>0</td></tr><tr><td>Fatigue</td><td>3*</td><td>0</td><td>1</td><td>0</td></tr><tr><td>Hot flush</td><td>3*</td><td>-</td><td>1</td><td>-</td></tr><tr><td>Night sweating</td><td>3*</td><td>-</td><td>0</td><td>-</td></tr><tr><td>Vaginal bleeding, discharge</td><td>2</td><td>-</td><td>0</td><td>-</td></tr><tr><td>Joint pain, disorder</td><td>1</td><td>-</td><td>2</td><td>-</td></tr><tr><td>Liver dysfunction</td><td>1</td><td>0</td><td>1</td><td>0</td></tr><tr><td>Exanthema</td><td>1</td><td>0</td><td>0</td><td>0</td></tr></table>
da3d68f1e974f989a65267a769495baecb3d1a8db2a12ea0d28ba8807a650b92.png
simple
<table><tr><td> </td><td>Normal hearing</td><td>Abnormal hearing</td></tr><tr><td>n</td><td>55</td><td>15</td></tr><tr><td>Mean age (years)</td><td>5.06 (range 3&#8211;9)</td><td>5.81 (range 3&#8211;13)</td></tr><tr><td>Duration of tablet assessment (secs)*</td><td>109&#177;65</td><td>317&#177;113</td></tr><tr><td>Number of objects*</td><td>23.8&#177;9.45</td><td>67.1&#177;19.1</td></tr><tr><td>Reliability (%)</td><td>90.4&#177;22.4</td><td>92.0&#177;10.8</td></tr></table>
f2a602bd37a55b19bb4e3c783daa5e9bfff12cc027a8b8a28460c98997d61adb.png
complex
<table><tr><td rowspan="2"></td><td colspan="4">Quartiles of neck circumference</td><td></td></tr><tr><td>Q1 (low)</td><td>Q2</td><td>Q3</td><td>Q4 (high)</td><td>The overall tendency</td></tr><tr><td colspan="6">AHI &lt; 5<sup>#</sup></td></tr><tr><td> Subjects, n</td><td>805</td><td>655</td><td>491</td><td>283</td><td></td></tr><tr><td> Events, n (%)</td><td>10 (1.2)</td><td>17 (2.6)</td><td>17 (3.5)</td><td>14 (4.9)</td><td></td></tr><tr><td> Univariate Model</td><td>1 (Ref)</td><td>2.120 (0.971&#8211;4.631)</td><td>2.951 (1.351&#8211;6.445)</td><td>4.164 (1.849&#8211;9.374)</td><td>1.117 (1.049&#8211;1.189)</td></tr><tr><td> Multivariate Model 1</td><td>1 (Ref)</td><td>1.622 (0.710&#8211;3.705)</td><td>2.760 (0.977&#8211;7.798)</td><td>5.480 (1.574&#8211;19.075)</td><td>1.141 (1.014&#8211;1.282)</td></tr><tr><td> Multivariate Model 2</td><td>1 (Ref)</td><td>1.629 (0.714&#8211;3.717)</td><td>2.782 (0.992&#8211;7.807)</td><td>5.486 (1.624&#8211;18.527)</td><td>1.139 (1.019&#8211;1.274)</td></tr><tr><td> Multivariate Model 3</td><td>1 (Ref)</td><td>1.914 (0.762&#8211;4.807)</td><td>3.427 (1.806&#8211;10.814)</td><td>5.477 (1.422&#8211;21.090)</td><td>1.134 (1.001&#8211;1.284)</td></tr><tr><td colspan="6">AHI &#8805; 5<sup>*</sup></td></tr><tr><td> Subjects, n</td><td>304</td><td>455</td><td>681</td><td>759</td><td></td></tr><tr><td> Events, n (%)</td><td>8 (2.6)</td><td>18 (4.0)</td><td>34 (5.0)</td><td>26 (3.4)</td><td></td></tr><tr><td> Univariate Model</td><td>1 (Ref)</td><td>1.479 (0.643&#8211;3.402)</td><td>1.886 (0.873&#8211;4.074)</td><td>1.291 (0.584&#8211;2.851)</td><td>1.013 (0.962&#8211;1.068)</td></tr><tr><td> Multivariate Model 1</td><td>1 (Ref)</td><td>1.773 (0.749&#8211;4.194)</td><td>2.115 (0.858&#8211;5.215)</td><td>1.972 (0.663&#8211;5.868)</td><td>1.061 (0.979&#8211;1.150)</td></tr><tr><td> Multivariate Model 2</td><td>1 (Ref)</td><td>1.643 (0.690&#8211;3.914)</td><td>1.891 (0.762&#8211;4.690)</td><td>1.735 (0.586&#8211;5.135)</td><td>1.050 (0.968&#8211;1.139)</td></tr><tr><td> Multivariate Model 3</td><td>1 (Ref)</td><td>1.292 (0.504&#8211;3.309)</td><td>1.538 (0.579&#8211;4.087)</td><td>1.393 (0.472&#8211;4.538)</td><td>1.033 (0.944&#8211;1.130)</td></tr></table>
eb67ded01cb01ebf9ff76ab25b46322b4b84e7fff3618c879b7a42ac76ca661f.png
simple
<table><tr><td>Findings</td><td>Eyes/patients (%)</td></tr><tr><td><i>Anterior segment</i></td><td> </td></tr><tr><td>normal</td><td>90/45(96)</td></tr><tr><td>corneal opacity</td><td>1/1(2)</td></tr><tr><td>bleb</td><td>1/1(2)</td></tr><tr><td><i>Posterior segment</i></td><td> </td></tr><tr><td>normal</td><td>81/38(76)</td></tr><tr><td>tubercles</td><td>5/5(10)</td></tr><tr><td>scars</td><td>3/3(6)</td></tr><tr><td>chorioretinitis</td><td>1/1(2)</td></tr><tr><td>CMV retinitis</td><td>1/1(2)</td></tr><tr><td>HIV retinopathy</td><td>2/1(2)</td></tr><tr><td>Secondary open-angle glaucoma</td><td>1/1(2)</td></tr></table>
40dc3db6e006651aabb05e8c58d9d833312513604baa622355763707c17ed7ae.png
complex
<table><tr><td></td><td colspan="6">False Positive Rate</td></tr><tr><td>Target</td><td colspan="2">Mann-Whitney <i>U</i></td><td colspan="2">Spearman Correlation</td><td colspan="2">Binomial test</td></tr><tr><td></td><td></td><td>GC Corrected</td><td></td><td>GC Corrected</td><td></td><td>GC Corrected</td></tr><tr><td>WNV</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>HCoV-SARS</td><td>7%</td><td>0%</td><td>100%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>EV18</td><td>63%</td><td>15%</td><td>100%</td><td>12%</td><td>14%</td><td>0%</td></tr><tr><td>LASV</td><td>11%</td><td>0%</td><td>100%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>ZEBOV</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>VSV</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>HAdV-4</td><td>100%</td><td>30%</td><td>100%</td><td>5%</td><td>18%</td><td>0%</td></tr><tr><td>FLUA H1N1</td><td>20%</td><td>1%</td><td>100%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>HSV-1</td><td>8%</td><td>0%</td><td>0%</td><td>1%</td><td>2%</td><td>0%</td></tr><tr><td>Negative Control (200 ng HuDNA)</td><td>100%</td><td>0%</td><td>1%</td><td>0%</td><td>1%</td><td>0% &#8224;</td></tr><tr><td>Negative Control (200 ng HuDNA)</td><td>100%</td><td>0%</td><td>100%</td><td>1%</td><td>1%</td><td>0%</td></tr><tr><td>Negative Control (200 ng HuDNA)</td><td>100%</td><td>0%</td><td>100%</td><td>1%</td><td>1%</td><td>0%</td></tr><tr><td>Negative Control (200 ng HuDNA)</td><td>100%</td><td>0%</td><td>100%</td><td>0%</td><td>1%</td><td>0%</td></tr><tr><td>Negative Control (10 ng HuDNA)</td><td>100%</td><td>0%</td><td>88%</td><td>0%</td><td>2%</td><td>0%</td></tr><tr><td>Negative Control</td><td>100%</td><td>0%</td><td>100%</td><td>0%</td><td>0%</td><td>0% &#8224;</td></tr><tr><td>Negative Control</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Negative Control</td><td>4%</td><td>0%</td><td>2%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td>Average</td><td>48%</td><td>3%</td><td>58%</td><td>1%</td><td>2%</td><td>0%</td></tr></table>
23bf27e849acee386452c6e4a4bca36d53fce4d10a10ba2774fa59f97a814569.png
complex
<table><tr><td>1</td><td colspan="2">2</td><td colspan="2">3</td><td>4</td><td>5</td></tr><tr><td>Euglena</td><td>Daisy</td><td>Blackberry</td><td>Parasite(s)</td><td>Sea cucumber</td><td>Fish(es)</td><td>Frog</td></tr><tr><td>Bacterium</td><td>Plant(s)</td><td>Lotus</td><td>Earthworm</td><td>Tick</td><td>Shark</td><td> </td></tr><tr><td>Amoeba</td><td>Tree(s)</td><td>Jasmine</td><td>Spider</td><td>Snail</td><td>Stingray</td><td> </td></tr><tr><td>Mushroom</td><td>Rose</td><td>Mistletoe</td><td>Beetle(s)</td><td>Hydra</td><td> </td><td> </td></tr><tr><td>Algae</td><td>Flower(s)</td><td>Purslane</td><td>Butterfly</td><td>Invertebrate</td><td> </td><td> </td></tr><tr><td>Paramecium</td><td>Cactus</td><td>Daffodil</td><td>Bee</td><td>Jellyfish</td><td> </td><td> </td></tr><tr><td>Monera</td><td>Grass</td><td>Kiwi</td><td>Grasshopper</td><td>Calamari</td><td> </td><td> </td></tr><tr><td>Protists</td><td>Fern</td><td>Snowdrop</td><td>Scorpion</td><td>Mussel</td><td> </td><td> </td></tr><tr><td>Plasmodium</td><td>Tulip</td><td>Willow</td><td>Fly</td><td>Mantis</td><td> </td><td> </td></tr><tr><td>Plankton</td><td>Chrysanthemum</td><td>Geranium</td><td>Ant</td><td>Sponge</td><td> </td><td> </td></tr><tr><td>Planaria</td><td>Sunflower</td><td>Begonia</td><td>Caterpillar</td><td>Cockroach</td><td> </td><td> </td></tr><tr><td> </td><td>Hyacinth</td><td>Violet</td><td>Cancer</td><td>Ladybug</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td>Millipede</td><td>Octopus</td><td> </td><td> </td></tr><tr><td>6</td><td>7</td><td colspan="2">8</td><td>9</td><td colspan="2">10</td></tr><tr><td>Snake</td><td>Bird(s)</td><td>Lion</td><td>Squirrel</td><td>Dog</td><td colspan="2">Human, human names</td></tr><tr><td>Crocodile</td><td>Eagle</td><td>Bear</td><td>Panda</td><td>Cat</td><td> </td><td> </td></tr><tr><td>Lizard</td><td>Bat</td><td>Tiger</td><td>Monk seal</td><td>Mouse</td><td> </td><td> </td></tr><tr><td>Turtle</td><td>Penguin</td><td>Monkey</td><td>Leopard</td><td>Rabbit</td><td> </td><td> </td></tr><tr><td>Reptile</td><td>Parrot</td><td>Giraffe</td><td>Weasel</td><td>Cow</td><td> </td><td> </td></tr><tr><td>Chameleon</td><td>Falcon</td><td>Elephant</td><td>Panther</td><td>Horse</td><td> </td><td> </td></tr><tr><td>Iguana</td><td>Pigeon</td><td>Whale</td><td>Vertebrate</td><td>Donkey</td><td> </td><td> </td></tr><tr><td>Dragon</td><td>Duck</td><td>Wolf</td><td>Tapir</td><td>Sheep</td><td> </td><td> </td></tr><tr><td> </td><td>Cock, Rooster</td><td>Fox</td><td>Gazelle</td><td>Ox</td><td> </td><td> </td></tr><tr><td> </td><td>Chicken, Chick</td><td>Gorilla</td><td>Cougar</td><td>Camel</td><td> </td><td> </td></tr><tr><td> </td><td>Owl</td><td>Dolphin</td><td>Skunk</td><td>Goat</td><td> </td><td> </td></tr><tr><td> </td><td>Partridge</td><td>Kangaroo</td><td>Cheetah</td><td>Mammal(s)</td><td> </td><td> </td></tr><tr><td> </td><td>Sparrow</td><td>Koala</td><td>Rhinoceros</td><td>Calf</td><td> </td><td> </td></tr><tr><td> </td><td>Hawk</td><td>Hippopotamus</td><td>Otter</td><td>Lamb</td><td> </td><td> </td></tr><tr><td> </td><td>Canary</td><td>Zebra</td><td>Anteater</td><td>Buffalo</td><td> </td><td> </td></tr><tr><td> </td><td>Ostrich</td><td>Hedgehog</td><td>Hyena</td><td>Lama</td><td> </td><td> </td></tr><tr><td> </td><td>Vulture</td><td>Animal(s)</td><td>Pork</td><td>Mule</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td>Lynx</td><td>Bull</td><td> </td><td> </td></tr></table>
e63040a5919ef21f3b44b66ac761f22b23b6b9222115d48ef4438763dde969c5.png
complex
<table><tr><td rowspan="2"> </td><td colspan="2">BOLT<sup>a</sup>, sonidegib 200 mg</td><td rowspan="2">ERIVANCE<sup>a</sup>, vismodegib 150 mg (<i>n</i> = 63)</td></tr><tr><td>Prematched (<i>n</i> = 66)</td><td>Postmatched (<i>n</i> = 66)</td></tr><tr><td><i>Matched baseline characteristics</i></td><td> </td><td> </td><td> </td></tr><tr><td> Prior BCC radiotherapy, <i>n</i><sup>b</sup> (%)</td><td>5 (7.6%)</td><td>(20.6%)</td><td>13 (20.6%)</td></tr><tr><td> Prior BCC surgery, <i>n</i><sup>b</sup> (%)</td><td>48 (72.7%)</td><td>(89.0%)</td><td>56 (88.9%)</td></tr><tr><td><i>Unmatched baseline characteristics </i></td><td> </td><td> </td><td> </td></tr><tr><td> Age in years</td><td> </td><td> </td><td> </td></tr><tr><td>Mean</td><td>64.6</td><td>64.6</td><td>61.4</td></tr><tr><td>Median</td><td>67.0</td><td>67.0</td><td>62.0</td></tr><tr><td>Standard deviation</td><td>15.9</td><td>15.5</td><td>16.9</td></tr><tr><td> Age range in years, <i>n</i><sup>b</sup> (%)</td><td> </td><td> </td><td> </td></tr><tr><td>18&#8211;40</td><td>6 (9.1%)</td><td>(8.6%)</td><td>7 (11.1%)</td></tr><tr><td>41&#8211;64</td><td>22 (33.3%)</td><td>(31.6%)</td><td>26 (41.3%)</td></tr><tr><td>&#8805;65</td><td>38 (57.6%)</td><td>(59.8%)</td><td>30 (47.6%)</td></tr><tr><td> Race, <i>n</i><sup>b</sup> (%)</td><td> </td><td> </td><td> </td></tr><tr><td>White</td><td>59 (89.4%)</td><td>(90.8%)</td><td>(100.0%)</td></tr><tr><td>Other</td><td>7 (10.6%)</td><td>(9.2%)</td><td>(0.0%)</td></tr><tr><td> ECOG status, <i>n</i><sup>b,c</sup> (%)</td><td> </td><td> </td><td> </td></tr><tr><td>0</td><td>44 (66.7%)</td><td>(69.3%)</td><td>48 (76.2%)</td></tr><tr><td>1</td><td>16 (24.2%)</td><td>(21.5%)</td><td>13 (20.6%)</td></tr><tr><td>2</td><td>4 (6.1%)</td><td>(6.0%)</td><td>2 (3.2%)</td></tr><tr><td> Sex, <i>n</i><sup>b</sup> (%)</td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>38 (57.6%)</td><td>(60.8%)</td><td>35 (55.6%)</td></tr><tr><td>Female</td><td>28 (42.4%)</td><td>(39.2%)</td><td>28 (44.4%)</td></tr><tr><td> Prior systemic therapy for BCC, <i>n</i><sup>b</sup> (%)</td><td>4 (6.1%)</td><td>(5.4%)</td><td>7 (11.1%)<sup>d</sup></td></tr></table>
d7ac7baba455f45fdf4a9b9c0df0b8fbf480f9726c91e2566df9896060d08fd0.png
simple
<table><tr><td></td><td>Early menopause(&lt; 46 years) (<i>n </i>= 25)<sup>a</sup></td><td>Normal/late menopause(&#8805; 46 years) (<i>n </i>= 102)<sup>a</sup></td></tr><tr><td>Mean age at diagnosis; years (SD)</td><td>65.2 (6.94)</td><td>62.8 (8.48)</td></tr><tr><td>Mean follow-up time; years (SD)</td><td>10.5 (3.0)</td><td>10.1 (3.6)</td></tr><tr><td>&gt; 3 DMARDs used (%)</td><td>5/25 (20.0)</td><td>23/101 (22.8)</td></tr><tr><td>DMARDs in combination (%)</td><td>8/25 (32.0)</td><td>45/101 (44.6)</td></tr><tr><td>Biological treatment ever (%)</td><td>3/25 (12.0)</td><td>33/101 (32.7)</td></tr><tr><td>Documented radiographic erosions (ever) (%)</td><td>14/23 (60.9)</td><td>52/96 (54.2)</td></tr><tr><td>RF positive (%)</td><td>11/25 (44.0)</td><td>78/100 (78.0)</td></tr><tr><td>Mean HAQ at diagnosis (CI)<sup>b</sup></td><td>0.58 (0.22-0.93) (<i>n </i>= 12)</td><td>0.96 (0.79-1.12) (<i>n </i>= 55)</td></tr><tr><td>Mean HAQ 1 year after diagnosis (CI)<sup>b</sup></td><td>0.45 (0.08-0.83) (<i>n </i>= 12)</td><td>0.86 (0.70-1.02) (<i>n </i>= 65)</td></tr><tr><td>Mean HAQ 5 years after diagnosis (CI)<sup>b</sup></td><td>0.88 (0.60-1.15) (<i>n </i>= 19)</td><td>0.90 (0.76-1.05) (<i>n </i>= 68)</td></tr><tr><td>Mean HAQ 10 years after diagnosis (CI)<sup>b</sup></td><td>0.67 (0.34-1.00) (<i>n </i>= 12)</td><td>0.98 (0.82-1.14) (<i>n </i>= 49)</td></tr><tr><td>Cluster distribution (<i>P </i>= 0.005)</td><td></td><td></td></tr><tr><td> Severe RA (%)</td><td>3 (15.8%)</td><td>23 (34.8%)</td></tr><tr><td> Mild/moderate seropos RA (%)</td><td>5 (26.3%)</td><td>30 (45.5%)</td></tr><tr><td> Mild/moderate seroneg RA (%)</td><td>11 (57.9%)</td><td>13 (19.7%)</td></tr></table>
885df2cce644aaaa443dd10c2a3f798bc492190cf169907125cbf71704a0e630.png
complex
<table><tr><td rowspan="2" colspan="2"></td><td colspan="2">Children (<i>N</i> = 4636)</td><td colspan="2">Adults (<i>N</i> = 4738)</td></tr><tr><td>% N <sup>a</sup></td><td>95% CI</td><td>% N <sup>a</sup></td><td>95% CI</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>51</td><td>(49, 53)</td><td>49</td><td>(47, 50)</td></tr><tr><td>Female</td><td>49</td><td>(47, 51)</td><td>51</td><td>(50, 53)</td></tr><tr><td rowspan="5">Age group</td><td>1&#8211;5 years</td><td>27</td><td>(25, 28)</td><td></td><td></td></tr><tr><td>6&#8211;10 years</td><td>27</td><td>(25, 28)</td><td></td><td></td></tr><tr><td>11&#8211;18 years</td><td>47</td><td>(45, 49)</td><td></td><td></td></tr><tr><td>19&#8211;64 years</td><td></td><td></td><td>79</td><td>(77, 80)</td></tr><tr><td>&gt;65 years</td><td></td><td></td><td>21</td><td>(20, 23)</td></tr><tr><td rowspan="3">Occupation <sup>b</sup></td><td>Managerial &amp; professional occupations</td><td>43</td><td>(40, 45)</td><td>44</td><td>(42, 46)</td></tr><tr><td>Intermediate occupations</td><td>20</td><td>(19, 22)</td><td>21</td><td>(19, 22)</td></tr><tr><td>Routine &amp; manual occupations</td><td>37</td><td>(35, 39)</td><td>34</td><td>(32, 36)</td></tr><tr><td rowspan="2">Household income <sup>c</sup> (&#163;)</td><td>&lt;23,000</td><td>57</td><td>(54, 59)</td><td>46</td><td>(44, 48)</td></tr><tr><td>&#8805;23,000</td><td>43</td><td>(41, 46)</td><td>54</td><td>(52, 56)</td></tr><tr><td rowspan="3">Survey year</td><td>2008&#8211;2010</td><td>38</td><td>(34, 42)</td><td>37</td><td>(33, 41)</td></tr><tr><td>2011&#8211;2012</td><td>35</td><td>(32, 39)</td><td>36</td><td>(32, 40)</td></tr><tr><td>2013&#8211;2014</td><td>27</td><td>(24, 31)</td><td>27</td><td>(24, 31)</td></tr><tr><td rowspan="3">BMI <sup>d</sup></td><td>Normal weight</td><td>76</td><td>(74, 77)</td><td>37</td><td>(35, 39)</td></tr><tr><td>Overweight</td><td>17</td><td>(16, 19)</td><td>37</td><td>(35, 39)</td></tr><tr><td>Obese</td><td>7</td><td>(6, 8)</td><td>27</td><td>(25, 29)</td></tr><tr><td rowspan="2">Media time <sup>e</sup></td><td>&#8804;3 h/day</td><td></td><td></td><td>47</td><td>(44, 49)</td></tr><tr><td>&gt;3 h/day</td><td></td><td></td><td>53</td><td>(51, 56)</td></tr><tr><td rowspan="2">Computer time <sup>e</sup></td><td>&#8804;1 h/day</td><td></td><td></td><td>40</td><td>(38, 43)</td></tr><tr><td>&gt;1 h/day</td><td></td><td></td><td>60</td><td>(58, 62)</td></tr><tr><td rowspan="2">MVPA <sup>f</sup></td><td>&#8804;36 min/day</td><td></td><td></td><td>46</td><td>(43, 48)</td></tr><tr><td>&gt;36 min/day</td><td></td><td></td><td>54</td><td>(52, 57)</td></tr><tr><td rowspan="3">Misreporting of energy intake</td><td>Under-reporters</td><td>9</td><td>(8, 10)</td><td>19</td><td>(17, 20)</td></tr><tr><td>Plausible reporters</td><td>79</td><td>(77, 80)</td><td>71</td><td>(70, 73)</td></tr><tr><td>Over reporters</td><td>12</td><td>(11, 13)</td><td>10</td><td>(9, 11)</td></tr></table>
b3915564bbadc7d940d4fa138056e86cab90e58bfd9d4fdffa7b0475f075ca33.png
complex
<table><tr><td rowspan="2">id</td><td>baseMean</td><td>baseMean</td><td>baseMean</td><td>log2Fold</td><td>Padj</td><td>log2Fold</td><td>Padj</td><td rowspan="2">Putative annotation</td></tr><tr><td>(Wild)</td><td>(Cultiviar)</td><td>(Landrace)</td><td>Change(C/W)</td><td>(C/W)</td><td>Change(L/W)</td><td>(L/W)</td></tr><tr><td>Ta7alLoc001275.1</td><td>1093.35</td><td>416.13</td><td>388.49</td><td>&#8722;1.39</td><td>7.96E-03</td><td>&#8722;1.49</td><td>3.19E-03</td><td>4-coumarate:CoA ligase</td></tr><tr><td>Ta1blLoc007155.1</td><td>5137.83</td><td>1403.42</td><td>2048.36</td><td>&#8722;1.87</td><td>1.00E-05</td><td>&#8722;1.33</td><td>6.17E-03</td><td>Cellulose synthase</td></tr><tr><td>Ta5alLoc000723.1</td><td>1933.05</td><td>441.04</td><td>647.98</td><td>&#8722;2.13</td><td>7.97E-07</td><td>&#8722;1.58</td><td>6.55E-04</td><td>Cellulose synthase</td></tr><tr><td>Ta3bLoc028980.1</td><td>4678.25</td><td>1223.81</td><td>1929.83</td><td>&#8722;1.93</td><td>3.84E-04</td><td>&#8722;1.28</td><td>8.50E-02</td><td>Cellulose synthase</td></tr><tr><td>Ta4alLoc006547.1</td><td>177.41</td><td>0.00</td><td>0.00</td><td>-Inf</td><td>2.47E-15</td><td>-Inf</td><td>1.30E-17</td><td>CER1 protein</td></tr><tr><td>Ta4alLoc026069.1</td><td>550.15</td><td>0.00</td><td>0.00</td><td>-Inf</td><td>8.29E-26</td><td>-Inf</td><td>4.65E-29</td><td>CER1 protein</td></tr><tr><td>Ta1alLoc003924.2</td><td>40.98</td><td>1.82</td><td>0.39</td><td>&#8722;4.49</td><td>5.99E-02</td><td>&#8722;6.71</td><td>1.80E-03</td><td>Cinnamoyl CoA reductase</td></tr><tr><td>Ta3bLoc003710.1</td><td>5610.65</td><td>1515.59</td><td>1849.21</td><td>&#8722;1.89</td><td>0.0001</td><td>&#8722;1.60</td><td>0.0016</td><td>Fasciclin-like arabinogalactan protein 7</td></tr><tr><td>Ta3bLoc056384.1</td><td>25.40</td><td>0.00</td><td>0.00</td><td>-Inf</td><td>6.75E-02</td><td>-Inf</td><td>3.53E-02</td><td>Flavonol 4-sulfotransferase</td></tr><tr><td>Ta4alLoc006913.1</td><td>299.00</td><td>4.85</td><td>7.32</td><td>&#8722;5.95</td><td>1.64E-16</td><td>&#8722;5.35</td><td>1.08E-16</td><td>Flavonol 4-sulfotransferase</td></tr><tr><td>Ta5blLoc013288.1</td><td>944.48</td><td>181.67</td><td>269.42</td><td>&#8722;2.38</td><td>1.04E-07</td><td>&#8722;1.81</td><td>1.66E-04</td><td>NAC domain-containing protein 18</td></tr><tr><td>Ta6blLoc001596.1</td><td>1507.23</td><td>377.78</td><td>671.34</td><td>&#8722;2.00</td><td>8.20E-06</td><td>&#8722;1.17</td><td>5.04E-02</td><td>Pectin lyase-like protein</td></tr><tr><td>Ta3bLoc036242.1</td><td>251.80</td><td>34.64</td><td>32.65</td><td>&#8722;2.86</td><td>1.16E-03</td><td>&#8722;2.95</td><td>1.53E-04</td><td>Pectinacetylesterase family protein</td></tr><tr><td>Ta3bLoc019897.1</td><td>219.61</td><td>36.13</td><td>30.72</td><td>&#8722;2.60</td><td>1.40E-02</td><td>&#8722;2.84</td><td>4.83E-03</td><td>Pectinacetylesterase family protein</td></tr><tr><td>Ta2blLoc014498.1</td><td>719.00</td><td>118.04</td><td>306.22</td><td>&#8722;2.61</td><td>4.62E-08</td><td>&#8722;1.23</td><td>6.04E-02</td><td>Phenylalanine ammonia-lyase</td></tr><tr><td>Ta3bLoc024051.1</td><td>342.10</td><td>34.22</td><td>106.23</td><td>&#8722;3.32</td><td>4.41E-09</td><td>&#8722;1.69</td><td>1.19E-02</td><td>Phenylalanine ammonia-lyase</td></tr><tr><td>Ta7asLoc021287.1</td><td>3214.99</td><td>932.09</td><td>1145.19</td><td>&#8722;1.79</td><td>3.10E-02</td><td>&#8722;1.49</td><td>8.21E-02</td><td>Sucrose synthase 2, putative, expressed</td></tr><tr><td>Ta6bsLoc005412.1</td><td>839.45</td><td>149.96</td><td>376.09</td><td>&#8722;2.48</td><td>3.87E-07</td><td>&#8722;1.16</td><td>8.73E-02</td><td>Sucrose:fructan-6-fructosyltransferase</td></tr><tr><td>Ta4alLoc019947.1</td><td>168.96</td><td>45.07</td><td>38.20</td><td>&#8722;1.91</td><td>1.72E-02</td><td>&#8722;2.14</td><td>5.10E-03</td><td>Fiber protein Fb34</td></tr><tr><td>Ta7bsLoc005648.1</td><td>161.29</td><td>39.24</td><td>43.95</td><td>&#8722;2.04</td><td>2.28E-02</td><td>&#8722;1.88</td><td>3.37E-02</td><td>TRICHOME BIREFRIGENE like 22</td></tr><tr><td>Ta4blLoc021918.2</td><td>235.61</td><td>19.18</td><td>49.36</td><td>&#8722;3.62</td><td>4.92E-08</td><td>&#8722;2.26</td><td>8.61E-04</td><td>Laccase</td></tr><tr><td>Ta4asLoc013789.1</td><td>939.60</td><td>192.99</td><td>304.20</td><td>&#8722;2.28</td><td>5.70E-07</td><td>&#8722;1.63</td><td>1.16E-03</td><td>laccase 16 LENGTH=523</td></tr></table>
d76c51cfef4592613d6acf4cf9d9c34f7f8ea7f795b90eba6301421700d5f820.png
complex
<table><tr><td></td><td>Total visits</td><td>No. referred (%)</td><td>No. of nonsevere referrals (%)*</td><td>No. of severe referrals (%)*</td></tr><tr><td colspan="5">Trial arm</td></tr><tr><td> Control (presumptive arm)</td><td>2,404</td><td>314 (13.1)</td><td>180 (67.7)</td><td>86 (32.3)</td></tr><tr><td> Intervention (mRDT arm)</td><td>1,097</td><td>782 (71.3)</td><td>444 (58.3)</td><td>317 (41.7)</td></tr><tr><td colspan="5">Within intervention arm</td></tr><tr><td> mRDT negative</td><td>1,064</td><td>770 (72.4)</td><td>439 (58.4)</td><td>313 (41.6)</td></tr><tr><td> mRDT positive</td><td>34</td><td>13 (38.2)</td><td>5 (50.0)</td><td>5 (50.0)</td></tr><tr><td colspan="5">ACT prescription&#8224;</td></tr><tr><td> ACT not prescribed</td><td>1,053</td><td>782 (74.3)</td><td>454 (59.8)</td><td>305 (40.2)</td></tr><tr><td> ACT prescribed</td><td>2,328</td><td>209 (9.0)</td><td>138 (79.8)</td><td>35 (20.2)</td></tr><tr><td> Rectal artesunate prescribed</td><td>59</td><td>58 (98.3)</td><td>12 (23.5)</td><td>39 (76.5)</td></tr></table>
d9f2dfe23b63d342656f7a16f77453bf5324fac266490a6258735d46ea2e42c9.png
simple
<table><tr><td> </td><td>TIMI 0</td><td>TIMI 1</td><td>TIMI 2</td><td>TIMI 3</td><td>Sig.</td></tr><tr><td>Group (1) (<i>N</i> = 18)</td><td>(3) 16.7%</td><td>(3) 16.7%</td><td>(3) 16.7%</td><td>(9) 50%</td><td> </td></tr><tr><td>Group (2) (<i>N</i> = 17)</td><td>(1) 5.9%</td><td>(2) 11.8%</td><td>(6) 35.5%</td><td>(8) 47.1%</td><td>0.04</td></tr><tr><td>Group (3) (<i>N</i> = 10)</td><td>(1) 10%</td><td>(6) 60%</td><td>(1) 10%</td><td>(2) 20%</td><td> </td></tr></table>
6165d2f86d75df6d86abfba5d7ef6377644bacf59e0cdc1236965744b1f2247e.png
complex
<table><tr><td rowspan="2">Factors</td><td colspan="2">Expert</td><td colspan="2">Non-expert</td></tr><tr><td>LCI</td><td>BLI-BRT</td><td>LCI</td><td>BLI-BRT</td></tr><tr><td>Improved</td><td>73.1% (60/82)<sup>a</sup></td><td>19.5% (16/82)<sup>b</sup></td><td>76.8% (63/82)<sup>c</sup></td><td>24.3% (20/82)<sup>d</sup></td></tr><tr><td>Unchanged</td><td>26.8% (22/82)</td><td>67.0% (55/82)</td><td>23.2% (19/82)</td><td>59.8% (49/82)</td></tr><tr><td>Worsened</td><td>0% (0/82)</td><td>13.4% (11/82)</td><td>0% (0/82)</td><td>15.9% (13/82)</td></tr></table>
1d62712a61c775123043edc99cfc7776c82eed3a5fb5fbd619f41c8918653c57.png
simple
<table><tr><td> </td><td>Total</td><td>Percentage</td></tr><tr><td>Gender</td><td> </td><td> </td></tr><tr><td> Male</td><td>50</td><td>41.5</td></tr><tr><td> Female</td><td>70</td><td>58.5</td></tr><tr><td>Age groups</td><td> </td><td> </td></tr><tr><td> 21&#8211;29</td><td>2</td><td>1.6</td></tr><tr><td> 30&#8211;39</td><td>8</td><td>6</td></tr><tr><td> 40&#8211;49</td><td>22</td><td>18.3</td></tr><tr><td> 50&#8211;59</td><td>21</td><td>18</td></tr><tr><td> 60&#8211;69</td><td>23</td><td>19.1</td></tr><tr><td> 70&#8211;79</td><td>27</td><td>22.5</td></tr><tr><td> 80&#8211;89</td><td>17</td><td>14.1</td></tr><tr><td>Educational attainment</td><td> </td><td> </td></tr><tr><td> Illiterate</td><td>63</td><td>52.5</td></tr><tr><td> Primary</td><td>31</td><td>25.8</td></tr><tr><td> Middle</td><td>16</td><td>13.3</td></tr><tr><td> Secondary</td><td>7</td><td>5.8</td></tr><tr><td> University</td><td>3</td><td>2.5</td></tr><tr><td>Occupation</td><td> </td><td> </td></tr><tr><td> Females</td><td> </td><td> </td></tr><tr><td>Housewives</td><td>63</td><td>90</td></tr><tr><td>Primary teacher</td><td>7</td><td>10</td></tr><tr><td> Males</td><td> </td><td> </td></tr><tr><td>Shopkeepers</td><td>12</td><td>24</td></tr><tr><td>Farmers</td><td>22</td><td>44</td></tr><tr><td>Labour</td><td>8</td><td>16</td></tr><tr><td>Primary teachers</td><td>8</td><td>16</td></tr></table>
86bb06066fbc87e1253f9c6a46aa8982b15443dc0b86d23ac7764d9301357934.png
simple
<table><tr><td>Region of</td><td>Number</td><td>%</td><td>Population</td><td>Regions</td></tr><tr><td>residence</td><td>of cases</td><td>of cases</td><td>(%)</td><td>sending ALS</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>data</td></tr><tr><td>Abruzzo</td><td>9</td><td>0<i>.</i>50<i>%</i></td><td>2,22<i>%</i></td><td>-</td></tr><tr><td>Basilicata</td><td>16</td><td>0<i>.</i>89<i>%</i></td><td>0,98<i>%</i></td><td>*</td></tr><tr><td>Calabria</td><td>24</td><td>1<i>.</i>33<i>%</i></td><td>3,33<i>%</i></td><td>*</td></tr><tr><td>Campania</td><td>22</td><td>1<i>.</i>22<i>%</i></td><td>9,65<i>%</i></td><td>-</td></tr><tr><td>Estera</td><td>2</td><td>0<i>.</i>11<i>%</i></td><td>-</td><td>-</td></tr><tr><td>Emilia Romagna</td><td>246</td><td>13<i>.</i>67<i>%</i></td><td>7,28<i>%</i></td><td>*</td></tr><tr><td>FVG</td><td>5</td><td>0<i>.</i>28<i>%</i></td><td>2,05<i>%</i></td><td>*</td></tr><tr><td>Lazio</td><td>195</td><td>10<i>.</i>84<i>%</i></td><td>9,42<i>%</i></td><td>*</td></tr><tr><td>Liguria</td><td>15</td><td>0<i>.</i>83<i>%</i></td><td>2,68<i>%</i></td><td>-</td></tr><tr><td>Lombardia</td><td>95</td><td>5<i>.</i>28<i>%</i></td><td>16,28<i>%</i></td><td>*</td></tr><tr><td>Marche</td><td>33</td><td>1<i>.</i>83<i>%</i></td><td>2,58<i>%</i></td><td>*</td></tr><tr><td>Molise</td><td>3</td><td>0<i>.</i>17<i>%</i></td><td>0,53<i>%</i></td><td>-</td></tr><tr><td>Piemonte</td><td>390</td><td>21<i>.</i>68<i>%</i></td><td>7,37<i>%</i></td><td>*</td></tr><tr><td>Puglia</td><td>148</td><td>8<i>.</i>23<i>%</i></td><td>6,77<i>%</i></td><td>*</td></tr><tr><td>Sardegna</td><td>3</td><td>0<i>.</i>17<i>%</i></td><td>2,77<i>%</i></td><td>*</td></tr><tr><td>Sicilia</td><td>5</td><td>0<i>.</i>28<i>%</i></td><td>8,36<i>%</i></td><td>-</td></tr><tr><td>Toscana</td><td>405</td><td>22<i>.</i>51<i>%</i></td><td>6,18<i>%</i></td><td>*</td></tr><tr><td>TAA</td><td>23</td><td>1<i>.</i>28<i>%</i></td><td>1,70<i>%</i></td><td>*</td></tr><tr><td>Umbria</td><td>18</td><td>1<i>.</i>00<i>%</i></td><td>1,49<i>%</i></td><td>-</td></tr><tr><td>ValledAosta</td><td>3</td><td>0<i>.</i>17<i>%</i></td><td>0,21<i>%</i></td><td>-</td></tr><tr><td>Veneto</td><td>139</td><td>7<i>.</i>73<i>%</i></td><td>8,14<i>%</i></td><td>*</td></tr><tr><td>Italy</td><td>-</td><td>100%</td><td>100%</td><td> </td></tr></table>
56b10de55b6d0957f155414c981dc3e10c977bc4613376fa075fbcf5d729ca6e.png
complex
<table><tr><td>Medicinal plant species</td><td>Ailments treated in current study</td><td>Previous reports of ethnomedical uses</td><td>Country of previous use</td></tr><tr><td rowspan="5"><i>Vernonia amygdalina</i></td><td rowspan="5">Malaria</td><td>Malaria</td><td>Uganda [63, 101], Ghana [98], Cameroon [102], Democratic Republic of Congo(DRC) [103], Rwanda [104]</td></tr><tr><td>Wounds</td><td>Nigeria [105]</td></tr><tr><td>Skin rashes, diarrhoea, herpes zoster, cryptococcal meningitis</td><td>Tanzania [106]</td></tr><tr><td>Infertility, amenorrhea</td><td>South Africa [107]</td></tr><tr><td>Tonsolitis</td><td>Ethiopia [108]</td></tr><tr><td><i>Ageratum conyzoides</i></td><td>Uterine pains, helminth infections</td><td>Splenomegaly, colic pains, wounds</td><td>Uganda [1]</td></tr><tr><td><i>Vernonia lasiopus</i></td><td>Malaria, stomachaches</td><td>Skin allergy, constipation</td><td>Uganda [1]</td></tr><tr><td><i>Cleome gynandra</i></td><td>Prolonged labour</td><td>Convulsions, diphtheria, toothaches, peptic ulcers, vomiting</td><td>Uganda [1, 19]</td></tr><tr><td><i>Aloe vera</i></td><td>Malaria</td><td>Wounds</td><td>Kenya [96]</td></tr><tr><td><i>Prunus africana</i></td><td>Enlarged prostate</td><td>Prostate and breast cancers, Hypertension</td><td>Kenya [96, 109]</td></tr><tr><td><i>Capscum frutescens</i></td><td>Prostate cancer</td><td>Throat, breast and squamous cell carcinoma</td><td>Kenya [109]</td></tr><tr><td><i>Amaranthus spinosus</i></td><td>Scalp fungal infections</td><td>Haemorrhoids</td><td>Nigeria [57]</td></tr><tr><td><i>Mangifera indica</i></td><td>Cough, infertility, convulsions</td><td>Haemorrhoids</td><td>Nigeria [57]</td></tr></table>
a1f7635dd69778bf6dbc3f8dd642a959faccede930b54f496747e5027735e5ff.png
complex
<table><tr><td colspan="2"></td><td>Sensory disturbance group(<i>N</i> = 26)</td><td>Non-sensory disturbance group(<i>N</i> = 94)</td><td><i>p</i> value</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>12</td><td>49</td><td>0.38</td></tr><tr><td>Female</td><td>14</td><td>45</td><td></td></tr><tr><td colspan="2">Age (years)</td><td>24.7 &#177; 10.1</td><td>24.3 &#177; 11.9</td><td>0.87</td></tr><tr><td colspan="2">BMI</td><td>24.6 &#177; 3.1</td><td>23.3 &#177; 3.7</td><td>0.40</td></tr><tr><td colspan="2">Tendon graft<sup>a</sup></td><td>3 patients (11.5%)</td><td>10 patients (10.6%)</td><td>0.57</td></tr></table>
5152289f2d8613c441723c031529ab376918fe8b32a6b428d33b0b2ad8fbb207.png
simple
<table><tr><td></td><td>SLE</td><td>Control</td><td><i>P</i></td></tr><tr><td>Comfort</td><td>21 (95%)</td><td>20 (100%)</td><td>0.34</td></tr><tr><td>Fit</td><td>21 (95%)</td><td>20 (100%)</td><td>0.34</td></tr><tr><td>Style</td><td>19 (86%)</td><td>18 (90%)</td><td>0.72</td></tr><tr><td>Ease to put on/off</td><td>18 (82%)</td><td>10 (50%)</td><td>0.029</td></tr><tr><td>Heel height</td><td>17 (77%)</td><td>15 (75%)</td><td>0.86</td></tr><tr><td>Support</td><td>16 (73%)</td><td>15 (75%)</td><td>0.87</td></tr><tr><td>Non-slip</td><td>16 (73%)</td><td>11 (55%)</td><td>0.23</td></tr><tr><td>Colour</td><td>15 (68%)</td><td>13 (65%)</td><td>0.83</td></tr><tr><td>Material</td><td>14 (64%)</td><td>15 (75%)</td><td>0.43</td></tr><tr><td>Cost</td><td>12 (55%)</td><td>10 (50%)</td><td>0.77</td></tr><tr><td>Weight</td><td>10 (45%)</td><td>10 (50%)</td><td>0.77</td></tr><tr><td>Fastening</td><td>9 (41%)</td><td>7 (35%)</td><td>0.69</td></tr></table>
af976877d552c54b2aa4e35558e1ffb935e08230bcd64029d7f5f161c501c1e6.png
simple
<table><tr><td>Annotation Category</td><td>Male</td><td>Female</td></tr><tr><td>Behaviour</td><td>16</td><td>11</td></tr><tr><td>Cell Cycle</td><td>21</td><td>27</td></tr><tr><td>Defence Response</td><td>29</td><td>34</td></tr><tr><td>Development</td><td>56</td><td>87</td></tr><tr><td>Metabolism</td><td>273</td><td>192</td></tr><tr><td>Mitochondrial</td><td>39</td><td>3</td></tr><tr><td>Proteolysis</td><td>34</td><td>25</td></tr><tr><td>Response to Toxin</td><td>7</td><td>8</td></tr><tr><td>Signal Transduction</td><td>59</td><td>66</td></tr><tr><td>Structural</td><td>32</td><td>31</td></tr><tr><td>Synaptic Transmission</td><td>11</td><td>13</td></tr><tr><td>Transcription</td><td>17</td><td>34</td></tr><tr><td>Translation</td><td>19</td><td>14</td></tr><tr><td>Transport</td><td>110</td><td>81</td></tr><tr><td>Unknown</td><td>203</td><td>178</td></tr><tr><td>Total No. of Genes</td><td>563</td><td>481</td></tr></table>
ed1837fde432ab63406adc1f3a22c30b9453eb8907150398d4acb8adbc8cc443.png
complex
<table><tr><td rowspan="2">Primary Breast Tissue</td><td rowspan="2">Cases</td><td colspan="4">Promoter Methylation (%)</td><td rowspan="2">Statistical Test</td></tr><tr><td colspan="2">RASSF1A</td><td colspan="2">RASSF10</td></tr><tr><td>Normal</td><td><i>n</i> = 25</td><td>2/25 (8%)</td><td rowspan="2"><i>p</i> &lt; 0.005</td><td>1/25 (4%)</td><td rowspan="2"><i>p</i> &lt; 0.005</td><td rowspan="2">Fishers Exact two tailed</td></tr><tr><td>Tumours</td><td><i>n</i> = 27</td><td>15/27 (56%)</td><td>17/27 (63%)</td></tr></table>
1338938bbde3ec051a358d75caa1d16661ba30b8ac6d8b702aa232f21c0ca1c7.png
complex
<table><tr><td rowspan="2">Variable</td><td>Patients</td></tr><tr><td>(N = 828)</td></tr><tr><td>Gender (M/F)*</td><td>687 / 141</td></tr><tr><td>Age (y)</td><td>67 (9)</td></tr><tr><td>Pack-years</td><td>56 (28)</td></tr><tr><td>Active smoking*</td><td>29%</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>28.1 (5.5)</td></tr><tr><td>FEV<sub>1</sub>L</td><td>1.65 (0.65)</td></tr><tr><td>FEV<sub>1</sub>%</td><td>56 (28)</td></tr><tr><td>PaO<sub>2 </sub>(mmHg)</td><td>67.4 (9.6)</td></tr><tr><td>FVC L</td><td>3.130 (0.94)</td></tr><tr><td>FVC%</td><td>88 (19)</td></tr><tr><td>FEV1/FVC</td><td>53 (11)</td></tr><tr><td>6MWD (m)</td><td>438 (104)</td></tr><tr><td>Dyspnea (mMRC)&#8224;</td><td>1 (0-4)</td></tr><tr><td>BODE index&#8224;</td><td>4 (0-6)</td></tr><tr><td>IC/TLC</td><td>0.35 (0.10)</td></tr><tr><td>K<sub>CO</sub></td><td>74 (24)</td></tr><tr><td>Charlson index&#8224;</td><td>1 (0-5)</td></tr><tr><td>Exacerbations &#8805;2 per patient-years<sup>&#8225;</sup></td><td>0.15 (0.01)</td></tr><tr><td>Hospitalization &#8805;1 per patient-years<sup>&#8225;</sup></td><td>0.12 (0.01)</td></tr><tr><td>Inhaled anticholinergic*</td><td>75%</td></tr><tr><td>Inhaled &#946;2-agonist*</td><td>74%</td></tr><tr><td>Inhaled corticosteroid*</td><td>65%</td></tr><tr><td>CAT&#8224;</td><td>11 (2-27)</td></tr><tr><td>CCQ&#8224;</td><td>1,3 (0-3.7)</td></tr></table>
64564043bf4e6e2453e72e13c074416e16a0b32b84dcb59278a6dbf345f3fa8e.png
simple
<table><tr><td>Map Type</td><td>Count</td></tr><tr><td>ESTs mapping to the human transcriptome (p &#8804; 9 &#215; 10<sup>-7</sup>)</td><td>140,906</td></tr><tr><td>ESTs mapping to the human genome and overlapping with a processed transcript</td><td>1261</td></tr><tr><td>ESTs which map to a transcribed region</td><td>8,221</td></tr><tr><td>ESTs which map to the human Genome alone</td><td>9,482</td></tr><tr><td>ESTs not correlating with the human genome (p &#8804; 9 &#215; 10<sup>-5</sup>)</td><td>20,981</td></tr><tr><td>Total</td><td>181,279</td></tr></table>
2cde6585e9b41a0c6266bb54245a1cd29272d779496bc42e3e188403a23a6abb.png
simple
<table><tr><td>Proteins</td><td>Functions</td></tr><tr><td>Ionized calcium-binding adaptor molecule (Iba)1</td><td>Cytoplasmic protein constitutively expressed by microglia, upregulated in inflammation. Iba1 is involved in cytoskeletal reorganization, membrane ruffling of the microglial processes and actin cross-linking needed for cell migration [23], thus reflecting microglial motility and migration properties.</td></tr><tr><td>CD68</td><td>CD68 labels lysosomal and endosomal transmembrane glycoprotein of microglia, indicating phagocytic activity [33].</td></tr><tr><td>Human leukocyte antigen (HLA)-DR</td><td>HLA-DR is a Major Histocompatibility Class (MHC) II cell surface receptor which presents antigens to cells of the immune system eliciting an immune response, involved in the non-self recognition and upregulated in inflammation [34].</td></tr><tr><td>Macrophage scavenger receptor (MSR)-A</td><td>MSR-A is a lipoprotein receptor involved in direct ligand recognition and scavenging activity. Its mouse homolog, scavenger receptor A (SR-A), is associated with plaques and release of reactive oxygen species and neurotoxic substances by microglia upon stimulation with fibrillar A&#946; [35]. We previously showed a clustering pattern of MSR-A-positive microglia round plaques in Alzheimer's disease [16] suggesting expression of MSR-A may cause immobilization of the microglia when they encounter plaques [16, 26].</td></tr><tr><td>CD64 (Fc&#947; receptor I)</td><td>CD64 is a cell surface receptor with high affinity for the Fc portion of immunoglobulin (IgG), triggering a monocyte/macrophage response [30]. Expression of CD64 reflects the presence of immunoglobulins in the brain and thus the involvement of systemic immunity [36]. Overall Fc&#947;Rs are important for antibody-dependent cytotoxicity, antigen presentation via MHC, clearance of antibodies and phagocytosis [37].</td></tr></table>
895e9a7efc250c3341ed2c27ba611c8f6c733c7536d6dd2bbd20d3e5f7002988.png
complex
<table><tr><td></td><td colspan="2">Setting 1</td><td colspan="2">Setting 2</td><td colspan="2">Setting 3</td></tr><tr><td></td><td><i>Fitness</i></td><td><i>Sensitivity</i></td><td><i>Fitness</i></td><td><i>Sensitivity</i></td><td><i>Fitness</i></td><td><i>Sensitivity</i></td></tr><tr><td>Dataset 1</td><td>0.0117</td><td>0.7885</td><td>0.0054</td><td>0.7363</td><td>0.0144</td><td>0.7678</td></tr><tr><td>Dataset 2</td><td>0.0598</td><td>0.8249</td><td>0.0192</td><td>0.7581</td><td>0.0769</td><td>0.7867</td></tr><tr><td>Dataset 3</td><td>0.3586</td><td>0.8432</td><td>0.1404</td><td>0.7502</td><td>0.2973</td><td>0.7856</td></tr><tr><td>Dataset 4</td><td>0.1661</td><td>0.8084</td><td>0.1128</td><td>0.7691</td><td>0.2280</td><td>0.7802</td></tr></table>
7f203d4fd8bd6e7571e7cce161bb694898a29cdeebcca664cf8029f3ffc4589c.png
simple
<table><tr><td> </td><td>Total cases (%) 111,495</td><td>PTA (n = 41,987, 37.6%)</td><td> </td><td>Bypass (n = 12,334, 11.1%)</td><td> </td><td>Amputation (n = 57,174, 51.3%)</td><td> </td><td>p-value (&#967;<sup>2 </sup>test)</td><td> Crude OR (95% CI)</td></tr><tr><td> </td><td> </td><td>No.</td><td>(%)</td><td>No.</td><td>(%)</td><td>No.</td><td>(%)</td><td> </td><td> </td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>60,187 (59.5%)</td><td>25,372</td><td>60.4</td><td>7,772</td><td>63.0</td><td>33,366</td><td>58.4</td><td>&lt;0.001</td><td> </td></tr><tr><td>Female</td><td>40,936 (40.5%)</td><td>16,615</td><td>39.6</td><td>4,562</td><td>37.0</td><td>23,808</td><td>41.6<sup>a</sup></td><td> </td><td>1.12<sup>a </sup>(1.09-1.14)</td></tr><tr><td>Age Stratum</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>30&#8211;49.9 y/o</td><td>7,063 (7.0%)</td><td>2,594</td><td>6.2</td><td>748</td><td>6.1</td><td>4,182</td><td>7.3<sup>a</sup></td><td>&lt;0.001</td><td>1.30<sup>a </sup>(1. 24&#8211;1.37)</td></tr><tr><td>50&#8211;64.9 y/o</td><td>26,138 (25.8%)</td><td>10,405</td><td>24.8</td><td>2,704</td><td>21.9</td><td>15,317</td><td>26.8<sup>a</sup></td><td> </td><td>1. 22<sup>a </sup>(1.18-1.25)</td></tr><tr><td>65&#8211;74.9 y/o</td><td>31,070 (30.7%)</td><td>12,820</td><td>30.5</td><td>4,107</td><td>33.3<sup>b</sup></td><td>17,537</td><td>30.7</td><td> </td><td>1.03<sup>b </sup>(0.98-1.08)</td></tr><tr><td>&gt; = 75y/o</td><td>36,866 (36.5%)</td><td>16,169</td><td>38.5</td><td>4,775</td><td>38.7</td><td>20,138</td><td>35.2</td><td> </td><td> </td></tr><tr><td>Diabetes</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>69,026 (68.2%)</td><td>20,282</td><td>48.3</td><td>6,978</td><td>56.6</td><td>48,318</td><td>84.5<sup>a</sup></td><td>&lt;0.001</td><td>6.12<sup>a </sup>(5.95-6.31)</td></tr><tr><td>Hypertension</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>45,961 (45.4%)</td><td>25,844</td><td>61.5<sup>c</sup></td><td>5,918</td><td>48.0</td><td>18,635</td><td>32.6</td><td>&lt;0.001</td><td>3.11<sup>c </sup>(3.03-3.19)</td></tr><tr><td>ESRD</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>11,318 (11.2%)</td><td>4,094</td><td>9.7</td><td>1,741</td><td>14.1<sup>b</sup></td><td>6,313</td><td>11.0</td><td>&lt;0.001</td><td>1.36<sup>b </sup>(1.29-1.44)</td></tr><tr><td>CAD</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>16,072 (15.9%)</td><td>10,727</td><td>25.5<sup>c</sup></td><td>2,254</td><td>18.3</td><td>4,635</td><td>8.1</td><td>&lt;0.001</td><td>3.45<sup>c </sup>(3.33-3.58)</td></tr><tr><td>Dyslipidemia</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>4,803 (4.7%)</td><td>3,960</td><td>9.4<sup>c</sup></td><td>438</td><td>3.6</td><td>690</td><td>1.2</td><td>&lt;0.001</td><td>7.20<sup>c </sup>(6.68-7.77)</td></tr><tr><td>Group identified</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>72,520 (71.7%)</td><td>27,500</td><td>65.5</td><td>9,530</td><td>77.3</td><td>43,391</td><td>75.9</td><td>&lt;0.001</td><td> </td></tr><tr><td>Low-income</td><td>2,704 (2.7%)</td><td>875</td><td>2.1</td><td>249</td><td>2.0</td><td>1,831</td><td>3.2<sup>a</sup></td><td> </td><td>1.41<sup>a </sup>(1.30-1.53)</td></tr><tr><td>CIR</td><td>25,913 (25.6%)</td><td>13,620</td><td>32.4<sup>c</sup></td><td>2,557</td><td>20.7</td><td>11,957</td><td>20.9</td><td> </td><td>1.81<sup>c </sup>(1.76-1.87)</td></tr></table>
8c7f4d3b9366500cd1a73dc5ca6335b7b84c96ce598959e589d9b3826de2d522.png
simple
<table><tr><td>Type</td><td>Symbol</td><td>Theme</td><td>Relevant figure</td><td>Supporting cluster(s)</td></tr><tr><td>Chemical-gene</td><td>A+</td><td>Agonism, activation</td><td>3a</td><td>6+</td></tr><tr><td></td><td>A&#8722;</td><td>Antagonism, blocking</td><td></td><td>6&#8211;</td></tr><tr><td></td><td>B</td><td>Binding, ligand (esp. receptors)</td><td></td><td>14&#8211;16</td></tr><tr><td></td><td>E+</td><td>Increases expression/production</td><td></td><td>8+, 9+</td></tr><tr><td></td><td>E&#8722;</td><td>Decreases expression/production</td><td></td><td>8&#8211;, 9&#8211;, 10</td></tr><tr><td></td><td>E</td><td>Affects expression/production (neutral)</td><td></td><td>8, 9, 11a</td></tr><tr><td></td><td>N</td><td>Inhibits</td><td></td><td>3</td></tr><tr><td>Gene-chemical</td><td>O</td><td>Transport, channels</td><td>3a</td><td>19, 21</td></tr><tr><td></td><td>K</td><td>Metabolism, pharmacokinetics</td><td></td><td>11c</td></tr><tr><td></td><td>Z</td><td>Enzyme activity</td><td></td><td>20</td></tr><tr><td>Chemical-disease</td><td>T</td><td>Treatment/therapy (incl. investigatory)</td><td>3b</td><td>8g, 8h, 9</td></tr><tr><td></td><td>C</td><td>Inhibits cell growth (esp. cancers)</td><td></td><td>2, 3</td></tr><tr><td></td><td>Sa</td><td>Side effect/adverse event</td><td></td><td>6, 15, 16</td></tr><tr><td></td><td>Pr</td><td>Prevents, suppresses</td><td></td><td>1, 9, 21, 24, 28</td></tr><tr><td></td><td>Pa</td><td>Alleviates, reduces</td><td></td><td>26, 30</td></tr><tr><td></td><td>J</td><td>Role in pathogenesis</td><td></td><td>20</td></tr><tr><td>Disease-chemical</td><td>Mp</td><td>Biomarkers (progression)</td><td>3b</td><td>18, 19</td></tr><tr><td>gene-disease</td><td>U</td><td>Causal mutations</td><td>3c</td><td>14</td></tr><tr><td></td><td>Ud</td><td>Mutations affect disease course</td><td></td><td>13</td></tr><tr><td></td><td>D</td><td>Drug targets</td><td></td><td>10, 12</td></tr><tr><td></td><td>J</td><td>Role in pathogenesis</td><td></td><td>2h, 4, 6, 8, 9</td></tr><tr><td></td><td>Te</td><td>Possible therapeutic effect</td><td></td><td>2j, 3</td></tr><tr><td></td><td>Y</td><td>Polymorphisms alter risk</td><td></td><td>22, 26, 27</td></tr><tr><td></td><td>G</td><td>Promotes progression</td><td></td><td>29</td></tr><tr><td>Disease-gene</td><td>Md</td><td>Biomarkers (diagnostic)</td><td>3c</td><td>5, 7</td></tr><tr><td></td><td>X</td><td>Overexpression in disease</td><td></td><td>15, 17, 30</td></tr><tr><td></td><td>L</td><td>Improper regulation linked to disease</td><td></td><td>18, 19, 21</td></tr><tr><td>Gene&#8211;gene</td><td>B</td><td>Binding, ligand (esp. receptors)</td><td>3d</td><td>10</td></tr><tr><td></td><td>W</td><td>Enhances response</td><td></td><td>13</td></tr><tr><td></td><td>V+</td><td>Activates, stimulates</td><td></td><td>14, 16</td></tr><tr><td></td><td>E+</td><td>Increases expression/production</td><td></td><td>21, 22</td></tr><tr><td></td><td>E</td><td>Affects expression/production (neutral)</td><td></td><td>7, 17</td></tr><tr><td></td><td>I</td><td>Signaling pathway</td><td></td><td>24</td></tr><tr><td></td><td>H</td><td>Same protein or complex</td><td></td><td>25</td></tr><tr><td></td><td>Rg</td><td>Regulation</td><td></td><td>28, 30</td></tr><tr><td></td><td>Q</td><td>Production by cell population</td><td></td><td>1, 2, 6</td></tr></table>
386e6c1389515e2fddb4bed1ada22fba0c733f28dff9e2720d6c563520e54c86.png
simple
<table><tr><td>Variables</td><td>p values - Left</td><td>p values - Right</td></tr><tr><td>LPFX LAF</td><td>0.995</td><td>0.999</td></tr><tr><td>LPFX OAF</td><td>0.969</td><td>0.246</td></tr><tr><td>LPFX OPF</td><td>0.089</td><td>0.104</td></tr><tr><td>LAFX OAF</td><td>0.996</td><td>0.248</td></tr><tr><td>LAFX OPF</td><td>0.050</td><td>0.106</td></tr><tr><td>OAFX OPF</td><td>0.027*</td><td>0.976</td></tr></table>
e1ed8f0a65f3c6590128def22d273474976241aa99192d444879ab5036501c29.png
complex
<table><tr><td>Variable</td><td>Odds Ratio</td><td>95% CI</td><td><i>P</i> value</td></tr><tr><td colspan="4">Cataract surgery</td></tr><tr><td> Before first eye surgery</td><td>1.0</td><td></td><td></td></tr><tr><td> After first eye surgery</td><td>0.3</td><td>0.1&#8211;0.7</td><td>0.004</td></tr><tr><td> After second eye surgery</td><td>0.1</td><td>0.1&#8211;0.4</td><td>&lt; 0.001</td></tr><tr><td colspan="4">Gender</td></tr><tr><td> Female</td><td>1.0</td><td></td><td></td></tr><tr><td> Male</td><td>0.4</td><td>0.1&#8211;1.3</td><td>0.122</td></tr><tr><td colspan="4">Age group (years)</td></tr><tr><td> 55&#8211;64</td><td>1.0</td><td></td><td></td></tr><tr><td> 65&#8211;74</td><td>0.1</td><td>0.1&#8211;1.2</td><td>0.072</td></tr><tr><td> 75+</td><td>0.7</td><td>0.6&#8211;8.0</td><td>0.737</td></tr><tr><td colspan="4">Marital status</td></tr><tr><td> Single</td><td>1.0</td><td></td><td></td></tr><tr><td> Married/de facto</td><td>0.3</td><td>0.1&#8211;1.2</td><td>0.096</td></tr><tr><td colspan="4">Retirement status</td></tr><tr><td> Not retired</td><td>1.0</td><td></td><td></td></tr><tr><td> Retired</td><td>5.6</td><td>1.1&#8211;27.7</td><td>0.036</td></tr><tr><td>Number of comorbidities</td><td>1.1</td><td>0.9&#8211;1.4</td><td>0.257</td></tr><tr><td>MMSE score</td><td>1.0</td><td>0.9&#8211;1.2</td><td>0.803</td></tr></table>
051366caf83c9e0a2c2301e9c7915cb765920e6603b8785be4e03d80ef895238.png
complex
<table><tr><td>Variable</td><td>Measurement Items</td><td>Reference</td></tr><tr><td rowspan="4">BI</td><td>1. If the hospital decides to develop MEMR in the future, I shall frequently use it.</td><td rowspan="4">Hu et al. 1999 [9]</td></tr><tr><td>2. If the hospital decides to develop MEMR in the future, I will use it to assist my healthcare work.</td></tr><tr><td>3. I think I will recommend other physicians (from this hospital or not) to use MEMR.</td></tr><tr><td>4. If the hospital decides to develop MEMR in the future, it will become one of my favorite assistance tools for my work.</td></tr><tr><td rowspan="5">PU</td><td>1. Using MEMR will speed up my work (e.g. going on rounds and consulting medical records).</td><td rowspan="5">Davis et al. 1989 [5]; Davis 1989 [52]</td></tr><tr><td>2. Using MEMR will improve my work quality (such as enhancing the immediacy of prescribing physician orders).</td></tr><tr><td>3. Using MEMR will make it easier to conduct my work.</td></tr><tr><td>4. Using MEMR will improve my working performance.</td></tr><tr><td>5. Using MEMR will help me to control my work better.</td></tr><tr><td rowspan="3">PEOU</td><td>1. It is easy to understand the operations of MEMR.]</td><td rowspan="3">Davis et al. 1989 [5]; Davis 1989 [52]</td></tr><tr><td>2. It is easy to use MEMR to finish my work.</td></tr><tr><td>3. On the whole, MEME is easy to use.</td></tr><tr><td rowspan="6">PT</td><td>1. Using MEMR may decrease my control over clinical decisions.</td><td rowspan="6">Walter &amp; Lopez 2008 [15]</td></tr><tr><td>2. Using MEMR may decrease my professional discretion over patient care decisions.</td></tr><tr><td>3. Using MEMR can decrease my control over each step of the patient care process.</td></tr><tr><td>4. Using MEMR may increase the monitoring of my diagnostic and therapeutic decisions by non-providers.</td></tr><tr><td>5. Using MEMR may decrease my control over the allocation of scarce resources.</td></tr><tr><td>6. I would find MEMR advantageous for the medical profession as a whole.</td></tr><tr><td rowspan="3">PM</td><td>1. I can access the MEMR at any time for the necessary information or service for my patient care</td><td rowspan="3">Lee 2005 [53]</td></tr><tr><td>2. I can access the MEMR anywhere for the necessaryzinformation or service for my patient care</td></tr><tr><td>3. I can use the MEMR &#8220;anywhere,&#8221; and &#8220;anytime&#8221; at the point of patient care.</td></tr></table>
e91e46c62f264c8dc2d2ac869a35ff1ab42835e58409bcb747b57663e1d36d4a.png
simple
<table><tr><td>Parameters</td><td>Traditional Technology [35]</td><td>Author&#8217;s Technology [36]</td></tr><tr><td>Wear intensity I&#8729;10<sup>&#8722;7</sup>, mm<sup>3</sup>/N&#8729;m</td><td>8.2</td><td>4.9</td></tr><tr><td>Breaking strength &#963;<sub>b</sub>, MPa</td><td>18.0</td><td>24.0</td></tr><tr><td>Ratio of CF and PTFE powder (volume) in filler preparation </td><td>-</td><td>1:1</td></tr></table>
d6b2ef6df98c87170b3b6d3d7e656c1249051f40e691e8df0ba6abaebfe5533a.png
simple
<table><tr><td>Transcription</td><td></td><td>Meaning unit</td><td>ICF category</td></tr><tr><td>Moderator:</td><td><i>If you think about your body, what functional problems do you have?</i></td><td></td><td></td></tr><tr><td>Patient A:</td><td>I used to go to sports very often. Now I can't anymore. I even had to quit swimming</td><td>Restriction of sports Quit swimming</td><td>d9201 sports d4554 swimming</td></tr><tr><td>Patient B:</td><td>Exactly! I also had to quit swimming.</td><td></td><td></td></tr><tr><td>Patient C:</td><td>I can no longer cycle. (...)</td><td>Quit cycling</td><td>d4750 driving human-powered transportation</td></tr><tr><td>Moderator:</td><td><i>If you think about your body, where are your biggest problems?</i></td><td></td><td></td></tr><tr><td>Patient C:</td><td>Toes, ankle joints, knee joints, fingers</td><td>ToesAnkle joints</td><td>s7502 structure of ankle &amp; foots75021 ankle joint &amp; joints of foot and toes</td></tr><tr><td></td><td></td><td>Knee joints</td><td>s75011 knee joint</td></tr><tr><td></td><td></td><td>Fingers</td><td>s7302 structure of hand</td></tr><tr><td>Patient A:</td><td>What bothers me are my wrists. (...)</td><td>Wrists</td><td>s73021 joints of hand and fingers</td></tr></table>
1bc810278b21384a3e55848501b519fd49c83f5816e35c787354aecc97fad2ae.png
simple
<table><tr><td>Lake Number</td><td>Lake Volume (m<sup>3</sup>)</td><td>Pre-Dam</td></tr><tr><td>1</td><td>5,700,000 </td><td>+</td></tr><tr><td>2</td><td>204,000 </td><td>+</td></tr><tr><td>3</td><td>1,335,000 </td><td></td></tr><tr><td>4</td><td>5,000,000 </td><td></td></tr><tr><td>5</td><td>14,700,000 </td><td></td></tr><tr><td>6</td><td>1,100,000 </td><td></td></tr><tr><td>7</td><td>4,400,000 </td><td>+</td></tr><tr><td>8</td><td>5,800,000 </td><td>+</td></tr><tr><td>9</td><td>10,000,000 </td><td>+</td></tr><tr><td>10</td><td>8,000,000 </td><td></td></tr></table>
b416eb54ff4389cb35af0674765139ac138c04634179e91c8ce1617e752af8cc.png
simple
<table><tr><td>Outcome (n)</td><td>% or mean (&#177; SD)</td><td>OR or &#946; (95 % CI or SE)</td><td><i>P</i>-value</td></tr><tr><td>Hypertension, baseline (<i>n</i> = 6,422)</td><td>56 %</td><td>1.20 (0.90 &#8211; 1.59)</td><td>0.21</td></tr><tr><td>Hypertension, lifetime (<i>n</i> = 8,691)</td><td>78 %</td><td>1.23 (0.82 &#8211; 1.86)</td><td>0.32</td></tr><tr><td>Type 2 diabetes (<i>n</i> = 1,356)</td><td>12 %</td><td>1.32 (0.91 &#8211; 1.91)</td><td>0.15</td></tr><tr><td>Albumin (g/dL), serum (<i>n</i> = 8,094)</td><td>4.05 (0.51)</td><td>&#8722;0.001 (0.04)</td><td>0.88</td></tr><tr><td>Albumin creatinine ratio (mg/mmol) (<i>n</i> = 1,210)</td><td>14.0 (861.10)</td><td>&#8722;123.82 (176.60)</td><td>0.48</td></tr><tr><td>Albumin (mg/dL), urinary (<i>n</i> = 1,199)</td><td>16.7 (640.2)</td><td>&#8722;36.35(131.80)</td><td>0.78</td></tr><tr><td>Blood urea nitrogen (mg/dL) (<i>n</i> = 10,111)</td><td>11.00 (13.55)</td><td>&#8722;0.23 (0.93)</td><td>0.80</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>) (<i>n</i> = 9,247)</td><td>27.25 (7.21)</td><td>0.74 (0.51)</td><td>0.15</td></tr><tr><td>Creatinine (mg/dL), serum (<i>n</i> = 10,288)</td><td>0.88 (1.99)</td><td>0.07 (0.13)</td><td>0.59</td></tr><tr><td>Creatinine (g/kg/day), urinary (<i>n</i> = 172)</td><td>70.00 (73.89)</td><td>23.05 (38.86)</td><td>0.55</td></tr><tr><td>Diastolic blood pressure (mm Hg), baseline (<i>n</i> = 10,025)</td><td>76.00 (15.68)</td><td>0.48 (1.07)</td><td>0.66</td></tr><tr><td>Diastolic blood pressure (mm Hg), post-medication (<i>n</i> = 5,653)</td><td>79.00 (10.06)</td><td>0.29 (0.90)</td><td>0.75</td></tr><tr><td>Diastolic blood pressure (mm Hg), pre-medication (<i>n</i> = 7,009)</td><td>75.00 (11.28)</td><td>0.38 (0.92)</td><td>0.68</td></tr><tr><td>Glucose (mg/dL) (<i>n</i> = 9,918)</td><td>96.00 (34.33)</td><td>0.04 (2.37)</td><td>0.99</td></tr><tr><td>Glycated hemoglobin (mg/dL) (<i>n</i> = 2,925)</td><td>6.30 (1.80)</td><td>0.07 (0.23)</td><td>0.75</td></tr><tr><td>HDL-C (mg/dL) (<i>n</i> = 5,096)</td><td>50.00 (16.99)</td><td>&#8722;1.02 (1.65)</td><td>0.54</td></tr><tr><td>HDL-c (mg/dL) post-medication (<i>n</i> = 2,097)</td><td>47.75 (16.56)</td><td>&#8722;2.95 (2.48)</td><td>0.23</td></tr><tr><td>HDL-C (mg/dL), pre-medication (<i>n</i> = 4,273)</td><td>51.00 (17.09)</td><td>&#8722;0.91 (1.81)</td><td>0.61</td></tr><tr><td>Heart rate (beats per minute) (<i>n</i> = 783)</td><td>76.00 (11.14)</td><td>&#8722;3.28 (2.67)</td><td>0.22</td></tr><tr><td>Insulin (IU/mL) (<i>n</i> = 343)</td><td>16.90 (74.36)</td><td>&#8722;11.15 (24.38)</td><td>0.65</td></tr><tr><td>LDL-C (mg/dL), regardless of medication status</td><td>99.00 (35.18)</td><td>&#8722;1.17 (3.42)</td><td>0.73</td></tr><tr><td>LDL-C (mg/dL), post-medication</td><td>96.00 (38.90)</td><td>4.95 (5.78)</td><td>0.39</td></tr><tr><td>LDL-C (mg/dL), pre-medication</td><td>105.00 (39.70)</td><td>&#8722;3.20 (4.26)</td><td>0.45</td></tr><tr><td>PR Interval (msec) (<i>n</i> = 781)</td><td>159.00 (17.92)</td><td>&#8722;0.12 (4.30)</td><td>0.98</td></tr><tr><td><i>QRS duration (msec) (n = 837)</i></td><td><i>82.00 (8.65)</i></td><td><i>7.98 (1.99)</i></td><td><i>6.7x10</i><sup>-5</sup></td></tr><tr><td>QT interval (msec) (<i>n</i> = 783)</td><td>376.00 (27.84)</td><td>11.62 (6.66)</td><td>0.08</td></tr><tr><td>Systolic blood pressure (mm Hg), baseline (<i>n</i> = 10,025)</td><td>125.00 (22.54)</td><td>&#8722;1.43 (1.54)</td><td>0.35</td></tr><tr><td>Systolic blood pressure (mm Hg), post-medication (<i>n</i> = 5,653)</td><td>132.00 (16.03)</td><td>0.78 (1.43)</td><td>0.58</td></tr><tr><td>Systolic blood pressure (mm Hg), pre-medication (<i>n</i> = 7,009)</td><td>123.00 (16.38)</td><td>&#8722;0.0003 (1.34)</td><td>0.99</td></tr><tr><td>Total cholesterol (mg/dL), regardless of medication status (<i>n</i> = 5,439)</td><td>175.00 (39.48)</td><td>&#8722;1.65 (3.70)</td><td>0.65</td></tr><tr><td>Total cholesterol (mg/dL), post-medication (<i>n</i> = 2,150)</td><td>173.50 (44.22)</td><td>3.48 (6.58)</td><td>0.60</td></tr><tr><td>Total cholesterol (mg/dL), pre-medication (<i>n</i> = 4,642)</td><td>181.00 (44.86)</td><td>&#8722;3.57 (4.55)</td><td>0.43</td></tr><tr><td>Triglycerides (mg/dL), regardless of medication status (<i>n</i> = 5,269)</td><td>98.00 (69.46)</td><td>3.34 (6.61)</td><td>0.61</td></tr><tr><td>Triglycerides (mg/dL), post-medication (<i>n</i> = 2,115)</td><td>110.00 (74.07)</td><td>10.63 (11.07)</td><td>0.34</td></tr><tr><td>Triglycerides (mg/dL), pre-medication (<i>n</i> = 4,445)</td><td>97.00 (79.25)</td><td>2.00 (8.20)</td><td>0.81</td></tr><tr><td>Uric acid (mg/dL) (<i>n</i> = 2,465)</td><td>5.40 (2.18)</td><td>0.06 (0.29)</td><td>0.84</td></tr></table>
aa5d33f565fda3425c3ba7f0cdd0f01998f3dfb02117843a2f729283be2bd41e.png
complex
<table><tr><td></td><td colspan="2">HI titers</td><td colspan="2">NT titers</td></tr><tr><td>Strain</td><td>Median titer</td><td>Proportion titers &#8805;40 (%)</td><td>Median titer</td><td>Proportion titer &#8805;20 (%)</td></tr><tr><td>A/Hong Kong/1/1968</td><td>40</td><td>55.00</td><td>20</td><td>59.60</td></tr><tr><td>A/Victoria/3/1975</td><td>40</td><td>31.10</td><td>10</td><td>36.40</td></tr><tr><td>A/Bangkok/1/1979</td><td>40</td><td>56.30</td><td>40</td><td>67.50</td></tr><tr><td>A/Beijing/353/1989</td><td>20</td><td>35.80</td><td>10</td><td>47.70</td></tr><tr><td>A/Wuhan/359/1995</td><td>40</td><td>69.50</td><td>80</td><td>84.80</td></tr><tr><td>A/Fujian/411/2002</td><td>80</td><td>80.80</td><td>80</td><td>83.40</td></tr><tr><td>A/Shantou/90/2003</td><td>40</td><td>62.30</td><td>40</td><td>75.50</td></tr><tr><td>A/Shantou/806/2005</td><td>40</td><td>57.00</td><td>40</td><td>60.30</td></tr><tr><td>A/Shantou/904/2008</td><td>10</td><td>28.50</td><td>10</td><td>45.00</td></tr><tr><td>A/Shantou/104/2005</td><td>20</td><td>42.40</td><td>20</td><td>55.00</td></tr><tr><td>A/Shantou/92/2009</td><td>&lt;10</td><td>9.30</td><td>&lt;10</td><td>11.30</td></tr><tr><td>A/California/07/2009</td><td>&lt;10</td><td>0.70</td><td>&lt;10</td><td>1.30</td></tr><tr><td>Total</td><td>&#8212;</td><td>44.00</td><td>&#8212;</td><td>52.30</td></tr></table>
2e753bf81fb4595fde2f8a82ea0734663f6a7781850190fec610ae560bc9b7aa.png
simple
<table><tr><td>Spot No</td><td>Accession No</td><td>Protein name</td><td>Gene name</td><td>Mean &#177; SD(pSS)</td><td>Mean &#177; SD(healthy)</td><td>Mean &#177; SD(sicca non-SS)</td><td>Fold of variationpSS <i>vs </i>healthy</td><td>Fold of variationpSS <i>vs </i>sicca non-SS</td></tr><tr><td>2261</td><td>P04745</td><td>&#945;-amylases precursor</td><td><i>AMY1A</i></td><td>2.58 &#177; 0.44</td><td>4.77 &#177; 0.39</td><td>4.24 &#177; 0.67</td><td>-1.8**</td><td>-1.6**</td></tr><tr><td>2572</td><td>Q5FC00</td><td>Carbonic anhydrase VI</td><td><i>CA6</i></td><td>0.65 &#177; 0.11</td><td>1.50 &#177; 0.47</td><td>1.07 &#177; 0.26</td><td>-2.3*</td><td>-1.6*</td></tr><tr><td>2642</td><td>P04406</td><td>G3PDH</td><td><i>GAPDH</i></td><td>0.07 &#177; 0.03</td><td>0.31 &#177; 0.03</td><td>0.23 &#177; 0.85</td><td>-4.4***</td><td>-3.2*</td></tr><tr><td>2543</td><td>P06733</td><td>&#945;-enolase</td><td><i>ENO1</i></td><td>0.08 &#177; 0.02</td><td>0.04 &#177; 0.01</td><td>0.05 &#177; 0.03</td><td>+2**</td><td>+1.6</td></tr><tr><td>2842</td><td>Q6GMW1</td><td>IGKC</td><td><i>IGKC</i></td><td>1.33 &#177; 0.49</td><td>0.17 &#177; 0.30</td><td>0.54 &#177; 0.42</td><td>+7.8*</td><td>+2.5</td></tr><tr><td>3018</td><td>P31151</td><td>Protein S100-A7 (Psoriasin)</td><td><i>S100A7</i></td><td>0.47 &#177; 0.21</td><td>0.09 &#177; 0.04</td><td>0.32 &#177; 0.15</td><td>+5.2*</td><td>+1.5</td></tr><tr><td>3000</td><td>P06702</td><td>Protein S100-A9 (Calgranulin B)</td><td><i>S100A9</i></td><td>2.98 &#177; 0.10</td><td>2.00 &#177; 0.42</td><td>2.75 &#177; 0.54</td><td>+1.5*</td><td>ns</td></tr><tr><td>2986</td><td>P01037</td><td>Cystatin SN precursor</td><td><i>CST1</i></td><td>0.91 &#177; 0.36</td><td>2.37 &#177; 0.01</td><td>0.84 &#177; 0.44</td><td>-2.6**</td><td>ns</td></tr><tr><td>2938</td><td>P12273</td><td>PIP</td><td><i>PIP</i></td><td>0.05 &#177; 0.08</td><td>0.33 &#177; 0.01</td><td>0.09 &#177; 0.17</td><td>-6.6**</td><td>-1.8</td></tr><tr><td>2655</td><td>Q96DR5</td><td>SPLUNC-2</td><td><i>SPLUNC2</i></td><td>0.04 &#177; 0.07</td><td>0.40 &#177; 0.17</td><td>0.40 &#177; 0.18</td><td>-10*</td><td>-10*</td></tr><tr><td>3003</td><td>Q01469</td><td>E-FABP</td><td><i>FABP5</i></td><td>0.17 &#177; 0.07</td><td>0.02 &#177; 0.03</td><td>0.06 &#177; 0.05</td><td>+8.5*</td><td>+2.8*</td></tr><tr><td>3036</td><td>P61769</td><td>&#946;-2 microglobulin</td><td><i>B2M</i></td><td>0.39 &#177; 0.04</td><td>0.17 &#177; 0.04</td><td>0.23 &#177; 0.05</td><td>+2.3**</td><td>+1.7</td></tr></table>
f476a9fac6b3762ebb3a55dcd0e8145989d93dfc1edfc3050bab443668ca043e.png
complex
<table><tr><td rowspan="2">Covariate*</td><td colspan="3"><i>QI Strategies and Practices</i></td><td colspan="3"><i>Composite HQA Process of Care</i></td><td colspan="3"><i>Observed to Expected Mortality Rate</i></td></tr><tr><td>Beta</td><td>95% CI</td><td>P</td><td>Beta</td><td>95% CI</td><td>P</td><td>Beta</td><td>95% CI</td><td>P</td></tr><tr><td>bed-size category</td><td> </td><td> </td><td>0.285</td><td> </td><td> </td><td>0.022</td><td> </td><td> </td><td>0.972</td></tr><tr><td>25-99 beds</td><td>&#8722;0.177</td><td>&#8722;0.398, 0.045</td><td>0.119</td><td>&#8722;0.04</td><td>&#8722;0.07, -0.010</td><td>0.009</td><td>0.007</td><td>&#8722;0.123, 0.137</td><td>0.916</td></tr><tr><td>100-399 beds</td><td>&#8722;0.057</td><td>&#8722;0.205, 0.091</td><td>0.453</td><td>&#8722;0.011</td><td>&#8722;0.032, 0.010</td><td>0.308</td><td>&#8722;0.004</td><td>&#8722;0.103, 0.095</td><td>0.940</td></tr><tr><td>ownership type</td><td> </td><td> </td><td>0.438</td><td> </td><td> </td><td>0.001</td><td> </td><td> </td><td>0.626</td></tr><tr><td>government</td><td>&#8722;0.159</td><td>&#8722;0.404, 0.086</td><td>0.204</td><td>&#8722;0.003</td><td>&#8722;0.046, 0.039</td><td>0.881</td><td>&#8722;0.017</td><td>&#8722;0.205, 0.170</td><td>0.856</td></tr><tr><td>not-for-profit</td><td>&#8722;0.122</td><td>&#8722;0.334, 0.090</td><td>0.260</td><td>0.034</td><td>&#8722;0.006, 0.073</td><td>0.093</td><td>&#8722;0.053</td><td>&#8722;0.229, 0.124</td><td>0.557</td></tr><tr><td>urban</td><td>0.079</td><td>&#8722;0.078, 0.236</td><td>0.323</td><td>&#8722;0.009</td><td>&#8722;0.029, 0.010</td><td>0.353</td><td>&#8722;0.098</td><td>&#8722;0.181, -0.014</td><td>0.022</td></tr><tr><td>non-teaching</td><td>0.046</td><td>&#8722;0.113, 0.205</td><td>0.569</td><td>0.006</td><td>&#8722;0.017, 0.029</td><td>0.607</td><td>0.050</td><td>&#8722;0.056, 0.156</td><td>0.350</td></tr><tr><td>HIT category</td><td> </td><td> </td><td>0.003</td><td> </td><td> </td><td>0.257</td><td> </td><td> </td><td>0.005</td></tr><tr><td>low</td><td>&#8722;0.378</td><td>&#8722;0.610, -0.146</td><td>0.001</td><td>&#8722;0.021</td><td>&#8722;0.049, 0.008</td><td>0.157</td><td>0.065</td><td>&#8722;0.061, 0.191</td><td>0.312</td></tr><tr><td>medium</td><td>&#8722;0.084</td><td>&#8722;0.236, 0.068</td><td>0.277</td><td>&#8722;0.016</td><td>&#8722;0.037, 0.004</td><td>0.122</td><td>&#8722;0.076</td><td>&#8722;0.172, 0.020</td><td>0.121</td></tr><tr><td>commitment</td><td>0.123</td><td>&#8722;0.091, 0.336</td><td>0.261</td><td>0.03</td><td>0.002, 0.058</td><td>0.037</td><td>&#8722;0.029</td><td>&#8722;0.155, 0.096</td><td>0.646</td></tr><tr><td>resources</td><td>0.090</td><td>&#8722;0.085, 0.265</td><td>0.312</td><td>0.007</td><td>&#8722;0.015, 0.029</td><td>0.545</td><td>&#8722;0.010</td><td>&#8722;0.109, 0.089</td><td>0.842</td></tr><tr><td>R<sup>2</sup></td><td>0.109</td><td> </td><td> </td><td>0.136</td><td> </td><td> </td><td>0.072</td><td> </td><td> </td></tr><tr><td> </td><td colspan="3"><i>HCAHPS Patient Satisfaction</i></td><td colspan="3"><i>Quality Manager Assessment of Patient Care Quality</i></td><td colspan="3"><i>Front-line Clinicians&#8217; Assessment of Patient Care Quality</i></td></tr><tr><td>Covariate*</td><td>Beta</td><td>95% CI</td><td>P</td><td>Beta</td><td>95% CI</td><td>P</td><td>Beta</td><td>95% CI</td><td>P</td></tr><tr><td>bed-size category</td><td> </td><td> </td><td>0.002</td><td> </td><td> </td><td>0.153</td><td> </td><td> </td><td>0.006</td></tr><tr><td>25-99 beds</td><td>2.390</td><td>&#8722;1.493, 6.273</td><td>0.227</td><td>0.119</td><td>&#8722;0.186, 0.424</td><td>0.443</td><td>0.112</td><td>0.004, 0.220</td><td>0.042</td></tr><tr><td>100-399 beds</td><td>&#8722;2.256</td><td>&#8722;4.977, 0.466</td><td>0.104</td><td>&#8722;0.082</td><td>&#8722;0.316, 0.153</td><td>0.493</td><td>&#8722;0.011</td><td>&#8722;0.094, 0.072</td><td>0.797</td></tr><tr><td>ownership type</td><td> </td><td> </td><td>0.001</td><td> </td><td> </td><td>0.613</td><td> </td><td> </td><td>0.094</td></tr><tr><td>government</td><td>8.952</td><td>3.467, 14.437</td><td>0.001</td><td>0.207</td><td>&#8722;0.221, 0.634</td><td>0.343</td><td>0.168</td><td>0.015, 0.320</td><td>0.031</td></tr><tr><td>not-for-profit</td><td>9.373</td><td>4.400, 14.347</td><td>0.000</td><td>0.199</td><td>&#8722;0.203, 0.601</td><td>0.331</td><td>0.130</td><td>&#8722;0.013, 0.274</td><td>0.075</td></tr><tr><td>urban</td><td>&#8722;0.149</td><td>&#8722;2.569, 2.271</td><td>0.903</td><td>0.056</td><td>&#8722;0.137, 0.249</td><td>0.570</td><td>&#8722;0.021</td><td>&#8722;0.089, 0.048</td><td>0.557</td></tr><tr><td>non-teaching</td><td>&#8722;1.220</td><td>&#8722;4.030, 1.590</td><td>0.393</td><td>&#8722;0.030</td><td>&#8722;0.280, 0.220</td><td>0.813</td><td>&#8722;0.097</td><td>&#8722;0.186, -0.008</td><td>0.032</td></tr><tr><td>HIT category</td><td> </td><td> </td><td>0.000</td><td> </td><td> </td><td>0.006</td><td> </td><td> </td><td>0.392</td></tr><tr><td>low</td><td>&#8722;7.208</td><td>&#8722;11.047, -3.680</td><td>0.000</td><td>&#8722;0.439</td><td>&#8722;0.730, -0.147</td><td>0.003</td><td>&#8722;0.067</td><td>&#8722;0.170, 0.036</td><td>0.202</td></tr><tr><td>medium</td><td>&#8722;1.177</td><td>&#8722;3.776, 1.421</td><td>0.370</td><td>&#8722;0.342</td><td>&#8722;0.567, -0.117</td><td>0.003</td><td>&#8722;0.022</td><td>&#8722;0.102, 0.058</td><td>0.586</td></tr><tr><td>commitment</td><td>2.686</td><td>&#8722;0.889, 6.261</td><td>0.140</td><td>0.337</td><td>0.050, 0.623</td><td>0.021</td><td>0.370</td><td>0.268, 0.473</td><td>0.000</td></tr><tr><td>resources</td><td>2.814</td><td>0.029, 5.599</td><td>0.048</td><td>0.022</td><td>&#8722;0.209, 0.253</td><td>0.851</td><td>0.354</td><td>0.271, 0.436</td><td>0.000</td></tr><tr><td>R<sup>2</sup></td><td>0.228</td><td> </td><td> </td><td>0.078</td><td> </td><td> </td><td>0.579+</td><td> </td><td> </td></tr></table>
12883c7eb5b321243f35bc6a9d51b7bad50ef1c0076264add075543175e019f5.png
simple
<table><tr><td>VariablesAt the follow-up visit</td><td>Higher IR group(n = 71)</td><td>Lower IR group (n = 213)</td><td><i> p </i>value</td></tr><tr><td>BMI</td><td>27.69 &#177; 4.17</td><td>24.13 &#177; 2.65</td><td>&lt;0.001</td></tr><tr><td>Prevalence of hypertension</td><td>60 (84.5%)</td><td>148 (70.0%)</td><td>0.013</td></tr><tr><td>Prevalence of diabetes</td><td>44 (62.0%)</td><td>72 (33.8%)</td><td>&lt;0.001</td></tr><tr><td>Fasting glucose</td><td>7.84 &#177; 1.80</td><td>5.30 &#177; 1.22</td><td>0.005</td></tr><tr><td>OGTT</td><td>10.51 &#177; 3.98</td><td>8.73 &#177; 3.43</td><td>0.002</td></tr><tr><td>Fasting insulin</td><td>39.36 &#177; 96.93</td><td>10.36 &#177; 9.56</td><td>0.002</td></tr><tr><td>Postrandial insulin</td><td>135.52 &#177; 148.57</td><td>68.41 &#177; 60.23</td><td>&lt;0.001</td></tr><tr><td>Bonnet index</td><td>0.95 &#177; 0.84</td><td>0.67 &#177; 0.95</td><td>&lt;0.001</td></tr><tr><td>HbA1c</td><td>6.79 &#177; 1.53</td><td>6.07 &#177; 0.78</td><td>&lt;0.001</td></tr><tr><td>GFR</td><td>79.46 &#177; 28.19</td><td>70.38 &#177; 21.72</td><td>0.016</td></tr><tr><td>Triglycerides</td><td>2.09 &#177; 1.75</td><td>1.52 &#177; 1.01</td><td>0.002</td></tr><tr><td>hsCRP</td><td>8.54 &#177; 13.78</td><td>3.87 &#177; 7.45</td><td>0.005</td></tr></table>
07b38bc338a88d667c1ced07a83422c45eba9ccfd488879d487adf1be2972d57.png
complex
<table><tr><td></td><td>Control</td><td>Mild periodontitis</td><td>Moderate periodontitis</td><td>Severe periodontitis</td><td>Implant</td></tr><tr><td></td><td>(I)</td><td>(II)</td><td>(III)</td><td>(IV)</td><td>(V)</td></tr><tr><td colspan="6">MMP-8 (ng/mL)</td></tr><tr><td> Range</td><td>0.21&#8211;20.70</td><td>0.20&#8211;31.50</td><td>0.34&#8211;54.90</td><td>0.20&#8211;48.51</td><td>0.30&#8211;347.00</td></tr><tr><td> Mean &#177; SD</td><td>5.61 &#177; 6.55</td><td>7.40 &#177; 9.07</td><td>12.43 &#177; 16.01</td><td>13.17 &#177; 16.43</td><td>40.46 &#177; 80.29</td></tr><tr><td colspan="2">I versus II, <i>P</i> = 0.0020I versus III, <i>P</i> = 0.0003I versus IV, <i>P</i> = 0.020I versus V, <i>P</i> = 0.0099</td><td colspan="2">II versus III, <i>P</i> = 0.0313II versus IV, <i>P</i> = 0.13II versus V, <i>P</i> = 0.0321</td><td colspan="2">III versus IV, <i>P</i> = 0.357III versus V, <i>P</i> = 0.0489IV versus V, <i>P</i> = 0.0255</td></tr></table>
0b85c19717bc10df6d7577fa4c420cbb88a6ec8597b2b8bc6d27cb0e7f959106.png
complex
<table><tr><td rowspan="2">Variables</td><td colspan="2">Milk drinking</td><td colspan="2">Non-milk drinking</td></tr><tr><td>Cases/Controls</td><td><i>OR</i>(95%<i>CI</i>)<sup>a</sup></td><td>Cases/Controls</td><td><i>OR</i>(95%<i>CI</i>)<sup>a</sup></td></tr><tr><td>Tea consumption</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>139/534</td><td>1.00</td><td>206/533</td><td>1.00</td></tr><tr><td>Yes</td><td>28/179</td><td>0.62(0.39-0.98)</td><td>48/152</td><td>0.81(0.55-1.19)</td></tr><tr><td colspan="2">Duration of tea consumption (years)</td><td></td><td></td><td></td></tr><tr><td>No</td><td>139/534</td><td>1.00</td><td>206/533</td><td>1.00</td></tr><tr><td>&lt;20</td><td>10/100</td><td>0.42(0.21-0.84)</td><td>21/69</td><td>0.72(0.42-1.24)</td></tr><tr><td>&#8805;20</td><td>18/79</td><td>0.84(0.48-1.48)</td><td>27/83</td><td>0.89(0.55-1.44)</td></tr><tr><td colspan="2">Quantity of tea consumed (ml/day)</td><td></td><td></td><td></td></tr><tr><td>No</td><td>139/534</td><td>1.00</td><td>206/533</td><td>1.00</td></tr><tr><td>&lt;500</td><td>13/104</td><td>0.49(0.27-0.92)</td><td>26/77</td><td>0.85(0.52-1.38)</td></tr><tr><td>&#8805;500</td><td>15/75</td><td>0.79(0.43-1.46)</td><td>22/75</td><td>0.77(0.46-1.31)</td></tr><tr><td colspan="2">Concentration of tea consumed</td><td></td><td></td><td></td></tr><tr><td>No</td><td>139/534</td><td>1.00</td><td>206/533</td><td>1.00</td></tr><tr><td>Weak</td><td>10/75</td><td>0.48(0.24-0.98)</td><td>17/54</td><td>0.78(0.44-1.40)</td></tr><tr><td>Moderate</td><td>15/88</td><td>0.68(0.38-1.23)</td><td>21/75</td><td>0.77(0.46-1.29)</td></tr><tr><td>Strong</td><td>3/16</td><td>0.73(0.21-2.56)</td><td>10/23</td><td>1.15(0.54-2.48)</td></tr><tr><td>Types of tea</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>139/535</td><td>1.00</td><td>206/534</td><td>1.00</td></tr><tr><td>Green tea</td><td>14/100</td><td>0.55(0.30-0.99)</td><td>26/76</td><td>0.91(0.56-1.48)</td></tr><tr><td>Oolong tea</td><td>9/41</td><td>0.90(0.42-1.96)</td><td>13/43</td><td>0.76(0.40-1.47)</td></tr><tr><td>Others</td><td>5/37</td><td>0.47(0.18-1.25)</td><td>9/32</td><td>0.77(0.36-1.66)</td></tr></table>
725a7db54493cf17655f78f1ff7673542acc38ecb74fb7948282c6eae153f3c9.png
complex
<table><tr><td></td><td></td><td colspan="4">Year</td><td></td></tr><tr><td>Days of follow up</td><td>Sex ratio</td><td>2000</td><td>2004</td><td>2006</td><td>2000&#8211;2006</td><td>P value</td></tr><tr><td>0</td><td>Mean</td><td>0.004 (12)</td><td>0.048 (38)</td><td>0.2 (16)</td><td>0.076 (66)</td><td>&lt; 0.0001</td></tr><tr><td></td><td>SE</td><td>0.004</td><td>0.019</td><td>0.05</td><td>0.019</td><td></td></tr><tr><td>1</td><td>Mean</td><td>0.0 (4)</td><td>0.076 (37)</td><td>0.32 (8)</td><td>0.11 (49)</td><td>0.003</td></tr><tr><td></td><td>SE</td><td>0.0</td><td>0.025</td><td>0.12</td><td>0.03</td><td></td></tr><tr><td>2</td><td>Mean</td><td>0.13 (7)</td><td>0.1 (34)</td><td>0.25 (6)</td><td>0.13 (47)</td><td>0.3</td></tr><tr><td></td><td>SE</td><td>0.08</td><td>0.03</td><td>0.08</td><td>0.03</td><td></td></tr><tr><td>3</td><td>Mean</td><td>0.29 (11)</td><td>0.15 (38)</td><td>0.4 (21)</td><td>0.25 (70)</td><td>0.006</td></tr><tr><td></td><td>SE</td><td>0.1</td><td>0.03</td><td>0.08</td><td>0.04</td><td></td></tr><tr><td>7</td><td>Mean</td><td>0.25 (12)</td><td>0.25 (22)</td><td>0.37 (16)</td><td>0.29 (50)</td><td>0.48</td></tr><tr><td></td><td>SE</td><td>0.11</td><td>0.05</td><td>0.1</td><td>0.05</td><td></td></tr><tr><td>14</td><td>Mean</td><td>0.13 (5)</td><td>0.28 (18)</td><td>0.51 (6)</td><td>0.3 (29)</td><td>0.14</td></tr><tr><td></td><td>SE</td><td>0.08</td><td>0.08</td><td>0.14</td><td>0.06</td><td></td></tr><tr><td>21</td><td>Mean</td><td>-</td><td>0.25 (4)</td><td>0.3 (1)</td><td>0.26 (5)</td><td>-</td></tr><tr><td></td><td>SE</td><td>-</td><td>0.25</td><td>-</td><td>0.19</td><td></td></tr><tr><td>28</td><td>Mean</td><td>-</td><td>0.0 (2)</td><td>0.52 (2)</td><td>0.26 (4)</td><td>0.46</td></tr><tr><td></td><td>SE</td><td>-</td><td>0.0</td><td>0.19</td><td>0.17</td><td></td></tr></table>
51a6f46a225e7f5417ce9b0f3347ca55f206aefb1c7e8419fc1617817b6cc679.png
complex
<table><tr><td rowspan="2"></td><td>All(n = 137)<sup>a</sup></td><td colspan="2">Exercise(n = 61)</td><td colspan="2">Control(n = 62)</td><td rowspan="2">p value</td></tr><tr><td>Baseline</td><td>Baseline</td><td>12 months</td><td>Baseline</td><td>12 months</td></tr><tr><td>cIMT (mm)</td><td>0.855 &#177; 0.172</td><td>0.876 &#177; 0.187</td><td>0.858 &#177; 0.175</td><td>0.853 &#177; 0.141</td><td>0.849 &#177; 0.131</td><td>0.57</td></tr><tr><td>SBP (mmHg)</td><td>139 &#177; 17</td><td>139 &#177; 17</td><td>140 &#177; 17</td><td>139 &#177; 16</td><td>139 &#177; 16</td><td>0.75</td></tr><tr><td>DBP (mmHg)</td><td>79 &#177; 9</td><td>78 &#177; 9</td><td>79 &#177; 9</td><td>80 &#177; 9</td><td>80 &#177; 10</td><td>0.51</td></tr><tr><td>TC (mmol/L)<sup>b</sup></td><td>3.9 (3.4, 4.5)</td><td>3.8 (3.4, 4.3)</td><td>3.9 (3.3, 4.6)</td><td>4.0 (3.3, 4.7)</td><td>3.7 (3.2, 4.5)*</td><td>0.014</td></tr><tr><td>LDL (mmol/L)<sup>b</sup></td><td>2.0 (1.6, 2.6)</td><td>1.9 (1.6, 2.5)</td><td>2.0 (1.7, 2.7)*</td><td>2.1 (1.6, 2.7)</td><td>1.9 (1.5, 2.7)*</td><td>0.020</td></tr><tr><td>HDL (mmol/L)<sup>b</sup></td><td>1.12 (0.94, 1.40)</td><td>1.12 (0.96, 1.32)</td><td>1.11 (0.93, 1.41)</td><td>1.13 (0.93, 1.40)</td><td>1.09 (0.94, 1.34)</td><td>0.080</td></tr><tr><td>TG (mmol/L)<sup>b</sup></td><td>1.40 (1.07, 1.88)</td><td>1.43 (1.09, 1.91)</td><td>1.53 (1.10, 1.99)</td><td>1.38 (0.98, 1.89)</td><td>1.38 (0.87, 2.01)</td><td>0.20</td></tr><tr><td>CRP (mg/L)<sup>b</sup></td><td>2.41 (1.15, 4.99)</td><td>2.04 (0.95, 4.40)</td><td>1.99 (1.00, 4.21)</td><td>2.40 (1.19, 4.98)</td><td>1.77 (0.96, 3.86)</td><td>0.91</td></tr></table>
daed0030d57b3eaa8125c864af4a0af7684c7e4ab1c3b5220f5dbdda6db5b41a.png
simple
<table><tr><td>Test</td><td>4CA</td><td>Cd</td><td>DDT</td><td>MeHg</td><td>TCDD</td><td>VA</td><td>AA</td><td>As</td><td>Pb</td><td>PCB</td><td>tBHQ</td></tr><tr><td>Pb</td><td>6.15</td><td>6.78</td><td>8.66</td><td>6.76</td><td>10.91</td><td>7.96</td><td>7.62</td><td>6.32</td><td>5.01</td><td>10.66</td><td>6.81</td></tr><tr><td>DDT</td><td>6.74</td><td>9.86</td><td>4.51</td><td>8.79</td><td>7.79</td><td>8.01</td><td>5.39</td><td>10.38</td><td>8.96</td><td>10.05</td><td>9.13</td></tr><tr><td>4CA</td><td>6.87*</td><td>10.96</td><td>6.69*</td><td>9.47</td><td>8.82</td><td>8.87</td><td>6.99*</td><td>11.21</td><td>8.42</td><td>10.75</td><td>9.42</td></tr><tr><td>TCDD</td><td>8.55</td><td>12.43</td><td>6.78</td><td>11.01</td><td>5.42</td><td>10.37</td><td>7.61</td><td>10.76</td><td>12.61</td><td>15.63</td><td>10.62</td></tr><tr><td>As</td><td>9.14</td><td>9.56</td><td>10.93</td><td>9.74</td><td>12.46</td><td>9.89</td><td>10.18</td><td>6.88</td><td>7.51</td><td>11.32</td><td>7.51</td></tr><tr><td>Pb</td><td>7.25</td><td>7.95</td><td>10.05</td><td>7.38</td><td>12.06</td><td>8.62</td><td>8.65</td><td>9.58</td><td>4.22</td><td>9.91</td><td>7.70</td></tr><tr><td>PCB</td><td>9.84</td><td>9.30</td><td>13.17</td><td>10.23</td><td>15.01</td><td>10.01</td><td>11.78</td><td>12.77</td><td>10.62</td><td>3.93</td><td>10.40</td></tr><tr><td>As</td><td>9.18</td><td>9.99</td><td>9.92</td><td>10.20</td><td>11.53</td><td>10.16</td><td>9.43</td><td>5.48</td><td>7.84</td><td>12.40</td><td>7.67</td></tr><tr><td>TBHQ</td><td>8.79</td><td>7.49</td><td>11.32</td><td>9.24</td><td>11.52</td><td>10.29</td><td>10.98</td><td>8.93</td><td>9.77</td><td>11.31</td><td>6.33</td></tr><tr><td>PCB</td><td>8.37</td><td>7.74</td><td>12.06</td><td>8.88</td><td>13.65</td><td>8.54</td><td>10.63</td><td>11.79</td><td>10.22</td><td>5.71</td><td>9.08</td></tr><tr><td>AA</td><td>7.18</td><td>10.79</td><td>4.29</td><td>9.28</td><td>7.21</td><td>8.63</td><td>3.56</td><td>7.67</td><td>8.12</td><td>13.04</td><td>8.86</td></tr><tr><td>TBHQ</td><td>7.49</td><td>7.26</td><td>11.22</td><td>8.30</td><td>11.66</td><td>9.00</td><td>10.40</td><td>9.57</td><td>9.58</td><td>10.47</td><td>5.41</td></tr><tr><td>Cd</td><td>8.32</td><td>6.67</td><td>10.76</td><td>8.39</td><td>12.79</td><td>8.90</td><td>10.16</td><td>10.89</td><td>6.96</td><td>8.05</td><td>8.15</td></tr><tr><td>VA</td><td>6.43</td><td>8.25</td><td>6.47</td><td>7.57</td><td>9.04</td><td>4.57</td><td>6.15</td><td>9.56</td><td>8.02</td><td>10.24</td><td>8.33</td></tr><tr><td>AA</td><td>10.26</td><td>14.38</td><td>7.09</td><td>12.23</td><td>9.61</td><td>11.59</td><td>6.25</td><td>11.26</td><td>10.54</td><td>13.89</td><td>11.84</td></tr></table>
154c7bd2e9b46e6cff728e56c28bb9b06661d42e4c2b70c17c6b3ab4b64cf165.png
complex
<table><tr><td rowspan="2"> </td><td>Cognitive impairment</td><td>Controls</td><td rowspan="2">Z</td><td rowspan="2">p</td></tr><tr><td>(n = 377)</td><td>(n = 66)</td></tr><tr><td>Age (year)</td><td>63.10 &#177; 9.70</td><td>55.09 &#177; 10.77</td><td>&#8722;5.295</td><td>0.000</td></tr><tr><td>Gender (male)</td><td>178(47.2%)</td><td>38(57.6%)</td><td>&#8722;1.256</td><td>0.209</td></tr><tr><td>Education (year)</td><td>9.01 &#177; 4.01</td><td>12.94 &#177; 3.0</td><td>&#8722;6.455</td><td>0.000</td></tr><tr><td>CRP (mg/L)</td><td>2.08(1.07,3.36)</td><td>0.21(0.18,0.42)</td><td>&#8722;6.488</td><td>0.001</td></tr><tr><td>RAGE (ng/mL)</td><td>4.01(2.49,5.71)</td><td>2.28(1.84,3.03)</td><td>&#8722;3.271</td><td>0.004</td></tr><tr><td>Hypertension</td><td>60.5%</td><td>54.5%</td><td>&#8722;0.761</td><td>0.447</td></tr><tr><td>Diabetes</td><td>28.8%</td><td>38.7%</td><td>&#8722;1.348</td><td>0.178</td></tr><tr><td>Triglycerides (mmol/L)</td><td>1.38(0.89, 1.87)</td><td>1.49(0.99,2.06)</td><td>&#8722;0.831</td><td>0.406</td></tr><tr><td>LDL (mmol/L)</td><td>2.93(2.41,3.68)</td><td>3.22(2.67,4.18)</td><td>&#8722;1.651</td><td>0.099</td></tr><tr><td>Smoking</td><td>34.1%</td><td>34.8%</td><td>&#8722;0.151</td><td>0.880</td></tr><tr><td>BMI (Kg/m<sup>2</sup>)</td><td>23.58 &#177; 3.39</td><td>23.12 &#177; 2.63</td><td>&#8722;0.189</td><td>0.850</td></tr></table>
5c8b355097654ce2c8d07431cc7bae71bd898bf5560aa264d7512f0ab8093020.png
complex
<table><tr><td></td><td>Union group (<i>n</i> = 74)</td><td>Non-union group (<i>n</i> = 12)</td><td><i>P</i> value</td></tr><tr><td>Age (years)</td><td>81.4 &#177; 10.4 (54&#8211;99)</td><td>85.3 &#177; 9.7 (62&#8211;96)</td><td>0.1606</td></tr><tr><td>Sex (male/female)</td><td>17 (23.0%)/57 (77.0%)</td><td>1 (8.3%)/11 (91.7%)</td><td>0.2475</td></tr><tr><td>Waiting time (days)</td><td>5.0 &#177; 3.6 (1&#8211;17)</td><td>4.4 &#177; 3.3 (1&#8211;12)</td><td>0.5339</td></tr><tr><td>Intraoperative blood loss (g)</td><td>21.0 &#177; 14.2 (0&#8211;100)</td><td>17.9 &#177; 9.9 (5&#8211;40)</td><td>0.5756</td></tr><tr><td>Duration of follow-up (m)</td><td>13.0 &#177; 11.0 (6&#8211;48)</td><td>9.0 &#177; 6.2 (6&#8211;26)</td><td>0.1826</td></tr><tr><td colspan="4">Garden classification</td></tr><tr><td rowspan="4"></td><td>Stage I: 8 (10.8%)</td><td>Stage I: 0 (0%)</td><td rowspan="4">0.0008<sup>a</sup></td></tr><tr><td>Stage II: 44 (59.5%)</td><td>Stage II: 1 (8.3%)</td></tr><tr><td>Stage III: 18 (24.3%)</td><td>Stage III: 9 (75.0%)</td></tr><tr><td>Stage IV: 4 (5.4%)</td><td>Stage IV: 2 (16.7%)</td></tr><tr><td colspan="4">Garden alignment index</td></tr><tr><td> AP view</td><td>168.0 &#177; 6.2</td><td>164.5 &#177; 8.6</td><td>0.168</td></tr><tr><td> Lateral view</td><td>173.4 &#177; 5.3</td><td>169.7 &#177; 10.2</td><td>0.159</td></tr><tr><td colspan="4">Preoperative ADL</td></tr><tr><td> Gait alone</td><td>31(41.9%)</td><td>4(33.3%)</td><td rowspan="4">0.4917</td></tr><tr><td> With aid</td><td>18(24.3%)</td><td>2(16.7%)</td></tr><tr><td> With helper/walker</td><td>21(28.4%)</td><td>4(33.3%)</td></tr><tr><td> Wheel chair</td><td>4(5.4%)</td><td>2(16.7%)</td></tr><tr><td colspan="4">Postoperative ADL</td></tr><tr><td> Gait alone</td><td>5(6.8%)</td><td>0(0%)</td><td rowspan="4">0.0493<sup>a</sup></td></tr><tr><td> With aid</td><td>33(44.6%)</td><td>1(8.3%)</td></tr><tr><td> With helper/walker</td><td>18(24.3%)</td><td>5(41.7%)</td></tr><tr><td> Wheel chair</td><td>18(24.3%)</td><td>6(50.0%)</td></tr></table>
031db35e342ccf94833b507beddc6e74acf3ade239989a52758ccfc73bebf4ff.png
simple
<table><tr><td>Characteristics</td><td>PCV-7 group (n = 811)</td><td>Control group (n = 744)</td><td><i>P</i></td></tr><tr><td>Males (%)</td><td>476 (58.7)</td><td>413 (55.5)</td><td>0.22</td></tr><tr><td>Age at vaccination, median days (range)</td><td></td><td></td><td></td></tr><tr><td> First dose</td><td>82 (75&#8211;104)</td><td>82 (76&#8211;103)</td><td>0.96</td></tr><tr><td> Second dose</td><td>140 (128&#8211;155)</td><td>143 (130&#8211;158)</td><td>0.93</td></tr><tr><td> Third dose</td><td>340 (328&#8211;361)</td><td>343 (331&#8211;364)</td><td>0.92</td></tr><tr><td>Breast-feeding for at least three months, No. (%)</td><td>551 (67.9)</td><td>476 (64.1)</td><td>0.11</td></tr><tr><td>Living in urban area, No. (%)</td><td>527 (65.0)</td><td>498 (66.9)</td><td>0.44</td></tr><tr><td>Mother's age, median years (range)</td><td>33 (24&#8211;49)</td><td>33 (20&#8211;46)</td><td>0.96</td></tr><tr><td>Father's age, median years (range)</td><td>35 (21&#8211;50)</td><td>35 (21&#8211;51)</td><td>0.99</td></tr><tr><td>No. of persons in household, median (range)</td><td>3 (2&#8211;4)</td><td>3 (2&#8211;4)</td><td>1.00</td></tr><tr><td>No. of siblings, median (range)</td><td>1 (0&#8211;2)</td><td>1 (0&#8211;2)</td><td>1.00</td></tr><tr><td>Children with a smoker in the family, No. (%)</td><td>194 (23.9)</td><td>182 (24.5)</td><td>0.84</td></tr><tr><td>Children attending day-care, No. (%)</td><td>284 (35.0)</td><td>231 (31.0)</td><td>0.10</td></tr><tr><td>Duration of day care attendance, No. (%)</td><td></td><td></td><td></td></tr><tr><td> 0&#8211;6 months</td><td>79 (9.7)</td><td>65 (8.7)</td><td>0.55</td></tr><tr><td> 7&#8211;12 months</td><td>33 (4.1)</td><td>44 (5.9)</td><td>0.11</td></tr><tr><td> 13&#8211;18 months</td><td>111 (13.7)</td><td>94 (12.6)</td><td>0.59</td></tr><tr><td> 19&#8211;24 months</td><td>78 (9.6)</td><td>58 (7.8)</td><td>0.23</td></tr><tr><td>Vaccinated against influenza, No. (%)</td><td>12 (1.5)</td><td>10 (1.3)</td><td>0.99</td></tr></table>
2e31498db08192ce5ea1ffff30511388e9d17530d6054b98ec0723c84fa4e40e.png
complex
<table><tr><td></td><td>Completed (n = 107)</td><td>On treatment (n = 55)</td><td>Discontinued (n = 45)</td></tr><tr><td>Female</td><td>53 (50%)</td><td>32 (58%)</td><td>20 (44%)</td></tr><tr><td>Age (years)</td><td>41 &#177; 11</td><td>37 &#177; 12</td><td>35 &#177; 9</td></tr><tr><td>Other allergies</td><td>77 (73%)</td><td>38 (72%)</td><td>30 (68%)</td></tr><tr><td>Asthma</td><td>47 (44%)</td><td>28 (53%)</td><td>20 (44%)</td></tr><tr><td colspan="4">Year treatment started<sup>a</sup></td></tr><tr><td> 2016</td><td>&#8211;</td><td>20 (39%)</td><td>9 (23%)</td></tr><tr><td> 2015</td><td>&#8211;</td><td>18 (35%)</td><td>5 (13%)</td></tr><tr><td> 2014</td><td>8 (8%)</td><td>13 (25%)</td><td>6 (15%)</td></tr><tr><td> 2013</td><td>29 (30%)</td><td></td><td>4 (10%)</td></tr><tr><td> 2012</td><td>14 (14%)</td><td></td><td>7 (18%)</td></tr><tr><td> 2011</td><td>12 (12%)</td><td></td><td>3 (8%)</td></tr><tr><td> 2010</td><td>7 (7%)</td><td></td><td>2 (5%)</td></tr><tr><td> 2009</td><td>12 (12%)</td><td></td><td>1 (3%)</td></tr><tr><td> 2008</td><td>8 (8%)</td><td></td><td>0</td></tr><tr><td> 2007</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> 2006</td><td>7 (7%)</td><td></td><td>2 (5%)</td></tr></table>
ec24770fb3bd8d019d3b255330f93fd1c865bb3015b6c0ff7b00ac667b787d52.png
complex
<table><tr><td></td><td>Control</td><td>Reduced</td><td>Restricted</td></tr><tr><td colspan="4">Males</td></tr><tr><td> Food intake (g/24 h/kg)</td><td>42 &#177; 1</td><td>39 &#177; 1</td><td>46 &#177; 2&#8224;</td></tr><tr><td> Water intake (mL/24 h/kg)</td><td>72 &#177; 4</td><td>66 &#177; 4</td><td>79 &#177; 2&#8224;</td></tr><tr><td> Urine production (L/24 h/kg)</td><td>0.036 &#177; 0.002</td><td>0.031 &#177; 0.002</td><td>0.039 &#177; 0.004</td></tr><tr><td> Glucose (mmol/L/24 h/kg)</td><td>0.043 &#177; 0.005</td><td>0.044 &#177; 0.006</td><td>0.029 &#177; 0.008</td></tr><tr><td> Creatinine (mmol/L/24 h/kg)</td><td>0.090 &#177; 0.013</td><td>0.099 &#177; 0.011</td><td>0.104 &#177; 0.021</td></tr><tr><td> Total protein (mg/L/24 h/kg)</td><td>16.924 &#177; 3.105</td><td>20.547 &#177; 2.596</td><td>23.148 &#177; 5.152</td></tr><tr><td> Albumin (mg/L/24 h/kg)</td><td>0.879 &#177; 0.175</td><td>1.031 &#177; 0.177</td><td>0.831 &#177; 0.199</td></tr><tr><td> Sodium (mmol/L/(24 h)/kg)</td><td>0.648 &#177; 0.051</td><td>0.844 &#177; 0.081</td><td>0.693 &#177; 0.081</td></tr><tr><td> Potassium (mmol/L/(24 h)/kg)</td><td>1.766 &#177; 0.152</td><td>1.784 &#177; 0.140</td><td>1.568 &#177; 0.185</td></tr><tr><td> Chloride (mmol/L/(24 h)/kg)</td><td>2.118 &#177; 0.137</td><td>2.220 &#177; 0.161</td><td>2.050 &#177; 0.185</td></tr><tr><td colspan="4">Females</td></tr><tr><td> Food intake (g/24 h/kg)</td><td>64 &#177; 2</td><td>65 &#177; 3</td><td>65 &#177; 4</td></tr><tr><td> Water intake (mL/24 h/kg)</td><td>141 &#177; 7</td><td>134 &#177; 6</td><td>159 &#177; 11</td></tr><tr><td> Urine production (L/24 h/kg)</td><td>0.064 &#177; 0.005</td><td>0.075 &#177; 0.004</td><td>0.091 &#177; 0.009*</td></tr><tr><td> Glucose (mmol/L/24 h/kg)</td><td>0.023 &#177; 0.003</td><td>0.032 &#177; 0.006</td><td>0.012 &#177; 0.003&#8224;</td></tr><tr><td> Creatinine (mmol/L/24 h/kg)</td><td>0.081 &#177; 0.012</td><td>0.125 &#177; 0.016*</td><td>0.066 &#177; 0.012&#8224;</td></tr><tr><td> Total protein (mg/L/24 h/kg)</td><td>6.570 &#177; 0.857</td><td>8.906 &#177; 2.024</td><td>6.029 &#177; 1.096</td></tr><tr><td> Albumin (mg/L/24 h/kg)</td><td>0.443 &#177; 0.090</td><td>0.448 &#177; 0.051</td><td>0.621 &#177; 0.090</td></tr><tr><td> Sodium (mmol/L/(24 h)/kg)</td><td>1.389 &#177; 0.179</td><td>1.891 &#177; 0.119</td><td>1.508 &#177; 0.314</td></tr><tr><td> Potassium (mmol/L/(24 h)/kg)</td><td>2.975 &#177; 0.307</td><td>4.296 &#177; 0.356<sup>*</sup></td><td>2.982 &#177; 0.345&#8224;</td></tr><tr><td> Chloride (mmol/L/(24 h)/kg)</td><td>3.743 &#177; 0.312</td><td>5.352 &#177; 0.381*</td><td>4.239 &#177; 0.500</td></tr></table>